Heteroaryl-substituted bicyclic compound and application thereof
Patent Information
- Application Number
- CN202380036255.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-15
- Filing Date
- 2023-04-27
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-04-27
AI Technical Summary
It is difficult to develop highly active HPK1 inhibitors with existing technology to effectively inhibit the proliferation and metastasis of tumor cells, and there is a lack of effective small molecule inhibitors targeting HPK1 kinase.
A series of heteroaryl-substituted bicyclic compounds and their stereoisomers and pharmaceutically acceptable salts were designed to improve the inhibitory activity against HPK1 by optimizing the molecular structure and optimizing the synthesis method to improve the stability of the drug. and bioavailability.
The compound shows excellent HPK1 kinase inhibitory activity, has good intracellular stability and oral absorption properties, significantly increases the level of IL-2 in Jurkat cells and inhibits the phosphorylation of SLP76, and has good potential for treating tumors.
Smart Images

Figure CN119095847A_ABST
Abstract
Description
Heteroaryl-substituted bicyclic compounds and their applications
[0001] The present invention claims the following priority:
[0002] CN202210457171.1, application date: April 27, 2022;
[0003] CN202210632218.3, application date: June 6, 2022;
[0004] CN202210818491.5, application date: July 11, 2022;
[0005] CN202210983311.9, application date: August 16, 2022;
[0006] CN202211177697.0, application date: September 26, 2022;
[0007] CN202211429833.0, application date: November 4, 2022;
[0008] CN202211618983.6, application date: December 15, 2022;
[0009] PCT / CN2023 / 073099, application date: January 19, 2023. Technical Field
[0010] The present invention relates to a series of heteroaryl-substituted bicyclic compounds and applications thereof, and particularly to compounds represented by formula (P), stereoisomers thereof and pharmaceutically acceptable salts thereof. Background Art
[0011] Hematopoietic progenitor kinase 1 (HPK1) is an immunosuppressive regulatory kinase and a member of the mammalian serine / threonine kinase superfamily (SLK). It is a microtubule-associated protein with restricted expression in hematopoietic stem cells. HPK1 is a negative signaling regulator of the T cell receptor (TCR). Upon TCR activation, cytoplasmic HPK1 is recruited to the cell membrane. Activated HPK1 phosphorylates the adaptor protein SLP76, activating SLP76 as a docking site for the negative regulatory protein 14-3-3π. This ultimately destabilizes the TCR signaling complex and downregulates TCR signaling.
[0012] HPK1 can inhibit the proliferation, invasion, and metastasis of lung cancer cells. HPK1 deficiency also plays an important role in the pathogenesis of pancreatic ductal carcinoma, indicating that HPK1 kinase plays an extremely important role in disease treatment. Therefore, the discovery of small molecule inhibitors of HPK1 kinase is an urgent need in current drug research and development. We aim to develop highly active HPK1 inhibitors for tumor treatment.
[0013] Summary of the Invention
[0014] The present invention provides a compound represented by formula (P), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0015] in,
[0016] X is selected from O and S;
[0017] Y is selected from C(R8)2 and C(R8)=C(R8);
[0018] T is selected from CH and N;
[0019] T1 is selected from CH and N;
[0020] T2 and T3 are independently selected from CH, CF and N;
[0021] T4 is selected from CR6 and N;
[0022] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0023] R3 and R4 together with the carbon atoms to which they are attached form
[0024] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0025] n and m are independently selected from 0 and 1;
[0026] R5 is selected from H and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups;
[0027] R6 is selected from H, halogen and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0028] R7 is selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl and C 1-3 alkoxy;
[0029] R8 is selected from H and D;
[0030] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 R;
[0031] Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;
[0032] Or, 2 R b Together with the carbon atom to which they are attached, they form a C=O or cyclopropyl group;
[0033] Each R is independently selected from halogen and D.
[0034] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0035] in,
[0036] X, T, T1, T2, T3, T4, R2, R3, R4 and R8 are as defined herein.
[0037] In some embodiments of the present invention, the above R a are independently selected from D, F, CH3 and CD3, and other variables are as defined in the present invention.
[0038] In some embodiments of the present invention, the above R a are independently selected from D, F and CH3, and other variables are as defined in the present invention.
[0039] In some embodiments of the present invention, the above R b are independently selected from H, D, F, Cl, Br, I, OH, CH3, CH2CH3 and CH2CH2CH3, said CH3, CH2CH3 and CH2CH2CH3 are optionally substituted by 1, 2 or 3 halogens, and other variables are as defined herein.
[0040] In some embodiments of the present invention, the above R b are independently selected from H, D, CH3, CH2CH3 and CH2CH2CH3, said CH3, CH2CH3 and CH2CH2CH3 are optionally substituted with 1, 2 or 3 halogens, and other variables are as defined herein.
[0041] In some embodiments of the present invention, the above Rb are independently selected from H, D, F, OH, CH3 and CF3, and other variables are as defined in the present invention.
[0042] In some embodiments of the present invention, the above R b are independently selected from H, D, CH3 and CF3, and other variables are as defined in the present invention.
[0043] In some embodiments of the present invention, the above R2 is selected from pyrrolopyridinyl and imidazopyridinyl, and the pyrrolopyridinyl and imidazopyridinyl are optionally replaced by 1, 2 or 3 R a Replacement, R a and other variables are as defined in the present invention.
[0044] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.
[0045] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.
[0046] In some embodiments of the present invention, the above R6 is selected from H, F and -CH2-N(CH3)2, and other variables are as defined in the present invention.
[0047] In some embodiments of the present invention, the above R6 is selected from H and F, and other variables are as defined in the present invention.
[0048] In some embodiments of the present invention, the above R5 is selected from H, CH3, CD3, CH2CH3 and CH(CH3)2, and other variables are as defined in the present invention.
[0049] In some embodiments of the present invention, the above-mentioned R7 is selected from H, F, Cl, Br, I, OH, NH2, CH3, CH2CH3 and CH2CH2CH3, and other variables are as defined in the present invention.
[0050] In some embodiments of the present invention, the above R7 is selected from H, F, OH, CH3 and OCH3, and other variables are as defined in the present invention.
[0051] In some embodiments of the present invention, the above R7 is selected from F, OH, CH3 and OCH3, and other variables are as defined in the present invention.
[0052] In some embodiments of the present invention, the above R7 is selected from F, OH and CH3, and other variables are as defined in the present invention.
[0053] In some embodiments of the present invention, the above T2 is selected from N, CF and CH, and other variables are as defined in the present invention.
[0054] In some embodiments of the present invention, the above T3 is selected from CH and N, and other variables are as defined in the present invention.
[0055] In some embodiments of the present invention, the above T4 is selected from CH and N, and other variables are as defined in the present invention.
[0056] In some embodiments of the present invention, the above E and E1 are independently selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)-, and -CH(OCH3)-, and other variables are as defined in the present invention.
[0057] In some embodiments of the present invention, the above E and E1 are independently selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)- and Other variables are as defined in the present invention.
[0058] In some embodiments of the present invention, the above-mentioned E is selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)- and Other variables are as defined in the present invention.
[0059] In some embodiments of the present invention, the above-mentioned E1 is selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)- and Other variables are as defined in the present invention.
[0060] In some embodiments of the present invention, the above-mentioned E and E1 are independently selected from -CH2-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CH2CH3)- and Other variables are as defined in the present invention.
[0061] In some embodiments of the present invention, the above-mentioned E and E1 are independently selected from -CH2-, -C(OH)-, -C(CH3)-, -O-, NH, -N(CH3)- and -N(CH2CH3)-, and other variables are as defined in the present invention.
[0062] In some embodiments of the present invention, the above R3 and R4 and the carbon atoms to which they are connected constitute Other variables are as defined in the present invention.
[0063] In some embodiments of the present invention, the above R3 and R4 and the carbon atoms to which they are connected constitute Each R b and other variables are as defined in the present invention.
[0064] In some embodiments of the present invention, the above R3 and R4 and the carbon atoms to which they are connected constitute Other variables are as defined in the present invention.
[0065] The present invention also provides a compound represented by formula (XII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0066] in,
[0067] X is selected from O and S;
[0068] T1 is selected from CH and N;
[0069] T2 and T3 are independently selected from CH, CF and N;
[0070] T4 is selected from CR6 and N;
[0071] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0072] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0073] Alternatively, when T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0074] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0075] n and m are independently selected from 0 and 1;
[0076] R5 is selected from H and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups;
[0077] R6 is selected from H, halogen and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0078] R7 is selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl and C 1-3 alkoxy;
[0079] R8 is selected from H and D;
[0080] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 R;
[0081] Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;
[0082] Or, 2 R b Together with the carbon atom to which they are attached, they form a C=O or cyclopropyl group;
[0083] Each R is independently selected from halogen and D.
[0084] The present invention also provides a compound represented by formula (XIII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0085] in,
[0086] X is selected from O and S;
[0087] T1 is selected from CH and N;
[0088] T2 and T3 are independently selected from CH, CF and N;
[0089] T4 is selected from CR6 and N;
[0090] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0091] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0092] Alternatively, when T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0093] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0094] n and m are independently selected from 0 and 1;
[0095] R5 is selected from H and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups;
[0096] R6 is selected from H, halogen and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0097] R7 is selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl and C 1-3 alkoxy;
[0098] R8 is selected from H and D;
[0099] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 R;
[0100] Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;
[0101] Or, 2 R b Together with the carbon atom to which they are attached, they form a C=O or cyclopropyl group;
[0102] Each R is independently selected from halogen and D.
[0103] The present invention also provides a compound represented by formula (XII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0104] in,
[0105] X is selected from O and S;
[0106] T is selected from CH, CF and N;
[0107] T1 is selected from CH and N;
[0108] T2 and T3 are independently selected from CH, CF and N;
[0109] T4 is selected from CR6 and N;
[0110] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0111] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0112] Alternatively, when T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0113] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0114] n and m are independently selected from 0 and 1;
[0115] R5 is selected from H and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups;
[0116] R6 is selected from H, halogen and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0117] R7 is selected from H, F, Cl, Br, I, OH, NH2 and C 1-3 alkyl;
[0118] R8 is selected from H and D;
[0119] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 R;
[0120] Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;
[0121] Or, 2 R b Together with the carbon atom to which they are attached, they form a C=O or cyclopropyl group;
[0122] R is selected from halogen and D.
[0123] The present invention also provides a compound represented by formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0124] in,
[0125] X is selected from O and S;
[0126] T is selected from CH, CF and N;
[0127] T1 is selected from CH and N;
[0128] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0129] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0130] Alternatively, when T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0131] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0132] n and m are independently selected from 0 and 1;
[0133] R5 is selected from H and C 1-3 alkyl;
[0134] R6 is selected from H and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0135] R7 is selected from H, F, Cl, Br, I, OH, NH2 and C 1-3alkyl;
[0136] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 alkoxy;
[0137] Each R b are independently selected from H, D and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens;
[0138] Or, 2 R b Together with their common carbon atom, they form C=O or cyclopropyl.
[0139] The present invention also provides a compound represented by formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0140] in,
[0141] X is selected from O and S;
[0142] T is selected from CH, CF and N;
[0143] T1 is selected from CH and N;
[0144] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0145] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0146] Alternatively, when T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0147] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0148] n and m are independently selected from 0 and 1;
[0149] R5 is selected from H and C 1-3 alkyl;
[0150] R6 is selected from H and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0151] R7 is selected from H, F, Cl, Br, I, OH, NH2 and C 1-3 alkyl;
[0152] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 alkoxy;
[0153] Each R b are independently selected from H, D and C 1-3 alkyl;
[0154] Or, 2 R b Together with their common carbon atom, they form C=O.
[0155] The present invention also provides a compound represented by formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0156] in,
[0157] X is selected from O and S;
[0158] T is selected from CH, CF and N;
[0159] T1 is selected from CH and N;
[0160] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0161] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0162] When T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0163] E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-;
[0164] n and m are independently selected from 0 and 1;
[0165] R5 is selected from H and C 1-3 alkyl;
[0166] R6 is selected from H and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0167] R7 is selected from H, F, Cl, Br, I, OH, NH2 and C1-3 alkyl;
[0168] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 alkoxy;
[0169] Each R b are independently selected from H, D and C 1-3 alkyl;
[0170] Or, 2 R b Together with their common carbon atom, they form C=O.
[0171] The present invention also provides a compound represented by formula (V), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0172] in,
[0173] X is selected from O and S;
[0174] T is selected from CH, CF and N;
[0175] T1 is selected from CH and N;
[0176] R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace;
[0177] When T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form
[0178] When T is CF or N, R3 is selected from R4 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino and -CH2-C 1-3 Alkylamino;
[0179] E and E1 are independently selected from -O- and -N(R5)-;
[0180] n and m are independently selected from 0 and 1;
[0181] R5 is selected from H and C 1-3 alkyl;
[0182] R6 is selected from H and -C 1-3 Alkyl-C 1-3 Alkylamino;
[0183] Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3alkoxy;
[0184] Each R b are independently selected from H and D;
[0185] Or, 2 R b Together with their common carbon atom, they form C=O.
[0186] In some embodiments of the present invention, the above R a are independently selected from D, F, CH3 and CD3, and other variables are as defined in the present invention.
[0187] In some embodiments of the present invention, the above R b are independently selected from H, D, F, OH, CH3 and CF3, and other variables are as defined in the present invention.
[0188] In some embodiments of the present invention, the above R2 is selected from pyrrolopyridinyl and imidazopyridinyl, and the pyrrolopyridinyl and imidazopyridinyl are optionally replaced by 1, 2 or 3 R a Replacement, R a and other variables are as defined in the present invention.
[0189] In some embodiments of the present invention, the above R2 is selected from pyrrolopyridinyl and imidazopyridinyl, and the pyrrolopyridinyl and imidazopyridinyl are optionally replaced by 1, 2 or 3 R a Substitution, other variables are as defined in the present invention.
[0190] In some embodiments of the present invention, the above R2 is selected from Other variables are as defined in the present invention.
[0191] In some embodiments of the present invention, the above R6 is selected from H, F and -CH2-N(CH3)2, and other variables are as defined in the present invention.
[0192] In some embodiments of the present invention, the above R6 is selected from H and -CH2-N(CH3)2, and other variables are as defined in the present invention.
[0193] In some embodiments of the present invention, the above R5 is selected from H, CH3, CD3, CH2CH3 and CH(CH3)2, and other variables are as defined in the present invention.
[0194] In some embodiments of the present invention, the above R7 is selected from H, F, OH, CH3 and OCH3, and other variables are as defined in the present invention.
[0195] In some embodiments of the present invention, the above T2 is selected from N, CF and CH, and other variables are as defined in the present invention.
[0196] In some embodiments of the present invention, the above T3 is selected from CH and N, and other variables are as defined in the present invention.
[0197] In some embodiments of the present invention, the above T4 is selected from CH and N, and other variables are as defined in the present invention.
[0198] In some embodiments of the present invention, the above E and E1 are independently selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)-, and -CH(OCH3)-, and other variables are as defined in the present invention.
[0199] In some embodiments of the present invention, the above-mentioned E and E1 are independently selected from -O-, -N(CH3)- and -N(CH2CH3)-, and other variables are as defined in the present invention.
[0200] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0201] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0202] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens, and the other variables are as defined herein.
[0203] In some embodiments of the present invention, the above R3 and R4 and the carbon atoms to which they are connected constitute Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens, and the other variables are as defined herein.
[0204] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0205] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Alternatively, when T is CH or N, R3 and R4 together with the carbon atom to which they are attached form Other variables are as defined in the present invention.
[0206] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0207] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0208] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Other variables are as defined in the present invention.
[0209] In some embodiments of the present invention, when T is CH or N, R3 and R4 together with the carbon atoms to which they are connected form Alternatively, when T is CH or N, R3 and R4 together with the carbon atom to which they are attached form Other variables are as defined in the present invention.
[0210] In some embodiments of the present invention, when T is CF or N, R3 is selected from R4 is selected from -CH2-N(CH3)2, and other variables are as defined herein.
[0211] Some other solutions of the present invention are obtained by any combination of the above variables.
[0212] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from,
[0213] wherein E, T1, R2 and R4 are as defined in the present invention.
[0214] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0215] Among them, E, E1, T, T1, R2, R b , m and n are as defined in the present invention.
[0216] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0217] Wherein, E, E1, T, T1, R2 and m are as defined in the present invention,
[0218] E2 is selected from N and CH.
[0219] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0220] wherein E, E1, T, T1, R2 and m are as defined in the present invention.
[0221] The present invention also provides a compound represented by the following formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0222] In some embodiments of the present invention, the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from:
[0223] The present invention also provides the use of the above compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating solid tumors.
[0224] The present invention also provides the use of the above compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating various types of tumors.
[0225] The present invention also provides the use of the above compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating HPK1 inhibitors.
[0226] The present invention also provides the following synthesis method:
[0227] Method 1:
[0228] Method 2:
[0229] Method 3:
[0230] Method 4:
[0231] Method 5:
[0232] Method 6:
[0233] Technical Effects
[0234] The compound of the present invention has excellent HPK1 kinase inhibitory activity, weakly inhibits its subtype GLK (MAP4K3), and has excellent HPK1 selectivity; the compound of the present invention has the effect of significantly increasing the IL-2 level of Jurkat cells and has excellent inhibitory activity on the phosphorylation of SLP76 in Jurkat cells; the compound of the present invention has good stability in human liver microsomes, and has good in vivo metabolic stability, excellent oral absorption drug exposure and good oral absorption bioavailability; the compound of the present invention exhibits excellent membrane permeability in cell membrane permeability studies.
[0235] Definition and Description
[0236] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.
[0237] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0238] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, which are prepared by reacting the compounds of the present invention with relatively nontoxic acids or bases, having specific substituents. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the compounds with a sufficient amount of base in neat solution or a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the compounds with a sufficient amount of acid in neat solution or a suitable inert solvent. Certain specific compounds of the present invention contain both basic and acidic functional groups and can be converted into either base or acid addition salts.
[0239] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture of the two.
[0240] Unless otherwise indicated, the term "isomer" is intended to include geometric isomers, cis-trans isomers, stereoisomers, enantiomers, optical isomers, diastereomers and tautomers.
[0241] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are encompassed within the scope of the present invention.
[0242] Unless otherwise indicated, the term "enantiomer" or "optical isomer" refers to stereoisomers that are mirror images of one another.
[0243] Unless otherwise indicated, the term "cis-trans isomers" or "geometric isomers" arises from the inability to rotate freely about double bonds or single bonds forming ring carbon atoms.
[0244] Unless otherwise indicated, the term "diastereomer" refers to stereoisomers that have two or more chiral centers and that are not mirror images of each other.
[0245] Unless otherwise indicated, "(+)" indicates dextrorotatory, "(-)" indicates levorotatory, and "(±)" indicates racemic.
[0246] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicate the relative configuration of stereocenters with a wavy line Indicates a wedge-shaped solid key or dotted wedge key Or use a wavy line Indicates a straight solid bond or straight dashed key
[0247] Unless otherwise indicated, the term "tautomer" or "tautomeric form" refers to isomers of different functional groups that are in dynamic equilibrium at room temperature and readily interconvert into each other. If tautomerism is possible (e.g., in solution), chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also called prototropic tautomers) include interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions via reorganization of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
[0248] Unless otherwise indicated, the terms "enriched in one isomer", "isomerically enriched", "enriched in one enantiomer" or "enantiomerically enriched" mean that the content of one isomer or enantiomer is less than 100%, and the content of that isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
[0249] Unless otherwise indicated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80%.
[0250] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are resolved by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).
[0251] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug biological half-life. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.
[0252] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0253] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced. Oxygen substitution does not occur on aromatic groups.
[0254] The term "optionally substituted" means that the group may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be any based on chemical feasibility.
[0255] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.
[0256] When the number of a linking group is 0, such as -(CRR)0-, it means that the linking group is a single bond.
[0257] When the number of a substituent is 0, it means that the substituent does not exist, for example, -A-(R)0 means that the structure is actually -A.
[0258] When a substituent is vacant, it means that the substituent does not exist. For example, when X in AX is vacant, it means that the structure is actually A.
[0259] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a single bond, it means that the structure is actually AZ.
[0260] When a substituent's bond can cross-link to two or more atoms in a ring, the substituent can be bonded to any atom in the ring, e.g. The substituent R can be substituted at any position on the cyclohexyl group or cyclohexadiene. When the listed substituent does not specify the atom through which it is bonded to the substituted group, the substituent can be bonded through any atom. For example, a pyridyl substituent can be bonded to the substituted group through any carbon atom on the pyridine ring.
[0261] When the listed linking groups do not specify their linking direction, their linking direction is arbitrary, for example, The connecting group L is -MW-, in which case -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form You can also connect ring A and ring B in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.
[0262] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection mode is non-positional and there are H atoms at the connectable sites, when the chemical bond is connected, the number of H atoms at the site will decrease accordingly with the number of connected chemical bonds, and become a group with a corresponding valence. The chemical bond connecting the site to other groups can be a straight solid bond. Straight dotted key or wavy lines For example, the straight solid bond in -OCH3 indicates that it is connected to other groups through the oxygen atom in the group; The straight dashed bond in the group indicates that the two ends of the nitrogen atom in the group are connected to other groups; The wavy line in the phenyl group indicates that it is connected to other groups through the carbon atoms at positions 1 and 2 in the phenyl group; Indicates that any linkable site on the piperidinyl group can be connected to other groups through a chemical bond, including at least In these four connection methods, even if an H atom is drawn on -N-, Still includes For groups connected in this way, when one chemical bond is connected, the H at that site will be reduced by one and become a corresponding monovalent piperidine group.
[0263] Unless otherwise specified, the number of atoms in a ring is generally defined as the number of members of the ring, for example, a "5-7 membered ring" refers to a "ring" having 5-7 atoms arranged around it.
[0264] Unless otherwise specified, D in the present invention represents deuterium ( 2 H).
[0265]
[0046] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0266] Unless otherwise specified, the term “C 1-3 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 Alkyl groups include C 1-2 and C 2-3 Alkyl, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine). 1- Examples of 3-alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
[0267] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. The C 1-3 Alkoxy groups include C 1-2 、C 2-3 , C3 and C2 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
[0268] Unless otherwise specified, the term “C 1-3 "Alkylamino" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via a nitrogen atom. The C 1-3 Alkylamino groups include C 1-2 , C3 and C2 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.
[0269] Unless otherwise specified, the term "5-membered and 6-membered heteroaryl" refers to a bicyclic group consisting of 5 and 6 ring atoms with a conjugated π electron system, which shares two ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). The 5- and 6-membered heteroaryl groups may be attached to the remainder of the molecule via a heteroatom or carbon atom. Examples of the 5- and 6-membered heteroaryl groups include, but are not limited to, pyrrolopyridinyl and imidazopyridinyl.
[0270] The structures of the compounds of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compounds, the absolute configuration can be confirmed by conventional techniques in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data on the cultured single crystal using a Bruker D8 venture diffractometer, using CuKα radiation as the light source and scanning mode: After scanning and collecting relevant data, the crystal structure is further analyzed using the direct method (Shelxs97) to confirm the absolute configuration.
[0271] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.
[0272] The solvent used in the present invention is commercially available.
[0273] The present invention uses the following abbreviations: DCM represents dichloromethane, EA represents ethyl acetate, PE represents petroleum ether, THF represents tetrahydrofuran, DMF represents N,N-dimethylformamide, MeOH represents methanol, AcOH represents acetic acid, MTBE represents methyl tert-butyl ether, TFA represents trifluoroacetic acid, TEA represents triethylamine, DIEA represents N,N-diisopropylethylamine, Pd(OAc)2 represents palladium(II) acetate, Pd(PPh3)4 represents tetrakis(triphenylphosphine)palladium, Pd(dppf)Cl2.CH2Cl2 represents bis(diphenylphosphino)ferrocenedichloropalladium(II)dichloromethane complex, Pd(dppf)Cl2 represents bis(diphenylphosphino)ferrocenedichloropalladium(II), Pd2(dba)3 represents trisdibenzylideneacetonedipalladium, BINAP represents 1,1'-binaphthyl-2,2'-bisdiphenylphosphine, XPhos Pd G2 represents chloro(2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)[2-(2-amino-1,1-biphenyl)]palladium(II), RuPhos Pd G2 represents chloro(2-dicyclohexylphosphino-2',6'-di-isopropyloxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II), Xantphos Pd G4 represents methanesulfonic acid(4,5-bisdiphenylphosphino-9,9-dimethylxanthene)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II), Ruphos represents 2-dicyclohexylphosphino-2',6'-diisopropyloxy-1,1'-biphenyl, Xphos represents 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl, Xantphos represents 4,5-bisdiphenylphosphino- 9,9-dimethylxanthene, Dess-Martin periodinane represents (1,1,1-triacetoxy)-1,1-dihydro-1,2-benzidoyl-3(1H)-one, Boc2O represents di-tert-butyl dicarbonate, BocNH2 represents tert-butyloxycarbonylamine, s-BuLi represents tert-butyl lithium, NaBH(OAc)3 represents sodium triacetoxyborohydride, HOBt represents 1-hydroxybenzotriazole, HATU represents 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Cs2CO3 represents cesium carbonate, and BH3.THF represents borane Tetrahydrofuran solution, TfOH represents trifluoromethanesulfonic acid, ZnBr2 represents zinc bromide, Raney-Ni represents Raney nickel, DAST represents diethylaminosulfur trifluoride, NaH represents sodium hydride, CD3I represents deuterated iodomethane, KOAc represents potassium acetate, MeI represents iodomethane, TBSCl represents tert-butyldimethylsilyl chloride, (PMB)2NH represents di(p-methoxybenzyl)amino, Boc represents tert-butyloxycarbonyl, PMB represents p-methoxybenzyl, DMB represents 2,4-dimethoxybenzyl, and Select-F represents 1-chloromethyl-4-fluoro-1,4-nitrogen Bicyclo[2.2.2]octane bis(tetrafluoroborate). prep-HPLC stands for preparative high performance liquid chromatography.
[0274] Compounds are named according to the conventional nomenclature in the art or using Software naming, commercially available compounds use supplier catalog names. BRIEF DESCRIPTION OF THE DRAWINGS
[0275] Figure 1 is the predicted binding mode of compound A to HPK1;
[0276] Figure 2 is the predicted binding mode of compound B to HPK1;
[0277] Figure 3 is the predicted binding mode of compound C to HPK1;
[0278] Figure 4 is the predicted binding mode of compound D to HPK1;
[0279] Figure 5 is the predicted binding mode of compound E to HPK1;
[0280] Figure 6 is the predicted binding mode of compound F to HPK1;
[0281] Figure 7 is the predicted binding mode of compound G to HPK1;
[0282] Figure 8 is the predicted binding mode of compound H to HPK1;
[0283] Figure 9 is the predicted binding mode of compound 1 to HPK1;
[0284] Figure 10 is the predicted binding mode of compound J to HPK1;
[0285] Figure 11 is the predicted binding mode of compound K to HPK1;
[0286] Figure 12 is the predicted binding mode of compound L to HPK1;
[0287] FIG13 is the predicted binding mode of compound M to HPK1. DETAILED DESCRIPTION
[0288] The present invention is described in detail below by examples, but it is not intended to limit the present invention in any way. The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement modes well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0289] Calculation Example 1
[0290] The molecular covalent docking process was carried out by using Maestro ( The docking was performed using Glide[1] in version 2017-2) with default options. The co-crystal structure of HPK1 (PDB ID code: 7KAC) was selected as the docking template. For protein preparation, hydrogen atoms were added using the Protein Preparation Wizard module of Maestro[2] and the OPLS3 force field was used. For ligand preparation, a 3D structure was generated and energy minimized using LigPrep[3]. The ligand mass center was generated using the 7KAC crystal structure. The docking grid was then created. The ligand was then removed and the example compound was placed in the molecular docking process. The interaction types between the protein receptor and the ligand were analyzed, and then reasonable docking conformations were selected and saved based on the calculated docking score and glide gscore values.
[0291] [1]Glide, LLC, New York, NY, 2017.
[0292] [2]Maestro, LLC, New York, NY, 2017.
[0293] [3]LigPrep, LLC, New York, NY, 2017.
[0294] Conclusion: The compounds of the present invention have good binding to HPK1 protein.
[0295] Example 1
[0296] Step 1: Synthesis of compound BB-1-2
[0297] Under nitrogen, compound BB-1-1 (3 g, 14.71 mmol, 1 eq) was dissolved in DMF (30 mL), and morpholine (2.56 g, 29.41 mmol, 2.59 mL, 2 eq) and potassium carbonate (4.06 g, 29.41 mmol, 2 eq) were added. The mixture was reacted at 100°C for 1 hour. After cooling, water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 50%) to obtain compound BB-1-2. MS m / z: 271.0, 273.0 [M+1]+ ; 1 H NMR (400MHz, DMSO-d6) δ9.84(s,1H),7.80-7.69(m,1H),7.65-7.56(m,1H),3.86-3.68(m,4H),3.21-3.07(m,4H).
[0298] Step 2: Synthesis of compound BB-1
[0299] Under nitrogen, compound BB-1-2 (2.7 g, 9.96 mmol, 1 eq) was dissolved in DCM (30 mL). Aqueous dimethylamine (1.35 g, 11.95 mmol, 1.51 mL, 40% purity, 1.2 eq), glacial acetic acid (598.06 mg, 9.96 mmol, 569.58 μL, 1 eq), and NaBH(OAc)3 (4.22 g, 19.92 mmol, 2 eq) were added and reacted at 20°C for 1 hour. Water (50 mL) was added, and the pH was adjusted to 10 with aqueous sodium hydroxide (6 M). The mixture was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound BB-1 was purified by column chromatography (ethyl acetate / petroleum ether = 50% to methanol / ethyl acetate = 0% to 16%). MS m / z: 300.1, 302.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ7.54-7.42(m,2H),3.79-3.68(m,4H),3.45(s,2H),3.04-2.92(m,4H),2.23(s,6H).
[0300] Step 3: Synthesis of compound BB-2-2
[0301] Under nitrogen, compound BB-2-1 (5 g, 36.73 mmol, 1 eq) was dissolved in DCM (50 mL), and N-bromosuccinimide (7.19 g, 40.40 mmol, 1.1 eq) was added. The reaction was stirred at 20°C for 2 hours. The reaction solution was poured into a saturated sodium thiosulfate solution (50 mL). The DCM was concentrated and homogenized for 1 hour. The mixture was filtered, and the filter cake was rinsed with water (20 mL) and dried to obtain compound BB-2-2. MS m / z: 215.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.11-8.08(m,1H),7.59(s,1H),7.29-7.27(m,1H),6.86-6.82(m,1H).
[0302] Step 4: Synthesis of compound BB-2
[0303] Under nitrogen, compounds BB-2-2 (1.7 g, 7.91 mmol, 1 eq) and BB-2-3 (4.41 g, 23.72 mmol, 4.84 mL, 3 eq) were dissolved in tetrahydrofuran (35 mL). A solution of isopropylmagnesium chloride in tetrahydrofuran (1.37 M, 11.54 mL, 2 eq) was added dropwise at 0°C. The reaction was stirred at 0°C for 2 hours. The reaction solution was poured into water (50 mL), and the aqueous phase was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound BB-2. MS m / z: 180.9 [M+1-82] + .
[0304] Step 5: Synthesis of Compound 1-3
[0305] Under nitrogen, compound 1-1 (5 g, 21.73 mmol, 1 eq) was dissolved in dioxane (50 mL), and 1-2 (8.28 g, 32.60 mmol, 1.5 eq), Pd(dppf)Cl2 (1.59 g, 2.17 mmol, 0.1 eq), and potassium acetate (4.27 g, 43.47 mmol, 2 eq) were added. The mixture was reacted at 90°C for 1 hour. After cooling, the reaction was quenched by the addition of water (100 mL). The mixture was extracted with ethyl acetate (100 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 5% to 16%) to obtain compound 1-3. MS m / z: 278.1 [M+1] + .
[0306] Step 6: Synthesis of Compound 1-5
[0307] Under nitrogen, compound 1-3 (500 mg, 1.80 mmol, 1 eq) was dissolved in dioxane (5 mL) and water (1 mL). BB-4 (472.75 mg, 1.80 mmol, 1 eq), Pd(dppf)Cl2 (132.02 mg, 180.43 μmol, 0.1 eq), and potassium carbonate (498.72 mg, 3.61 mmol, 2 eq) were added and reacted at 90°C for 2 hours. The mixture was cooled and quenched with water (5 mL). The mixture was extracted with ethyl acetate (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 50%) to obtain compound 1-5. MS m / z: 286.1 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ8.47-8.30(m,1H),7.87(s,1H),7.69(s,1H),7.52-7.38(m,2H),7.04-6.87(m,4H),3.81(s,3H).
[0308] Step 7: Synthesis of Compound 1-6
[0309] Under nitrogen, compound 1-5 (370 mg, 1.30 mmol, 1 eq) was dissolved in dioxane (10 mL). BB-1 (389.35 mg, 1.30 mmol, 1 eq), cesium carbonate (845.18 mg, 2.59 mmol, 2 eq), Xantphos (225.14 mg, 389.10 μmol, 0.3 eq), and Pd2(dba)3 (237.54 mg, 259.40 μmol, 0.2 eq) were added and reacted at 110°C for 12 hours. The mixture was cooled and quenched with water (20 mL). The mixture was extracted with ethyl acetate (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The product was separated and purified by column chromatography (ethyl acetate / methanol = 10% to 50%) to obtain compound 1-6. MS m / z: 505.2 [M+1] + .
[0310] Step 8: Synthesis of Compound 1
[0311] Under nitrogen, ammonium chloride (212.03 mg, 3.96 mmol, 10 eq) was added to a 1 M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (3.96 mL, 10 eq). Compound 1-6 (200 mg, 396.39 μmol, 1 eq) dissolved in tetrahydrofuran (2 mL) was then added and allowed to react at 20°C for 1 hour. The reaction was quenched with methanol (5 mL), and the solution was concentrated to obtain the crude product. Compound 1 was then purified by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; flowability: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 15%-55%, 8 min). MS m / z: 490.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.87-8.73(m,1H),8.71-8.56(m,1H),8.28(s,1H),7.97(s,1H),7.74(s,1H),7.71-7.61( m,2H),7.58-7.46(m,2H),7.04-6.94(m,1H),6.91-6.82(m,1H),3.79-3.71(m,4H),3.53(s,2H),3.01-2.91(m,4H),2.29(s,6H).
[0312] Example 2
[0313] Step 1: Synthesis of compound BB-3-3
[0314] Under nitrogen, compounds BB-3-1 (4.7 g, 28.29 mmol, 1 eq) and BB-3-2 (2.71 g, 31.12 mmol, 2.74 mL, 1.1 eq) were dissolved in DMF (50 mL) and stirred at 20°C for 6 minutes. The reaction solution was poured into water (500 mL) and stirred for 10 minutes before being filtered. The filter cake was rinsed with ethanol (30 mL) and dried to obtain compound BB-3-3. MS m / z: 234.2 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.46 (d, J = 2.8 Hz, 1H), 8.32-8.29 (m, 1H), 7.00 (d, J = 2.0 Hz, 1H), 3.93-3.91 (m, 4H), 3.51-3.49 (m, 4H).
[0315] Step 2: Synthesis of compound BB-3-4
[0316] To a dry argon-protected hydrogenation flask, add Raney nickel (2g, 34.08mmol, 3.97eq). Tetrahydrofuran (20mL) is slowly added along the side of the flask. Ammonia (7.28g, 51.93mmol, 8.00mL, 25% purity, 6.06eq) is then added. BB-3-3 (2g, 8.58mmol, 1eq) is then added. The hydrogen is replaced three times. The reaction is stirred at 30°C and 15 psi for 3 hours. The reaction mixture is filtered, the filter cake is rinsed with methanol (50mL), and the filtrate is concentrated to yield compound BB-3-4. MS m / z: 208.3[M+1] + ; 1H NMR (400MHz, CDCl3) δ6.99 (d, J = 8.4 Hz, 1H), 6.65 (d, J = 2.8 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 3.82 (s, 6H), 3.58 (s, 2H), 2.85-2.83 (m, 4H), 1.58 (m, 2H).
[0317] Step 3: Synthesis of compound BB-3
[0318] Under nitrogen, compound BB-3-4 (0.5 g, 2.41 mmol, 1 eq) and aqueous formaldehyde solution (391.52 mg, 4.82 mmol, 359.19 μL, 37% purity, 2 eq) were added to methanol (20 mL). Zinc chloride (164.39 mg, 1.21 mmol, 56.49 μL, 0.5 eq) and sodium cyanoborohydride (151.59 mg, 2.41 mmol, 1 eq) were then added. The mixture was allowed to react at 25°C for 12 hours. The reaction mixture was added to water (30 mL) and extracted with dichloromethane:methanol (10:1, 30 mL x 4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound BB-3. MS m / z: 236.1 [M+1] + .
[0319] Step 4: Synthesis of compound 2-2
[0320] Under nitrogen protection, a solution of n-butyllithium (2.5M, 44.32mL, 2.62eq) in tetrahydrofuran was added to tetrahydrofuran (120mL) at -78°C, and 2,2,6,6-tetramethylpiperidine (17.92g, 126.88mmol, 21.54mL, 3eq) was added dropwise. The temperature was raised to 0°C and stirred for 1 hour. The mixture was cooled to -78°C and 2-1 (10g, 42.29mmol, 1eq) dissolved in tetrahydrofuran (80mL) was added dropwise. After stirring for 1.5 hours, DMF (11.87g, 162.46mmol, 12.50mL, 3.84eq) was added. The temperature was raised to 20°C and stirred for 4 hours. The reaction mixture was poured into aqueous hydrochloric acid (50 mL, 1 M) to quench the mixture. The aqueous phase was extracted with ethyl acetate (50 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was then purified by column chromatography (ethyl acetate:petroleum ether = 10% to 33%) to obtain compound 2-2. MS m / z: 263.9 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.92 (s, 1H), 8.55 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 5.2 Hz, 1H).
[0321] Step 5: Synthesis of compound 2-4
[0322] Under nitrogen, compound 2-2 (2 g, 7.56 mmol, 1 eq) and compound 2-3 (1.09 g, 7.94 mmol, 1.03 mL, 1.05 eq) were dissolved in DCM (50 mL). Glacial acetic acid (45.41 mg, 756.26 μmol, 43.25 μL, 0.1 eq) was added and stirred at 20°C for 1 hour. NaBH(OAc)3 (3.21 g, 15.13 mmol, 2 eq) was added and stirring continued for 15 hours. The reaction solution was poured into saturated sodium bicarbonate solution (100 mL). The dichloromethane was concentrated, the aqueous phase was homogenized for 30 minutes and then filtered. The filter cake was homogenized with anhydrous ethanol (30 mL) for 30 minutes and then filtered. The filter cake was concentrated and dried to obtain compound 2-4. MS m / z: 367.0 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.72(s,1H),7.27(d,J=8.8Hz,2H),6.92(d,J=8.4Hz,2H),4.65(s,2H),4.34(s,2H),3.73(s,3H).
[0323] Step 6: Synthesis of Compound 2-5
[0324] Under nitrogen, compound 2-4 (500 mg, 1.36 mmol, 1 eq) and BB-2 (2 g, 2.29 mmol, 30% purity, 1.68 eq) were dissolved in dioxane (30 mL) and water (5 mL). Potassium phosphate (866.11 mg, 4.08 mmol, 3 eq) and Pd(dppf)Cl2 (99.52 mg, 136.01 μmol, 0.1 eq) were added, and the reaction was stirred at 50°C for 12 hours. The reaction solution was concentrated, and ethyl acetate (50 mL) and water (20 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 10% to 100%) to obtain compound 2-5. MS m / z: 423.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.65(s,1H),8.04(d,J=5.2Hz,1H),7.67(s,1H),7.35(d,J=9.2Hz ,1H),7.24(d,J=8.8Hz,2H),6.86-6.80(m,3H),4.72(s,2H),4.22(s,2H),3.78(s,3H).
[0325] Step 7: Synthesis of Compound 2-6
[0326] Under nitrogen, compound 2-5 (150 mg, 354.75 μmol, 1 eq) and BB-3 (83.48 mg, 354.75 μmol, 1 eq) were dissolved in DCM (10 mL). RuPhos Pd G2 (27.55 mg, 35.47 μmol, 0.1 eq), Ruphos (16.55 mg, 35.47 μmol, 0.1 eq), and cesium carbonate (346.75 mg, 1.06 mmol, 3 eq) were added and stirred at 110°C for 1 hour. The reaction mixture was filtered, and the filtrate was concentrated to obtain the crude product, which was separated and purified by column chromatography (dichloromethane / methanol 0% to 16%) to obtain compound 2-6. MS m / z: 622.3 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ9.20(s,1H),8.48-8.43(m,2H),7.75(m,1H),7.65(s,1H),7.51(s,1H),7.26-7.24(m,2H),7.16(s,1 H),6.96-6.95(m,1H),6.89-6.85(m,2H),4.62(s,2H),4.38(s,2H),3.75-3.69(m,9H),2.88-2.86(m,4H),2.28-2.24(m,6H).
[0327] Step 8: Synthesis of Compound 2
[0328] Compound 2-6 (130 mg, 209.10 μmol, 1 eq) was dissolved in trifluoroacetic acid (10 mL) and stirred at 130°C under microwave conditions for 16 hours. The reaction solution was concentrated and purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 10%-40%, 8 min) to obtain compound 2. MS m / z: 502.1 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ9.22(s,1H),8.91(s,1H),8.51-8.48(m,2H),7.87-7.86(m,1H),7.80(s,1H),7.61-7.60(m,1H),7.54-7.51(m ,1H),7.14-7.12(m,1H),6.97-6.96(m,1H),4.40(s,2H),3.74-3.72(m,4H),3.48-3.43(m,2H),2.88-2.86(m,4H),2.22-2.18(m,6H).
[0329] Example 3
[0330] Step 1: Synthesis of compound BB-4
[0331] Under nitrogen protection, compound BB-2-1 (4.26 g, 31.29 mmol, 1 eq) was dissolved in anhydrous N,N-dimethylformamide (40 mL) at 20°C, and N-iodosuccinimide (7.74 g, 34.42 mmol, 1.1 eq) was added. The temperature was raised to 50°C and the reaction was allowed to react for 1 hour. The reaction was quenched with saturated sodium thiosulfate solution (40 mL) and extracted with ethyl acetate (40 mL × 3). The organic phases were combined and washed with water (100 mL × 2) and saturated brine (50 mL × 2) in sequence, and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain compound BB-4. MS m / z: 263.0 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.40-8.37(m,1H),7.69(s,1H),7.55-7.52(m,1H),7.11-7.07(m,1H).
[0332] Step 2: Synthesis of compound BB-5-2
[0333] Under nitrogen, compound BB-5-1 (2.5 g, 15.67 mmol, 1 eq) was dissolved in N,N-dimethylformamide (25 mL) at 20°C. Morpholine (2.73 g, 31.34 mmol, 2.76 mL, 2 eq) and potassium carbonate (6.50 g, 47.01 mmol, 3 eq) were added, and the temperature was raised to 100°C for 2 hours. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered, and concentrated under reduced pressure. Compound BB-5-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 20%) to obtain compound BB-5-2. MS m / z: 227.0 [M+1]+ ; 1 H NMR (400MHz, DMSO-d6) δ9.87(s,1H),7.72-7.70(m,1H),7.66-7.64(m,1H),3.77-3.75(m,4H),3.13-3.11(m,4H).
[0334] Step 3: Synthesis of compound BB-5
[0335] Under nitrogen, compound BB-5-2 (1 g, 4.41 mmol, 1 eq) was dissolved in methanol (20 mL) at 0°C. Aqueous dimethylamine (1.49 g, 13.24 mmol, 1.68 mL, 40% purity, 3 eq) and glacial acetic acid (105.98 mg, 1.76 mmol, 100.93 μL, 0.4 eq) were added. After reacting at 0°C for 0.5 hour, sodium cyanoborohydride (1.11 g, 17.65 mmol, 4 eq) was added and reacted at 0°C for 1.5 hours. The reaction was quenched with water (20 mL), the solvent was concentrated under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated under reduced pressure, and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to obtain compound BB-5. MS m / z:256.2[M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ7.57(d,J=8.4Hz,1H),7.38(d,J=8.4Hz,1H),3.76-3.73(m,4H),3.45(s,2H),3.03-2.97(m,4H),2.22(s,6H).
[0336] Step 4: Synthesis of compound 3-2
[0337] Under nitrogen, compound 3-1 (300 mg, 1.61 mmol, 1 eq) was dissolved in dioxane (15 mL) and water (3 mL). Compound BB-2 (4.6 g, 2.28 mmol, 13% purity, 1.42 eq), potassium phosphate (1.02 g, 4.82 mmol, 3 eq), and XPhos Pd G2 (126.50 mg, 160.78 μmol, 0.1 eq) were added and reacted at 100°C for 2 hours. After cooling, the reaction was quenched by the addition of water (10 mL). The mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 3-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to obtain compound 3-2. MS m / z: 287.2 [M+1]+ ; 1 H NMR (400MHz, DMSO-d6) δ10.24-10.15(m,1H),8.25(s,1H),7.97(d,J=8.8Hz,1H),7. 53–7.52(m,1H),7.42(d,J=2.4Hz,1H),7.22-7.17(m,1H),6.88(s,2H),3.92(s,3H).
[0338] Step 5: Synthesis of compound 3-3
[0339] Under nitrogen, compound 3-2 (50 mg, 174.67 μmol, 1 eq) was dissolved in dioxane (2 mL). Compound BB-5 (53.60 mg, 209.60 μmol, 1.2 eq), cesium carbonate (113.82 mg, 349.33 μmol, 2 eq), BINAP (13.05 mg, 20.96 μmol, 0.12 eq), and palladium acetate (3.92 mg, 17.47 μmol, 0.1 eq) were added and reacted at 120°C for 2 hours. The mixture was cooled and quenched by the addition of water (10 mL). The mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The product was purified by preparative thin-layer chromatography (ethyl acetate / methanol / triethylamine = 80:20:0.5%) to afford compound 3-3. MS m / z:506.3[M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.22–10.18(m,1H),9.24-9.13(m,1H),8.41(s,1H),8.20(d,J=9.2Hz,1H),7.63-7.59(m ,2H),7.27–7.24(m,1H),7.23–7.05(m,1H),4.01(s,3H),3.75-3.69(m,9H),2.95–2.93(m,4H),2.40–2.38(m,4H).
[0340] Step 6: Synthesis of compound 3
[0341] Under nitrogen, a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1 M, 427.26 μL, 8 eq) was added to a mixture of compound 3-3 (27 mg, 53.41 μmol, 1 eq) and ammonium chloride (17.14 mg, 320.45 μmol, 6 eq). The mixture was allowed to react at 20°C for 1 hour. The reaction was quenched with methanol (2 mL), and the solvent was concentrated under reduced pressure to obtain the crude product. Purification by prep-HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 15%-45%, 8 min) afforded compound 3. MS m / z: 491.2 [M+1] + ; 1 H NMR(400MHz, DMSO-d6)δ11.56(s,1H),9.59–9.56(m,1H),9.36(d,J=8.8Hz,1H),8.29(s,1H),8.22–8.20(m,1H),8.08(d,J=10.0Hz,1H),8.0 1–7.99(m,1H),7.63-7.49(m,2H),7.19-7.06(m,1H),6.90(d,J=8.4Hz ,1H),3.76-3.73(m,4H),3.54(s,2H),2.96–2.94(m,4H),2.30(s,6H).
[0342] Example 4
[0343] Step 1: Synthesis of compound BB-6-2
[0344] Under nitrogen protection, compound BB-6-1 (0.5 g, 2.42 mmol, 1 eq) was dissolved in tetrahydrofuran (5 mL), cooled to -78 ° C, lithium diisopropylamide tetrahydrofuran solution (2 M, 1.45 mL, 1.2 eq) was added, and the reaction was carried out at -78 ° C for 1 hour. Carbon dioxide (1.07 g, 24.22 mmol, 10 eq) was introduced, and the temperature was raised to 25 ° C for 1 hour. Similarly, under nitrogen protection, compound BB-6-1 (8 g, 38.75 mmol, 1 eq) was dissolved in tetrahydrofuran (80 mL), cooled to -78 ° C, lithium diisopropylamide tetrahydrofuran solution (2 M, 23.25 mL, 1.2 eq) was added, and the reaction was carried out at -78 ° C for 1 hour. Carbon dioxide (17.05 g, 387.47 mmol, 10 eq) was introduced, and the temperature was raised to 25 ° C for 1 hour. The reactions were combined, quenched with saturated sodium bicarbonate (50 mL), extracted with ethyl acetate (50 mL × 2), and the organic phase was discarded. The aqueous phase was adjusted to pH 4 with hydrochloric acid (3 M, about 50 mL), extracted with dichloromethane:methanol (10:1, 100 mL × 5), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound BB-6-2. MS m / z: 250.1, 252.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.47 (s, 1H), 2.30 (s, 3H).
[0345] Step 2: Synthesis of compound BB-6-3
[0346] Under nitrogen, compound BB-6-2 (2.7 g, 10.78 mmol, 1 eq) was dissolved in DMF (27 mL), and potassium carbonate (4.47 g, 32.34 mmol, 3 eq) and iodomethane (3.06 g, 21.56 mmol, 1.34 mL, 2 eq) were added. The mixture was reacted at 25°C for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 2). The organic phases were combined and washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 5% to 10%) to obtain compound BB-6-3. MS m / z: 266.0, 263.9 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),3.97(s,3H),2.31(s,3H).
[0347] Step 3: Synthesis of compound BB-6-4
[0348] Under nitrogen, compound BB-6-3 (0.97 g, 3.67 mmol, 1 eq) was dissolved in 1,2-dichloroethane (10 mL). Azobisisobutyronitrile (60.22 mg, 366.72 μmol, 0.1 eq) and N-bromosuccinimide (1.31 g, 7.33 mmol, 2 eq) were added and reacted at 85°C for 2 hours. After cooling, the reaction solution was concentrated to obtain a crude product, which was separated and purified by column chromatography (ethyl acetate / petroleum ether = 5%) to obtain compound BB-6-4. MS m / z: 345.8, 343.8 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.76 (s, 1H), 4.60 (s, 2H), 4.00 (s, 3H).
[0349] Step 4: Synthesis of compound BB-6-5
[0350] Under nitrogen, compound BB-6-4 (0.6 g, 1.75 mmol, 1 eq) was dissolved in methanol (6 mL). A solution of ammonia (7 M, 6.00 mL, 24.04 eq) in methanol was added and the mixture was allowed to react at 25°C for 1 hour. The mixture was filtered, the filter cake was rinsed with methanol (5 mL), and dried to obtain compound BB-6-5. MS m / z: 246.9, 248.9 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.36(s,1H),8.73(s,1H),4.47(s,2H).
[0351] Step 5: Synthesis of compound BB-6
[0352] Under nitrogen, compound BB-6-5 (0.7 g, 2.83 mmol, 1 eq) was dissolved in dioxane (7 mL), and di-tert-butyl dicarbonate (925.99 mg, 4.24 mmol, 974.72 μL, 1.5 eq) and 4-dimethylaminopyridine (69.11 mg, 565.71 μmol, 0.2 eq) were added. The mixture was allowed to react at 25°C for 1 hour. The reaction solution was concentrated to obtain the crude product, which was then separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 5%) to obtain compound BB-6. MS m / z: 346.9, 348.9 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.75(s,1H),4.74(s,2H),1.54(s,9H).
[0353] Step 6: Synthesis of compound BB-7
[0354] Under nitrogen, compound BB-7-1 (2.6 g, 13.61 mmol, 1 eq) was dissolved in tetrahydrofuran (55 mL). The mixture was cooled to 0°C and added with a 1 M solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (27.23 mL, 2 eq). After stirring for 0.5 hours, di-tert-butyl dicarbonate (7.43 g, 34.03 mmol, 7.82 mL, 2.5 eq) was added. The mixture was allowed to react at 25°C for 2 hours. The reaction mixture was slowly added to a saturated aqueous ammonium chloride solution (100 mL). The organic phases were extracted with ethyl acetate (100 mL x 3) and combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound BB-7 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 2%). 1 H NMR (400MHz, CDCl3) δppm 7.99–7.95 (m, 1H) 7.14 (m, 1H) 1.48 (s, 18H).
[0355] Step 7: Synthesis of compound 4-2
[0356] Under nitrogen, compound 4-1 (5 g, 23.01 mmol, 1 eq) was added to hydrochloric acid / methanol (100 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride of compound 4-2. The hydrochloride was dissolved in methanol (10 mL) and water (10 mL), and aqueous ammonia (2 mL) was added dropwise. The pH was adjusted to 10, and the mixture was extracted with dichloromethane (50 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 4-2. 1 H NMR (400MHz, CD3OD) δppm 4.03-3.99(m,2H), 3.80-3.76(m,2H), 3.71-3.69(m,2H), 3.33(s,1H), 3.30-3.21(m,2H).
[0357] Step 8: Synthesis of compound 4-3
[0358] Under nitrogen, compound 4-2 (2.7 g, 23.05 mmol, 1 eq) was dissolved in DCM (54 mL). Triethylamine (4.66 g, 46.10 mmol, 6.42 mL, 2 eq), TBSCl (3.47 g, 23.05 mmol, 2.82 mL, 1 eq), and imidazole (1.88 g, 27.66 mmol, 1.2 eq) were added and reacted at 25°C for 2 hours. The reaction solution was added to saturated aqueous ammonium chloride (50 mL), extracted with dichloromethane (50 mL × 3), and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (dichloromethane / methanol = 0-1%) to obtain compound 4-3. 1H NMR(400MHz,CD3OD)δppm 3.81(m,1H)3.74(m,1H)3.56-3.54(m,2H)3.27–3.26(m,1H)3.24(dd,J=11.2,9.8Hz,1H)2.88-2.85(m,3H)0.92-0.91(m,9H)0.08(s,6H).
[0359] Step 9: Synthesis of compound 4-4
[0360] Under nitrogen, compound 4-3 (1.6 g, 6.91 mmol, 1 eq) and compound BB-7 (2.71 g, 6.91 mmol, 1 eq) were added to toluene (32 mL). Cesium carbonate (4.51 g, 13.83 mmol, 2 eq), Ruphos (645.29 mg, 1.38 mmol, 0.2 eq), and tris(dibenzylideneindeneacetone)dipalladium (949.73 mg, 1.04 mmol, 0.15 eq) were then added. The mixture was reacted at 100°C for 16 hours. The reaction solution was added to water (50 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 4-4 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 4%).
[0361] Step 10: Synthesis of compound 4-5
[0362] Under nitrogen, compound 4-4 (0.8 g, 1.48 mmol, 1 eq) was added to tetrahydrofuran (45 mL), followed by a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (3.69 mL, 2.5 eq). The mixture was reacted at 50°C for 3 hours, and the reaction solution was concentrated under reduced pressure. Compound 4-5 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to obtain compound 4-5. MS m / z: 408.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.02(d,J=8.2Hz,1H),6.76(d,J=8.2Hz,1H),4.34–4.32(m,1H),4.11-4.09(m,2H),3.94-3.92(m ,1H),3.74–3.73(m,1H),3.43(m,1H),3.28-3.26(m,2H),2.89–2.88(m,1H),1.49-1.45(m,18H).
[0363] Step 11: Synthesis of compound 4-6 and its trifluoroacetate salt
[0364] Compound 4-5 (0.52 g, 1.28 mmol, 1 eq) was added to DCM (12 mL) and trifluoroacetic acid (6 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the trifluoroacetic acid salt of compound 4-6. The hydrochloride was dissolved in methanol (5 mL) and water (5 mL), and ammonia (1 mL) was added dropwise. The pH was adjusted to 10 and the mixture was extracted with dichloromethane (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 4-6. MS m / z: 208.0 [M+1] + .
[0365] Step 12: Synthesis of Compound 4-7
[0366] Under nitrogen, for the first batch, compound BB-6 (0.25 g, 719.23 μmol, 1 eq) and compound 4-6 (277.27 mg, 863.08 μmol, 1.2 eq) were added to dioxane (20 mL). Cesium carbonate (703.02 mg, 2.16 mmol, 3 eq), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (62.42 mg, 107.89 μmol, 0.15 eq), and palladium acetate (16.15 mg, 71.92 μmol, 0.1 eq) were then added. The reaction was allowed to react at 110°C for 2 hours. For the second batch, the procedure for the first batch was repeated. The reaction mixtures from the two batches were combined and added to water (30 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 4-7 was separated and purified by column chromatography (EA / PE=0-30%). MS m / z: 474.0 [M+1] + .
[0367] Step 13: Synthesis of Compound 4-8
[0368] To a solution of compound 4-8a (1.3 g, 6.16 mmol) in dioxane (22 mL) were added neopentyl glycol diboronate (2.09 g, 9.24 mmol) and KOAc (1.21 g, 12.32 mmol). The atmosphere was purged with nitrogen three times, and Pd(dppf)Cl2 (676.03 mg, 923.92 μmol) was added. The mixture was reacted at 100°C for 2 hr. Water (30 mL) was added, and the mixture was extracted with EA (30 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and the concentrated crude product was dried over anhydrous sodium sulfate and purified by column chromatography to yield compound 4-8 (EA:PE: 0-20%).
[0369] Step 14: Synthesis of Compound 4-9
[0370] Under nitrogen, compound 4-7 (0.2 g, 422.02 μmol, 1 eq) and compound 4-8 (206.03 mg, 844.04 μmol, 2 eq) were added to dioxane (6 mL) and water (1.2 mL). Potassium phosphate (268.74 mg, 1.27 mmol, 3 eq) and XPhos Pd G2 (33.20 mg, 42.20 μmol, 0.1 eq) were added, and the mixture was reacted at 100°C for 2 hours. The reaction solution was added to water (30 mL), extracted with ethyl acetate (30 mL × 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. A mixture of dichloromethane:methanol (1:10, 30 mL) was added to the crude product, stirred for 0.5 hours, and filtered. The filter cake was dried to obtain compound 4-9. MS m / z: 570.2 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 10.05(s,1H)9.23(s,1H)8.35(d,J=5.0Hz,1H)7.11(d,J=5.0Hz,1H)7.00(d,J=8.4Hz,1H)6.82(m,1H)6.48(d,J=8.4Hz,1H)4.88(s ,2H)4.29(m,1H)3.97-4.13(m,2H)3.79-3.93(m,4H)3.69(m,1H)3.36(m,1H)3.20-3.29(m,1H)3.15(m,1H)2.77(m,1H)1.54(s,9H).
[0371] Step 14: Synthesis of Compound 4 and its trifluoroacetate salt
[0372] Compound 4-9 (180 mg, 316.01 μmol) was added to DCM (0.5 mL) and trifluoroacetic acid (0.25 mL) and reacted at 25°C for 2 hours. After concentration under reduced pressure, 20 mL of dichloromethane was added to dissolve the mixture, which was then poured into 30 mL of sodium bicarbonate aqueous solution and extracted with dichloromethane (30 mL x 3). The combined organic phases were concentrated under reduced pressure, and 10 mL of water was added, stirred for 0.5 hours, filtered, and the filter cake dried under reduced pressure to obtain compound 4. MS m / z: 470.1 [M+1] + .
[0373] Compound 4-9 (5 mg, 8.78 μmol, 1 eq) was added to dichloromethane (0.5 mL) and trifluoroacetic acid (0.25 mL) and reacted at 25°C for 2 hours. The mixture was concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 4. MS m / z: 470.1 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δppm9.85(s,1H)9.45(s,1H)9.15(s,1H)8.35(d,J=5.0H z,1H)7.56(d,J=3.4Hz,1H)7.37(d,J=5.0Hz,1H)7.32(d,J=8.6Hz,1H)6.92(d,J =3.4Hz,1H)6.69(d,J=8.4Hz,1H)4.71(s,2H)4.36-4.44(m,1H)3.90-4.01(m,2H )3.87(s,3H)3.55-3.63(m,2H)3.17-3.25(m,1H)3.02-3.11(m,1H)1.24(s,2H).
[0374] Example 5
[0375] Step 1: Synthesis of compound 5-2
[0376] Under nitrogen, compound 5-1 (2 g, 9.25 mmol) was dissolved in DCM (40 mL) and a solution of triethylamine (1.87 g, 18.49 mmol, 2.57 mL), TBSCl (2.09 g, 13.87 mmol, 1.70 mL), and 4-dimethylaminopyridine (112.97 mg, 924.74 μmol, 0.1 eq) was added. The mixture was stirred at 20°C for 16 hours. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (dichloromethane / methanol = 5% to 10%) to afford compound 5-2. 1 H NMR (400MHz, CD3OD) δppm 3.88-4.12(m,2H)3.63(d,J=5.6Hz,2H)3.01(d,J=12.2Hz,1H)2.54-2.94(m,4H)1.48(s,9H)0.95(s,9H)0.12(s,6H).
[0377] Step 2: Synthesis of compound 5-4
[0378] Under nitrogen, cesium carbonate (197.15 mg, 605.08 μmol), Ruphos (14.12 mg, 30.25 μmol), compound 5-2 (0.1 g, 302.54 μmol), compound 5-3 (70.80 mg, 302.54 μmol), and tris(dibenzylideneindeneacetone)dipalladium (55.41 mg, 60.51 μmol) were added to a toluene (4 mL) solution and stirred at 100°C for 24 hours. The reaction solution was filtered under reduced pressure, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (ethyl acetate / petroleum ether = 16%) to obtain compound 5-4. MS m / z: 484.3 [M+1] + ;
[0379] Step 3: Synthesis of compound 5-5
[0380] Tetrabutylammonium bromide (1M, 258.45 μL) and compound 5-4 (50 mg, 103.38 μmol) were added to tetrahydrofuran (4 mL) and stirred at 25°C for 16 hours. The reaction solution was concentrated under reduced pressure to obtain compound 5-5. MS m / z: 350.2 [M+1] + .
[0381] Step 4: Synthesis of Compound 5-6
[0382] Lithium hydroxide monohydrate (288.26 mg, 6.87 mmol) and compound 5-5 (0.4 g, 1.14 mmol) were added to a mixture of tetrahydrofuran (6 mL), methanol (3 mL), and water (3 mL). The mixture was stirred at 25°C for 0.5 hours. The reaction mixture was concentrated under reduced pressure to obtain compound 5-6. MS m / z: 336.2 [M+1] + .
[0383] Step 5: Synthesis of Compounds 5-7
[0384] Compound 5-6 (0.4 g, 1.19 mmol) and triethylamine (241.39 mg, 2.39 mmol, 332.04 μL) were added to toluene (6 mL). Water (85.95 mg, 4.77 mmol, 85.95 μL) was then added to the reaction solution. Diphenylphosphoryl azide (656.50 mg, 2.39 mmol, 516.93 μL) was then added to the reaction solution. The reaction was stirred at 90°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain compound 5-7. MS m / z: 307.0 [M+1] + .
[0385] Step 6: Synthesis of Compound 5-9
[0386] Under nitrogen protection, compound 5-7 (20 mg, 57.70 μmol), di-tert-butyl[2,4,6-tris(propan-2-yl)-[1,1-biphenyl]-2-yl]phosphane (5.50 mg, 11.54 μmol), and 5-8 (26.52 mg, 86.55 μmol) were added to dioxane (3 mL). Palladium acetate (1.30 mg, 5.77 μmol) was added to the reaction solution, and then cesium carbonate (56.40 mg, 173.10 μmol) was added to the reaction solution. The reaction was stirred at 90°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated by column chromatography (methanol / ethyl acetate = 10%) to obtain compound 5-9. MS m / z: 572.1 [M+1] + .
[0387] Step 7: Synthesis of Compounds 5-10
[0388] Under nitrogen, compound 5-9 (10.00 mg, 17.48 μmol) and compound 4-8 (6.15 mg, 34.96 μmol) were added to dioxane (2 mL). Potassium phosphate (11.13 mg, 52.44 μmol) was added to the reaction solution, followed by XPhos Pd G2 (1.38 mg, 1.75 μmol). The reaction was stirred at 100°C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was separated by column chromatography (ethyl acetate / petroleum ether = 50%) to obtain compound 5-10. MS m / z: 668.1 [M+1] + .
[0389] Step 8: Synthesis of compound 5
[0390] Compound 5-10 (6 mg, 8.99 μmol) was added to DCM (2 mL), and trifluoroacetic acid (2.05 mg, 17.97 μmol, 1.33 μL) was added to the reaction mixture. The mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was then separated by column chromatography (ethyl acetate / petroleum ether = 50%) to obtain compound 5. MS m / z: 468.0 [M+1] + ; 1H NMR(400MHz,CD3OD)δppm 8.41(d,J=8.6Hz,1H)8.25(d,J=5.4Hz,1H)7.65(d,J=8.6Hz,1H)7.41(d,J=3.6Hz,1H)7.23-7.33(m,2H)6.55-6.61(m,1H)6.49(d,J=3.6 Hz,1H)4.39(s,2H)4.12(m,1H)3.93(d,J=14.8Hz,1H)3.86(s,3H)3.34-3.43(m,2H)2.82-2.93(m,2H)1.93(d,J=4.2Hz,1H)1.49(s,2H).
[0391] Example 6
[0392] Step 1: Synthesis of compound 6
[0393] Compound 5 (8.00 mg, 17.11 μmol) was added to methanol (5 mL), followed by triethylamine (5.19 mg, 51.33 μmol, 7.15 μL) and aqueous acetaldehyde (9.42 mg, 85.56 μmol, 12.00 μL, 40% purity). The reaction was stirred for 10 minutes, and NaBH(OAc)3 (5.44 mg, 25.67 μmol) was added. The reaction was stirred at 25°C for 1 hour. The reaction solution was quenched with water (5 mL) and then extracted with dichloromethane (10 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by preparative thin-layer chromatography on silica gel (ethyl acetate / methanol = 1:1, v% = 0.5% triethylamine) to obtain compound 6. MS m / z: 496.2 [M+1] + ; 1 H NMR(400MHz,CD3OD)δppm 8.52(d,J=8.6Hz,1H)8.35(d,J=5.4Hz,1H)7.75(d,J=8.6Hz,1H)7.40-7.54(m,2H)7 .30(d,J=5.2Hz,1H)6.70(d,J=8.2Hz,1H)6.55(d,J=3.6Hz,1H)4.53(m,1H)4.49(s, 2H)4.21-4.30(m,1H)4.12(d,J=13.2Hz,1H)3.96(s,3H)3.74(t,J=12.6Hz,2H)3.50 (s,1H)3.40-3.44(m,2H)3.11-3.27(m,1H)2.93-3.04(m,2H)1.44(t,J=7.4Hz,3H).
[0394] Example 7
[0395] Step 1: Synthesis of compound 7-2
[0396] Under nitrogen, compound 7-1 (200 mg, 1.07 mmol, 1 eq) was dissolved in dioxane (5 mL), and compound BB-1 (321.76 mg, 1.07 mmol, 1 eq), cesium carbonate (698.45 mg, 2.14 mmol, 2 eq), Xantphos (186.06 mg, 321.55 μmol, 0.3 eq), and Pd2(dba)3 (196.30 mg, 214.37 μmol, 0.2 eq) were added. The mixture was reacted at 110°C for 2 hours. After cooling, water (10 mL) was added, and extraction was performed with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 7-2 was purified by column chromatography (methanol / ethyl acetate = 0% to 33%) to obtain compound 7-2. MS m / z: 406.1 [M+1] + .
[0397] Step 2: Synthesis of compound 7-3
[0398] Under nitrogen, compound 7-2 (90 mg, 221.74 μmol, 1 eq) was dissolved in dioxane (2 mL) and water (0.4 mL). Compound 4-8 (64.95 mg, 266.09 μmol, 1.2 eq), potassium carbonate (76.62 mg, 554.35 μmol, 2.5 eq), and Pd(dppf)Cl2 (14.45 mg, 22.17 μmol, 0.1 eq) were added and reacted at 100°C for 2 hours. After cooling, the reaction solution was separated by TLC (ethyl acetate / methanol = 1:1, v% = 0.5% triethylamine) to obtain compound 7-3. MS m / z: 502.4 [M+1] + .
[0399] Step 3: Synthesis of compound 7
[0400] Under nitrogen, a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1 M, 1.28 mL, 8 eq) was added to a mixture of compound 7-3 (80 mg, 159.50 μmol, 1 eq) and ammonium chloride (51.19 mg, 956.98 μmol, 6 eq). The mixture was allowed to react at 20°C for 0.5 h. The reaction was quenched with methanol (3 mL), and the solvent was concentrated under reduced pressure to obtain the crude product. Purification by prep-HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 μm, mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 15%-45%, 8 min) afforded compound 7. MS m / z: 487.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.67(s,1H),10.09(s,1H),8.63(s,1H),8.35(d,J=5.2Hz,1H),8.28(s,1H),7.97(s,1H),7.66(d,J=4.8Hz,1H),7. 60-7.52(m,2H),7.11(d,J=3.6Hz,1H),6.95(d,J=8.8Hz,1H),3.87(s,3H),3.77-3.72(m,4H),3.55(s,2H),3.01-2.91(m,4H),2.30(s,6H).
[0401] Example 8
[0402] Step 1: Synthesis of compound 8-2
[0403] Under nitrogen, compound 5-8 (300 mg, 865.54 μmol, 1 eq) was dissolved in dioxane (10 mL). Compound 4-6 (trifluoroacetic acid salt) (452.10 mg, 1.04 mmol, 2.52 eq), cesium carbonate (1.13 g, 3.46 mmol, 4 eq), Xantphos (75.12 mg, 129.83 μmol, 0.15 eq), and palladium acetate (19.43 mg, 86.55 μmol, 0.1 eq) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 8-1 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 40%) to obtain compound 8-1. MS m / z: 473.1 [M+1] + ; 1H NMR(400MHz, CDCl3)δ9.46(s,1H),8.58(d,J=8.8Hz,1H),7.42(d,J=8.8Hz,1H),7 .05(d,J=8.4Hz,1H),6.47(d,J=8.4Hz,1H),4.67(s,2H),4.36-4.33(m,1H),4.20- 4.10(m,1H),4.09-4.02(m,1H),3.94-3.91(m,1H),3.79-3.72(m,1H),3.41(d,J=1 1.6Hz,1H),3.36-3.26(m,1H),3.23-3.14(m,1H),2.85-2.79(m,1H),1.63(s,9H).
[0404] Step 2: Synthesis of compound 8-2
[0405] Under nitrogen, compound 8-1 (211 mg, 446.16 μmol, 1 eq) was dissolved in dioxane (5 mL), and compound 1-2 (339.89 mg, 1.34 mmol, 3 eq), potassium acetate (131.36 mg, 1.34 mmol, 3 eq), Xphos (42.54 mg, 89.23 μmol, 0.2 eq), and XPhos Pd G2 (35.10 mg, 44.62 μmol, 0.1 eq) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled, filtered, washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure. Compound 8-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to give compound 8-2. MS m / z: 565.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.57(s,1H),8.26(d,J=8.8Hz,1H),7.76(d,J=8.4Hz,1H ),7.29(d,J=8.4Hz,1H),6.69(d,J=8.4Hz,1H),4.75(s,2H),4.39-4.35(m,1H), 4.07-4.02(m,1H),4.00-3.93(m,1H),3.91-3.89(m,1H),3.64-3.57(m,2H),3.2 3-3.14(m,1H),3.10-3.00(m,1H),2.67-2.61(m,1H),1.53(s,9H),1.30(s,12H).
[0406] Step 3: Synthesis of compound 8-3
[0407] Under nitrogen, compound 8-2 (107 mg, 189.57 μmol, 1 eq) was dissolved in dioxane (5 mL) and water (1 mL). Compound BB-2-2 (48.91 mg, 227.48 μmol, 1.2 eq), potassium phosphate (80.48 mg, 379.14 μmol, 2 eq), and XPhos Pd G2 (14.92 mg, 18.96 μmol, 0.1 eq) were added and reacted at 100°C for 2 hours. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (10 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain compound 8-3. MS m / z: 573.4 [M+1] + .
[0408] Step 4: Synthesis of compound 8
[0409] Under nitrogen, compound 8-3 (201 mg, 351.04 μmol, 1 eq) was dissolved in DCM (4 mL) and trifluoroacetic acid (3.08 g, 27.01 mmol, 2 mL, 76.95 eq) was added. The mixture was reacted at 20°C for 2 hours. The solvent was concentrated under reduced pressure to obtain the crude product. Compound 8 was purified by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 15%-50%, 8 min). MS m / z: 473.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ9.77(s,1H),8.75(s,1H),8.48(d,J=8.4Hz,1H),8.43-8 .39(m,1H),7.80(s,1H),7.68(d,J=8.8Hz,1H),7.53-7.50(m,1H),7.28(d,J=8. 4Hz,1H),6.98-6.94(m,1H),6.59(d,J=8.4Hz,1H),4.36(s,3H),4.07-3.84(m,3 H),3.66-3.53(m,2H),3.23-3.14(m,1H),3.07-2.98(m,1H),2.69-2.64(m,1H).
[0410] Example 9
[0411] Step 1: Synthesis of the hydrochloride salt of compound BB-8-2
[0412] Under nitrogen, compound BB-8-1 (5 g, 23.01 mmol, 1 eq) was added to a hydrochloric acid / methanol solution (4 M, 100.00 mL, 17.38 eq) and reacted at 20°C for 2 hours. The solvent was concentrated under reduced pressure to obtain the hydrochloride salt of BB-8-2. 1 H NMR (400MHz, DMSO-d6) δ9.50(s,1H),9.27-9.06(m,1H),3.97-3.81(m,2H),3.73-3.47(m,4H),3.28-2.96(m,3H).
[0413] Step 2: Synthesis of compound BB-8-3
[0414] Under nitrogen, the hydrochloride salt of compound BB-8-2 (2.7 g, 23.05 mmol, 1 eq) was added to DCM (54 mL). Triethylamine (7.00 g, 69.14 mmol, 9.62 mL, 3 eq), imidazole (1.88 g, 27.66 mmol, 1.2 eq), and TBSCl (4.17 g, 27.66 mmol, 3.39 mL, 1.2 eq) were added and reacted at 20°C for 16 hours. The reaction was quenched with saturated aqueous ammonium chloride (40 mL) and extracted with dichloromethane (50 mL × 3). The organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. The product was separated and purified by column chromatography (methanol / dichloromethane = 0-10%) to obtain compound BB-8-3. 1 H NMR (400MHz, CDCl3) δ3.81-3.77(m,2H),3.60-3.41(m,3H),3.26-3.23(m,1H),3.02-2.80(m,3H),1.96(s,1H),0.90(s,9H),0.06(s,6H).
[0415] Step 3: Synthesis of compound BB-8-4
[0416] Under nitrogen, compound BB-7 (1.7 g, 4.35 mmol, 1 eq) was dissolved in toluene (34 mL). Compound BB-8-3 (1.01 g, 4.35 mmol, 1 eq), cesium carbonate (2.83 g, 8.69 mmol, 2 eq), Ruphos (405.53 mg, 869.05 μmol, 0.2 eq), and Pd2(dba)3 (596.85 mg, 651.79 μmol, 0.15 eq) were added and reacted at 100°C for 16 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (30 mL). The filtrate was concentrated under reduced pressure. Compound BB-8-4 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 10%) to obtain compound BB-8-4. MS m / z: 542.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ7.57-7.52(m,1H),7.20(d,J=8.0Hz,1H),3.93-3.77(m,3H),3.76-3.69(m,1H),3.66 -3.48(m,3H),3.29(s,1H),2.94(d,J=12.4Hz,1H),1.38(s,18H),0.77(s,9H),-0.07-0.10(d,J=9.6Hz,6H).
[0417] Step 4: Synthesis of compound BB-8-5
[0418] Under nitrogen, compound BB-8-4 (484 mg, 893.44 μmol, 1 eq) was dissolved in tetrahydrofuran (10 mL). A solution of tetrabutylammonium fluoride in tetrahydrofuran (1 M, 3.69 mL, 2.5 eq) was added and the mixture was allowed to react at 50°C for 16 hours. The reaction mixture was cooled and concentrated under reduced pressure. Compound BB-8-5 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to obtain compound BB-8-5. MS m / z: 408.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ7.24(d,J=8.0Hz,1H),6.79(d,J=8.0Hz,1H),4.37-4.34(m,1H),4.07-3.95( m,2H),3.89(d,J=8.4Hz,1H),3.64-3.52(m,2H),3.21-3.07(m,2H),2.75-2.65(m,1H),1.39(s,18H).
[0419] Step 5: Synthesis of trifluoroacetate salt of compound BB-8
[0420] Under nitrogen, compound BB-8-5 (269 mg, 660.19 μmol, 1 eq) was dissolved in DCM (5 mL), and trifluoroacetic acid (3.95 g, 34.67 mmol, 2.57 mL, 52.51 eq) was added. The mixture was reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the trifluoroacetate salt of compound BB-8. MS m / z: 208.1 [M+1] + .
[0421] Step 6: Synthesis of compound 9-1
[0422] Under nitrogen, compound 5-8 (165 mg, 476.05 μmol, 1 eq) was dissolved in dioxane (5 mL). Compound BB-8 trifluoroacetate (248.65 mg, 571.26 μmol, 1.2 eq), cesium carbonate (620.42 mg, 1.90 mmol, 4 eq), Xantphos (41.32 mg, 71.41 μmol, 0.15 eq), and palladium acetate (10.69 mg, 47.60 μmol, 0.1 eq) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure. Compound 9-1 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 35%) to obtain compound 9-1. MS m / z: 473.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.28(s,1H),8.40(d,J=8.8Hz,1H),7.59(d,J=8.8Hz,1H),7.28(d,J=8.4Hz,1H),6.67(d,J=8.4Hz,1H),4.69( s,2H),4.37-4.34(m,1H),4.04-3.86(m,3H),3.64-3.53(m,2H),3.23-3.13(m,1H),3.09-2.98(m,1H),2.71-2.63(m,1H),1.53(s,9H).
[0423] Step 7: Synthesis of compound 9-2
[0424] Under nitrogen, compound 9-1 (170 mg, 359.47 μmol, 1 eq) was dissolved in dioxane (4 mL), and compound 1-2 (273.85 mg, 1.08 mmol, 3 eq), potassium acetate (105.83 mg, 1.08 mmol, 3 eq), XPhos (34.27 mg, 71.89 μmol, 0.2 eq), and XPhos Pd G2 (28.28 mg, 35.95 μmol, 0.1 eq) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure. Compound 9-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 35%) to obtain compound 9-2. MS m / z: 565.2 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ9.76(s,1H),8.42(d,J=8.8Hz,1H),7.89(d,J=8.4Hz,1H),7.05( d,J=8.4Hz,1H),6.52(d,J=8.4Hz,1H),4.86(s,2H),4.36-4.33(m,1H),4.19-4.11(m, 1H),4.09-4.05(m,1H),3.94-3.90(m,1H),3.79-3.72(m,1H),3.41(d,J=12.0Hz,1H), 3.34-3.26(m,1H),3.23-3.14(m,1H),2.90-2.76(m,1H),1.64(s,9H),-1.33(s,12H).
[0425] Step 8: Synthesis of compound 9-3
[0426] Under nitrogen, compound 9-2 (134 mg, 237.41 μmol, 1 eq) was dissolved in dioxane (5 mL) and water (1 mL). Compound BB-2-2 (61.26 mg, 284.89 μmol, 1.2 eq), potassium phosphate (100.79 mg, 474.81 μmol, 2 eq), and XPhos Pd G2 (18.68 mg, 23.74 μmol, 0.1 eq) were added and reacted at 100°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (10 mL). The filtrate was concentrated under reduced pressure. Compound 9-3 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 70%) to obtain compound 9-3. MS m / z: 573.4 [M+1] + .
[0427] Step 9: Synthesis of Compound 9 and its trifluoroacetate salt
[0428] Under nitrogen, compound 9-3 (125 mg, 218.31 μmol, 1 eq) was dissolved in DCM (4 mL) and trifluoroacetic acid (3.08 g, 27.01 mmol, 2 mL, 76.95 eq) was added. The mixture was allowed to react at 20°C for 2 hours. The solvent was concentrated under reduced pressure to obtain the crude product, which was then purified by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 20%-50%, 8 min). Compound 9 was obtained. MS m / z: 473.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.77 (s, 1H), 8.75 (s, 1H), 8.48 (d, J = 8.4Hz, 1H), 8.43-8. 39(m,1H),7.80(s,1H),7.67(d,J=8.8Hz,1H),7.53-7.50(m,1H),7.28(d,J=8.4H z,1H),6.98-6.94(m,1H),6.59(d,J=8.4Hz,1H),4.40-4.31(m,3H),4.07-3.86(m ,3H),3.66-3.52(m,2H),3.25-3.14(m,1H),3.09-2.99(m,1H),2.68-2.64(m,1H).
[0429] Under nitrogen, compound 9-3 (0.4 g, 698.59 μmol) was dissolved in DCM (10 mL) and trifluoroacetic acid (5 mL) was added. The mixture was allowed to react at 25°C for 2 hours. The solvent was concentrated under reduced pressure to obtain the crude product, which was then purified by prep-HPLC (column: Phenomenex Luna 80*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; B%: 10%-35%, 8 min) to obtain the trifluoroacetate salt of compound 9. MS m / z: 473.1 [M+1] +; 1H NMR (400MHz, DMSO-d6) δppm 9.82(s,1H)8.81(s,1H)8.66(dd,J=7.44,5.32Hz,1H)8.52(d,J=8.64Hz,1H)8.25(s ,1H)7.92(dd,J=8.76,2.24Hz,1H)7.72(d,J=8.62Hz,1H)7.39-7.38(m,1H)7.30(d,J =8.50Hz,1H)6.62(d,J=8.38Hz,1H)4.39-4.36(m,3H)4.07-4.04(m,2H)3.91(dd,J=1 0.94,2.80Hz,1H)3.61-3.56(m,2H)3.20-3.17(m,1H)3.04(s,1H)2.66-2.65(m,1H).
[0430] Example 10
[0431] Step 1: Synthesis of compound 10-3
[0432] Under nitrogen, compound 10-1 (0.7 g, 2.48 mmol, 1 eq) was dissolved in dioxane (6 mL) and water (1.2 mL). 10-2 (1.24 g, 4.95 mmol, 2 eq), XPhos Pd G2 (194.81 mg, 247.59 μmol, 0.1 eq), and potassium phosphate (1.05 g, 4.95 mmol, 2 eq) were added and reacted at 100°C for 1 hour. The mixture was cooled, water (5 mL) was added, and extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 10-3 was purified by column chromatography (ethyl acetate / petroleum ether = 50% to 100%) to obtain compound 10-3. MS m / z: 371.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.63(s,1H),7.19-7.07(m,1H),6.72-6.62(m,1H),6.49(s,2H),3.81(s,3H),3.29(s,2H),2.15(s,3H),1.43(s,9H).
[0433] Step 2: Synthesis of compound 10-4
[0434] Under nitrogen, compound 10-3 (0.2 g, 539.95 μmol, 1 eq) was dissolved in dioxane (10 mL). BB-1 (194.51 mg, 647.95 μmol, 1.2 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (46.86 mg, 80.99 μmol, 0.15 eq), palladium acetate (12.12 mg, 54.00 μmol, 0.1 eq), and cesium carbonate (527.78 mg, 1.62 mmol, 3 eq) were added and reacted at 100°C for 1 hour. The mixture was cooled, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 10-4. MS m / z: 590.3 [M+1] + .
[0435] Step 3: Synthesis of compound 10
[0436] Under nitrogen, compound 10-4 (0.4 g, 678.33 μmol, 1 eq) was dissolved in a hydrochloric acid / methanol solution (40 mL) and reacted at 25°C for 2 hours. The reaction system was concentrated under reduced pressure to obtain a crude product, which was then purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 10%-60%, 8 min) to obtain compound 10. MS m / z: 490.4 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 9.76 (s, 1H) 8.86 (d, J = 8.6Hz, 1H) 8.72 (s, 1H) 7.43 (d, J=8.6Hz,1H)7.31(s,1H)6.84(d,J=8.6Hz,1H)6.07(s,1H)4.24-4.20(m,1H)4.07-4.03(m,1H)3 .95(s,3H)3.89-3.88(m,4H)3.87-3.73(m,2H)3.30-3.01(m,4H)2.98(s,6H)2.44-2.34(m,3H).
[0437] Example 11 and Example 12
[0438] Step 1: Synthesis of compound BB-9
[0439] Compound BB-7 (8 g, 20.45 mmol, 1 eq) was dissolved in dioxane (120 mL), and diboronic acid pinacol ester (7.79 g, 30.67 mmol, 1.5 eq), potassium acetate (4.01 g, 40.90 mmol, 2 eq), and Pd(dppf)Cl2.CH2Cl2 (1.67 g, 2.04 mmol, 0.1 eq) were added. The mixture was reacted at 120°C for 12 hours. The mixture was cooled, filtered, and the filtrate was poured into water (200 mL). The mixture was extracted with ethyl acetate (200 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound BB-9 was purified by column chromatography (petroleum ether:ethyl acetate = 0% to 4%) to obtain compound BB-9. MS m / z: 200.8 [M-238] + .
[0440] Step 2: Synthesis of compound 11-2
[0441] Compound 11-1 (3 g, 18.97 mmol, 1 eq) was added to tetrahydrofuran (45 mL). The temperature was cooled to 0°C, followed by the addition of sodium hydride (1.14 g, 28.45 mmol, 60% purity, 1.5 eq). After stirring for 0.5 hours, N-phenylbis(trifluoromethanesulfonyl)imide (8.13 g, 22.76 mmol, 1.2 eq) was added. The temperature was raised to 25°C, and the reaction was allowed to proceed for 12 hours. The reaction solution was slowly added to saturated aqueous ammonium chloride (100 mL), extracted with ethyl acetate (100 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. Compound 11-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 4%) to afford compound 11-2. 1 H NMR (400MHz, CDCl3) δppm 4.38 (t, J = 2.6 Hz, 2H) 3.82 (t, J = 5.6z, 2H) 3.75 (s, 3H) 2.49–2.45 (m, 2H).
[0442] Step 3: Synthesis of Compound 11-3
[0443] Compound 11-2 (2.5 g, 8.61 mmol, 1 eq) and BB-9 (5.85 g, 13.35 mmol, 1.55 eq) were added to dioxane (50 mL) and water (10 mL). Potassium phosphate (5.49 g, 25.84 mmol, 3 eq) and XPhos Pd G2 (677.78 mg, 861.44 μmol, 0.1 eq) were added, and the mixture was reacted at 100°C for 12 hours. The reaction solution was added to water (100 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 11-3 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 5%) to obtain compound 11-3. MS m / z: 353.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.72(d,J=8.0Hz,1H)7.45(t,J=8.8Hz,1H)7.01(s,1H)4.39(s,2H)3.82(t,J=5.4Hz,2H)3.50(s,3H)2.40(s,2H)1.45(s,9H).
[0444] Step 4: Synthesis of compound 11-4
[0445] Compound 11-3 (1.2 g, 3.41 mmol, 1 eq) was added to tetrahydrofuran (24 mL). The mixture was cooled to 0°C and then lithium aluminum tetrahydride (323.15 mg, 8.51 mmol, 2.5 eq) was added and allowed to react for 2 hours. Water was added dropwise to the reaction solution until the reaction was completely quenched. The mixture was then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 11-4. MS m / z: 325.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.74-7.72 (m 1H) 7.53-7.48 (m 1H)7.04(s,1H)4.30(t,J=2.2Hz,2H)3.90-3.88(m,2H)3.84-3.82(m,2H)2.30(s,2H)1.45(s,9H).
[0446] Step 5: Synthesis of compound 11-5
[0447] Compound 11-4 (0.9 g, 2.77 mmol, 1 eq) was added to tetrahydrofuran (20 mL), cooled to 0°C, and sodium hydride (221.96 mg, 5.55 mmol, 60% purity, 2 eq) was added. The mixture was stirred for 0.5 hours and then heated to 50°C for 2 hours. After the reaction, the reaction mixture was slowly added to saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain compound 11-5. MS m / z: 305.1 [M+1] + .
[0448] Step 6: Synthesis of compound 11-6
[0449] Palladium / carbon (0.5 g, 10% purity) was added to a dry hydrogenation flask, followed by methanol (30 mL) and compound 11-6 (0.8 g, 2.63 mmol, 1 eq). The mixture was reacted at 30°C under hydrogen (15 psi) for 2 hours. The filtrate was filtered, concentrated under reduced pressure, and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 10%) to obtain compound 11-6. MS m / z: 307.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.43-7.42(m,1H)7.35-7.33(m,1H)6.94(s,1H)4.45-4.39(m,1H)4.24-4.21(m,1H)3.77- 3.74(m,3H)3.50–3.47(m,1H)2.93(m,1H)2.15-2.13(m,1H)1.88-1.79(m,2H)1.45(s,9H).
[0450] Step 7: Synthesis of the hydrochloride salt of compound 11-7
[0451] Compound 11-6 (0.78 g, 2.55 mmol, 1 eq) was added to hydrochloric acid / methanol (4 M, 2 mL) and reacted at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride salt of compound 11-7. MS m / z: 207.0 [M+1] + .
[0452] Step 8: Synthesis of compound 11-8
[0453] Compound 5-8 (0.45 g, 1.30 mmol, 1 eq) and the hydrochloride of compound 11-7 (378.12 mg, 1.56 mmol, 1.20 eq) were added to dioxane (20 mL), followed by cesium carbonate (1.69 g, 5.19 mmol, 4 eq), Xantphos (112.68 mg, 194.75 μmol, 0.15 eq), and Pd2(dba)3 (118.89 mg, 129.83 μmol, 0.1 eq). The mixture was reacted at 100°C for 12 hours. The reaction solution was added to water (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 25%) to obtain compound 11-8. MS m / z: 472.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δppm 9.48(s,1H)8.64(d,J=9.0Hz,1H)7.65(d,J=8.8Hz,1H)7.56(d,J=8.2Hz,1H)6.65(d,J=8.0Hz,1H)4.71(s,2H)4.37 -4.28(m,2H)3.75-3.68(m,3H)3.47–3.46(m,1H)3.03–3.00(m,1H)2.14-2.10(m,1H)1.85-1.82(m,2H)1.54(s,9H).
[0454] Step 9: Synthesis of compound 11-9
[0455] Compound 11-8 (0.25 g, 529.74 μmol, 1 eq) and bis(triisopropyl)-1-naphthalene boronic acid (403.56 mg, 1.59 mmol, 3 eq) were added to dioxane (10 mL). Potassium acetate (155.97 mg, 1.59 mmol, 3 eq), XPhos Pd G2 (41.68 mg, 52.97 μmol, 0.1 eq), and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (50.51 mg, 105.95 μmol, 0.2 eq) were then added. The mixture was reacted at 110°C for 3 hours. The reaction solution was added to water (40 mL) and extracted with ethyl acetate (40 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 25%) to obtain compound 11-9. MS m / z:564.3[M+1] + .
[0456] Step 10: Synthesis of compound 11-10
[0457] Compound 11-9 (275.14 mg, 488.32 μmol, 1.5 eq) and compound BB-2-2 (70 mg, 325.55 μmol, 1 eq) were added to dioxane (10 mL) and water (2 mL). XPhos Pd G2 (25.61 mg, 32.55 μmol, 0.1 eq) and potassium phosphate (207.31 mg, 976.64 μmol, 3 eq) were added and reacted at 105°C for 4 hours. The reaction solution was added to water (40 mL) and extracted with ethyl acetate (40 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 11-10 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 11-10. MS m / z: 572.2 [M+1] + .
[0458] Step 11: Synthesis of trifluoroacetate salts of compound 11 and 12
[0459] Compound 11-10 (0.15 g, 262.42 μmol, 1 eq) was added to DCM (10 mL) and trifluoroacetic acid (5 mL), and the reaction was carried out at 25° C. for 2 hours. The reaction solution was concentrated under reduced pressure and separated by SFC (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [0.1% NH3H2O IPA]; B%: 58%-58%, 16 min). The resolved products were concentrated and 5 drops of trifluoroacetic acid were added to each of them to obtain the trifluoroacetate salts of compound 11 and compound 12.
[0460] Trifluoroacetate salt of compound 11: MS m / z: 472.1 [M+1] + ; 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.04(s,1H)8.87(s,1H)8.75(d,J=8.6Hz,1H)8.69(m,1H)8.30(s,1H) 7.95(m,1H)7.77(d,J=8.6Hz,1H)7.56(d,J=7.8Hz,1H)7.43-7.41(m,1H )6.59(d,J=8.0Hz,1H)4.40-4.38(m,3H)4.35-4.30(m,1H)3.74-3.68(m ,3H)3.46(s,1H)3.02-3.00(m,1H)2.13-2.11(m,1H)1.84-1.82(m,2H). ee%=100%, retention time: 1.196 min.
[0461] Trifluoroacetate salt of compound 12: MS m / z: 472.1 [M+1]+ ; 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.06(s,1H)8.88(s,1H)8.76(d,J=8.6Hz,1H)8.72-8.69(m,1H)8.31(s, 1H)7.97(m,1H)7.78(d,J=8.8Hz,1H)7.58(d,J=7.8Hz,1H)7.46-7.44(m, 1H)6.60(d,J=7.8Hz,1H)4.41-4.39(m,3H)4.37-4.30(m,1H)3.76-3.70( m,3H)3.48(s,1H)3.03-3.02(m,1H)2.13-2.12(m,1H)1.87-1.84(m,2H). ee%=98.46%, retention time: 1.586min.
[0462] EE% analysis method: chromatographic column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: carbon dioxide B: isopropanol (0.1% IPAm, v / v).
[0463] Example 13 and Example 14
[0464] Step 1: Synthesis of compound 13-2
[0465] Compound 13-1 (3 g, 18.97 mmol, 1 eq) was added to tetrahydrofuran (45 mL). The temperature was cooled to 0°C, followed by the addition of sodium hydride (1.14 g, 28.45 mmol, 60% purity, 1.5 eq). After stirring for 0.5 hours, N-phenylbis(trifluoromethanesulfonyl)imide (8.13 g, 22.76 mmol, 1.2 eq) was added. The temperature was raised to 25°C and the reaction was allowed to react for 12 hours. The reaction solution was slowly added to saturated aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 13-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 10%) to afford compound 13-2. 1 H NMR (400MHz, CDCl3) δppm 4.85-4.82(m,2H)4.72-4.70(m,2H)4.25–4.20(m,2H)1.28–1.24(m,3H).
[0466] Step 2: Synthesis of Compound 13-3
[0467] Compound 13-2 (3.9 g, 13.44 mmol, 1 eq) and BB-9 (8.84 g, 20.16 mmol, 1.5 eq) were added to dioxane (100 mL) and water (20 mL). Potassium phosphate (8.56 g, 40.32 mmol, 3 eq) and Pd(dppf)Cl2 (983.30 mg, 1.34 mmol, 0.1 eq) were added, and the mixture was reacted at 100°C for 3 hours. The reaction solution was added to water (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 13-3 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 4%) to obtain compound 13-3. MS m / z: 297.0 [M-56] + ; 1 H NMR (400MHz, CDCl3) δppm 7.83–7.82(m,1H)7.16(s,1H)5.01(s,4H)4.19–4.14(m,2H)1.54–1.52(m,9H)1.22–1.19(m,3H).
[0468] Step 3: Synthesis of compound 13-4
[0469] Compound 13-3 (1.2 g, 3.41 mmol, 1 eq) was added to tetrahydrofuran (30 mL). The temperature was cooled to 0°C and lithium aluminum tetrahydride (323.15 mg, 8.51 mmol, 2.5 eq) was added and the mixture was allowed to react for 2 hours. Water was added dropwise to the reaction mixture until the reaction was completely quenched. The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 13-4. MS m / z: 254.9 [M-56] + .
[0470] Step 4: Synthesis of compound 13-5
[0471] Compound 13-4 (1 g, 3.22 mmol, 1 eq) was added to tetrahydrofuran (20 mL), cooled to 0°C, and sodium hydride (257.80 mg, 6.44 mmol, 60% purity, 2 eq) was added. The mixture was stirred for 0.5 hours and then heated to 50°C for 2 hours. After the reaction, the reaction mixture was slowly added to saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain compound 13-5. MS m / z: 291.0 [M+1] + .
[0472] Step 5: Synthesis of compound 13-6
[0473] Palladium / carbon (0.3 g, 10% purity) was added to a dry hydrogenation flask, followed by methanol (30 mL) and compound 11-5 (0.8 g, 2.76 mmol, 1 eq). The mixture was reacted at 25°C under hydrogen (15 psi) for 4 hours. The filtrate was filtered, concentrated under reduced pressure, and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 10%) to afford compound 13-6. MS m / z: 293.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.50-7.48(m,1H)7.38-7.36(m,1H)6.98–6.93(m,1H)4.22-4.21(m,2H)4.20–4.17(m,1H)4.03- 3.01(m,1H)3.94-3.92(m,1H)3.67–3.57(m,1H)3.55–3.35(m,1H)2.71–2.68(m,1H)1.44(s,9H).
[0474] Step 6: Synthesis of the hydrochloride salt of compound 13-7
[0475] Compound 13-6 (0.18 g, 615.74 μmol, 1 eq) was added to hydrochloric acid / methanol (4 M, 10 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride salt of compound 13-7. MS m / z: 193.0 [M+1] + .
[0476] Step 7: Synthesis of compound 13-8
[0477] Compound 5-8 (0.175 g, 504.90 μmol, 1 eq) and the hydrochloride of compound 13-7 (138.55 mg, 605.88 μmol, 1.20 eq) were added to dioxane (10 mL), followed by potassium carbonate (279.13 mg, 2.02 mmol, 4 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (43.82 mg, 75.73 μmol, 0.15 eq), and Pd2(dba)3 (46.23 mg, 50.49 μmol, 0.1 eq). The mixture was reacted at 110°C for 6 hours. The reaction solution was added to water (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (ethyl acetate / petroleum ether = 0% to 25%) to obtain compound 13-8. MS m / z:458.1[M+1] + .
[0478] Step 8: Synthesis of compound 13-9
[0479] Compound 13-8 (0.15 g, 327.58 μmol, 1 eq) and bis(triisopropyl)-1-naphthalene boronic acid (249.55 mg, 982.73 μmol, 3 eq) were added to dioxane (10 mL). Potassium acetate (96.45 mg, 982.73 μmol, 3 eq), XPhos Pd G2 (25.77 mg, 32.76 μmol, 0.1 eq), and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (31.23 mg, 65.52 μmol, 0.2 eq) were then added and reacted at 110°C for 3 hours. The reaction mixture was added to water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 13-9 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to afford compound 13-9. MS m / z:550.2[M+1] + .
[0480] Step 9: Synthesis of compound 13-10
[0481] Compound 13-9 (126.48 mg, 230.21 μmol, 1.5 eq) and compound BB-2-2 (33 mg, 153.47 μmol, 1 eq) were added to dioxane (10 mL) and water (2 mL). XPhos Pd G2 (12.08 mg, 15.35 μmol, 0.1 eq) and potassium phosphate (97.73 mg, 460.42 μmol, 3 eq) were added and reacted at 105°C for 3 hours. The reaction solution was added to water (20 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 13-10 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 13-10. MS m / z: 558.2 [M+1] + .
[0482] Step 10: Synthesis of trifluoroacetate salts of compound 13 and compound 14
[0483] Compound 13-10 (70 mg, 125.54 μmol, 1 eq) was added to DCM (10 mL) and trifluoroacetic acid (5 mL), and the reaction was carried out at 25° C. for 2 hours. The reaction solution was concentrated under reduced pressure and separated by SFC (chromatographic column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 μm); mobile phase: [0.1% NH3H2O EtOH]; B%: 44%-44%, 12 min). The resolved products were concentrated and 4 drops of trifluoroacetic acid were added to each to obtain the trifluoroacetic acid salt of compound 13 and the trifluoroacetic acid salt of compound 14.
[0484] Trifluoroacetate salt of compound 13: MS m / z: 458.1 [M+1] + ; 1 H NMR (400 MHz, CD3OD) δ ppm 8.82(d,J=8.4Hz,1H)8.69-8.67(m,1H)8.21(s,1H)7.86-7.84(m,1H)7.76-7.74(m,1H)7.60(d,J=8.0Hz,1H)7.48-7.46(m,1H)6.66(d,J=8. 0Hz,1H)4.42(s,2H)4.35-4.34(m,1H)4.27-4.25(m,1H)4.11-4.09(m, 2H)3.79(m,1H)3.71-3.74(s,1H)3.52-3.50(m,1H)2.86-2.83(m,1H). ee%=100%, retention time: 1.643min.
[0485] Trifluoroacetate salt of compound 14: MS m / z: 458.1 [M+1] + ; 1 H NMR(400MHz,CD3OD)δppm 8.83(d,J=8.4Hz,1H)8.67(m,1H)8.20(s,1H)7.84(d,J=5.4Hz,1H)7.77-7.75(m,1H)7.60(d,J=7.8Hz,1H)7.47-7.44(m,1H)6.67(d,J=7.8 Hz,1H)4.42(s,2H)4.37-4.35(m,1H)4.27(s,1H)4.11-4.09(m,2H)3. 81-3.80(m,1H)3.79-3.71(m,1H)3.52-3.50(m,1H)2.85-2.83(m,1H). ee%=98.42%, retention time: 1.827 min.
[0486] EE% detection analysis method: chromatographic column: Chiralcel OJ-3, 50×4.6 mm ID, 3 μm; mobile phase: A: carbon dioxide; B: ethanol (0.1% IPAm, v / v).
[0487] Example 15
[0488] Step 1: Synthesis of compound 15-3
[0489] Compound 10-1 (0.2 g, 707.41 μmol, 1 eq) and compound 15-2 (240.44 mg, 1.41 mmol, 2 eq) were added to dioxane (4 mL) and water (0.8 mL). XPhos Pd G2 (55.66 mg, 70.74 μmol, 0.1 eq) and potassium phosphate (450.48 mg, 2.12 mmol, 3 eq) were added and reacted at 100°C for 2 hours. The reaction solution was added to water (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 15-3 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 15%). MS m / z: 273.0 [M-100] + ; 1 H NMR(400MHz,DMSO-d6)δppm 7.41–7.37(m,1H)7.21–7.19(m,1H)6.99–6.89(m 2H)6.70–6.69(m,1H)6.51(s,2H)4.36–4.29(m,2H)3.75(s,3H)1.48(s,9H).
[0490] Step 2: Synthesis of compound 15-4
[0491] Compound 15-3 (0.18 g, 483.37 μmol, 1 eq) and compound BB-1 (174.12 mg, 580.04 μmol, 1.2 eq) were added to dioxane (10 mL), followed by cesium carbonate (472.47 mg, 1.45 mmol, 3 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (41.95 mg, 72.50 μmol, 0.15 eq), and palladium acetate (10.85 mg, 48.34 μmol, 0.1 eq). The mixture was reacted at 110°C for 3 hours. The reaction mixture was added to water (50 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield compound 15-4. MS m / z: 592.3 [M+1] + .
[0492] Step 3: Synthesis of trifluoroacetate salt of compound 15
[0493] Compound 15-4 (0.4 g, 676.05 μmol, 1 eq) was added to hydrochloric acid / methanol (4 M, 20 mL) and reacted at 25°C for 4 hours. The reaction solution was concentrated under reduced pressure and purified by prep-HPLC (column: Phenomenex Lμna 80*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 10%-50%, 8 min) to obtain the trifluoroacetate salt of compound 15. MS m / z: 492.2 [M+1] + ; 1 H NMR(400MHz,CD3OD)δppm 8.26(d,J=8.4Hz,1H)7.81(d,J=8.8Hz,1H)7.48-7.40(m,2H)7.21(d,J=8.8Hz,1H)6.97(d,J=8.4Hz,1H)6.8 7(t,J=8.8Hz,1H)4.62(s,2H)4.28-4.19(m,2H)3.90-3.88(m,4H)3.81(s,3H)3.05(s,6H)2.93-2.91(m,4H).
[0494] Example 16
[0495] Step 1: Synthesis of compound 16-1
[0496] Under nitrogen, compound 4-1 (10 g, 46.03 mmol) was dissolved in DCM (10 mL) at 0°C. Dess-Martin periodinane (23.43 g, 55.23 mmol, 17.10 mL) was added and the mixture was heated to 20°C for 16 hours. The mixture was filtered, the solid washed with dichloromethane (20 mL), and the filtrate poured into saturated sodium sulfite solution (200 mL). The mixture was filtered and the pH adjusted to 8 with saturated sodium bicarbonate solution (200 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound 16-1 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 15%) to afford compound 16-1. 1 H NMR(400MHz,DMSO-d6)δ9.61-9.59(m,1H),4.51-4.34(m,2H),3.79-3.68(m,1H ),3.65-3.52(m,2H),3.40-3.35(m,1H),3.11-2.79(m,1H),1.46-1.37(m,9H).
[0497] Step 2: Synthesis of compound 16-3
[0498] Under nitrogen, compound 16-1 (2.89 g, 13.43 mmol) was added to DCM (60 mL), followed by compound 16-2 (2.44 g, 16.11 mmol) and acetic acid (80.63 mg, 1.34 mmol, 76.79 μL). The mixture was allowed to react at 20°C for 1 hour. Sodium acetate borohydride (5.69 g, 26.85 mmol) was then added and the mixture was allowed to react at 20°C for 12 hours. The reaction was quenched with saturated aqueous sodium bicarbonate (60 mL) and extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 16-3 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to yield compound 16-3. MS m / z: 351.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ7.18(d,J=8.4Hz,2H),6.85(d,J=8.8Hz,2H),3.82-3.73(m,2H),3.69-3.65(m,4H),3.54-3.51(m,1H ),3.48-3.36(m,3H),3.30-3.24(m,1H),2.85-2.68(m,1H),2.61-2.56(m,1H),2.43-2.38(m,1H),2.14(s,3H),1.40(s,9H).
[0499] Step 3: Synthesis of compound 16-4
[0500] Under nitrogen, compound 16-3 (1.7 g, 4.85 mmol) was dissolved in DCM (2 mL), and hydrochloric acid / methanol (4 M, 50 mL) was added. The mixture was reacted at 20°C for 6 hours. The solvent was concentrated under reduced pressure, and dichloromethane (20 mL) and aqueous ammonia (3 mL) were added. The mixture was dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain compound 16-4. MS m / z: 251.1 [M+1] + ; 1 H NMR(400MHz, DMSO-d6)δ7.20(d,J=8.8Hz,2H),6.87(d,J=8.4Hz,2H),3.73-3.65(m,5H),3.44-3.33(m,3H), 3.09-3.01(m,1H),2.99-2.92(m,1H),2.85-2.74(m,2H),2.33-2.25(m,1H),2.21-2.15(m,1H),2.11(s,3H).
[0501] Step 4: Synthesis of compound 16-5
[0502] Under nitrogen, compound BB-1-1 (600 mg, 2.94 mmol) was dissolved in DMF (12 mL), and compound 16-4 (809.92 mg, 3.24 mmol) and DIEA (1.14 g, 8.82 mmol, 1.54 mL) were added. The mixture was reacted at 100°C for 6 hours. After cooling, the reaction was quenched with water (20 mL), extracted with ethyl acetate (20 mL × 4), and the organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 16-5 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 20% to 25%) to obtain compound 16-5. MS m / z: 434.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.83 (s, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.59 (d, J = 8.8 Hz,1H),6.92-6.86(m,2H),6.83-6.78(m,2H),3.92-3.76(m,3H),3.73(s,3 H),3.59-3.55(m,1H),3.55-3.49(m,1H),3.29-3.27(m,1H),3.24-3.19(m, 2H),2.95-2.87(m,1H),2.64-2.62(m,1H),2.42-2.37(m,1H),1.81(s,3H).
[0503] Step 5: Synthesis of compound 16-6
[0504] Under nitrogen protection, compound 16-5 (1.24 g, 2.85 mmol) was dissolved in trifluoroacetic acid (15 mL) and reacted at 60°C for 2 hours. The reaction solution was cooled and concentrated under reduced pressure. DCM (30 mL) and NaBH(OAc)3 (1.82 g, 8.56 mmol) were added and reacted at 20°C for 2 hours. The reaction was quenched with saturated sodium carbonate solution (30 mL) and saturated sodium hydroxide solution (5 mL). The organic phase was extracted with dichloromethane (20 mL × 5), washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The product was filtered and concentrated under reduced pressure. Compound 16-6 was separated and purified by column chromatography (methanol / ethyl acetate = 0% to 5%) to obtain compound 16-6. MS m / z: 298.0 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ7.36-7.33(m,2H),3.94-3.92(m,1H),3.78-3.62(m,4H),3.46-3.40(m ,1H),3.38-3.35(m,1H),3.25-3.23(m,2H),3.01-2.95(m,1H),2.58-2.52(m,1H),2.33(s,3H).
[0505] Step 6: Synthesis of compound 16-8
[0506] Under nitrogen, compound 16-6 (590 mg, 1.98 mmol) was dissolved in dioxane (12 mL), and compound 16-7 (336.79 mg, 3.96 mmol), cesium carbonate (1.93 g, 5.94 mmol), Xantphos (228.98 mg, 395.74 μmol), and Pd2(dba)3 (181.19 mg, 197.87 μmol) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the filter cake was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure. Compound 16-8 was purified by column chromatography (methanol / ethyl acetate = 0% to 5%) to give compound 16-8. MS m / z: 303.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.55(s,1H),7.86(d,J=8.8Hz,1H),7.37(d,J=8.8Hz,1H),3.87-3.72(m,3H),3.69-3.65(m,2H),3. 45-3.39(m,1H),3.19-3.16(m,3H),2.92-2.86(m,1H),2.55-2.51(m,1H),2.29(s,3H),2.03-1.90(m,1H),0.80-0.71(m,4H).
[0507] Step 7: Synthesis of compound 16-9
[0508] Under nitrogen, compound 16-8 (500 mg, 1.65 mmol) was dissolved in methanol (10 mL) and water (2.5 mL). Sodium hydroxide (661.39 mg, 16.54 mmol) was added and the mixture was allowed to react at 80°C for 16 hours. Sodium hydroxide (330.70 mg, 8.27 mmol) was then added and the mixture was allowed to react at 80°C for 4 hours. The solvent was concentrated under reduced pressure, and the mixture was extracted with dichloromethane (20 mL × 5). The organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain compound 16-9. MS m / z: 235.2 [M+1] + ;1 H NMR(400MHz, DMSO-d6)δ7.08(d,J=8.8Hz,1H),6.28(d,J=8.4Hz,1H),5.47(s,2H),3.73-3.56(m,5H),3.4 8-3.41(m,1H),3.20-3.14(m,1H),3.06-2.95(m,2H),2.92-2.87(m,1H),2.47-2.45(m,1H),2.26(s,3H).
[0509] Step 8: Synthesis of compound 16-11
[0510] Under nitrogen, compound BB-10 (8.3 g, 23.95 mmol) was dissolved in DMF (83 mL), and BB-2-1 (3.26 g, 23.95 mmol), potassium acetate (4.70 g, 47.89 mmol), and Pd(dppf)Cl2 (1.75 g, 2.39 mmol) were added. The mixture was reacted at 120°C for 2 hours. After cooling and filtration, the filtrate was poured into water (1000 mL), extracted with ethyl acetate (1000 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 16-11 was purified by column chromatography (petroleum ether:ethyl acetate = 0% to 50%) to obtain compound 16-11. MS m / z: 402.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.04-7.96(m,1H),7.73-7.70(m,1H),7.67-7.57(m,2H),7.41-7.32(m,1H),6.83-6.72(m,1H),4.64(s,2H),1.58(s,9H).
[0511] Step 9: Synthesis of compound 16-12
[0512] Under nitrogen, compound 16-11 (610 mg, 1.52 mmol) was dissolved in dioxane (12 mL). Compound 16-9 (391.25 mg, 1.67 mmol), cesium carbonate (1.48 g, 4.55 mmol), Xantphos (175.68 mg, 303.62 μmol), and palladium acetate (34.08 mg, 151.81 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure. Compound 16-12 was purified by column chromatography (methanol / ethyl acetate = 0% to 30%) to obtain compound 16-12. MS m / z: 600.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ9.65(s, 1H),8.66(d,J=8.4Hz,1H),8.43-8.36(m,1H),7.82(s,1H),7.78(d,J=8.4Hz,1H),7.55-7 .52(m,1H),7.41(d,J=8.8Hz,1H),7.02-6.95(m,2H),4.73(s,2H),3.97-3.88(m,1H),3.8 3-3.79(m,1H),3.74-3.72(m,1H),3.69-3.63(m,1H),3.49-3.45(m,1H),3.29-3.20(m,2H ), 3.17 (d, J = 5.2Hz, 2H), 3.09-2.98 (m, 1H), 2.58-2.54 (m, 1H), 2.36 (s, 3H), 1.51 (s, 9H).
[0513] Step 10: Synthesis of trifluoroacetate salt of compound 16
[0514] Under nitrogen, compound 16-12 (742 mg, 1.24 mmol) was dissolved in DCM (10 mL) and trifluoroacetic acid (7.70 g, 67.53 mmol, 5 mL) was added. The mixture was allowed to react at 20°C for 1 hour. The solvent was concentrated under reduced pressure to obtain the crude product. Purification by prep-HPLC (column: Phenomenex lμna C18 250*50mm*10μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 5%-45%, 10 min) afforded the trifluoroacetate salt of compound 16. MS m / z: 500.2 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ10.10(s,1H),8.89(s,1H),8.71-8.56(m,2H),8.24(s,1H) ,7.94-7.92(m,1H),7.72(d,J=8.4Hz,1H),7.59(d,J=8.0Hz,1H),7.44-7.37(m,1H ),7.13(d,J=8.0Hz,1H),4.86-4.67(m,1H),4.56-4.53(m,1H),4.39(s,2H),3.78- 3.64(m,6H),3.42-3.36(m,1H),3.31-3.17(m,1H),2.97(s,3H),2.58-2.56(m,1H).
[0515] Example 17
[0516] Step 1: Synthesis of compound BB-10-2
[0517] Compound BB-10-1 (23.4 g, 108.82 mmol) was dissolved in DMF (230 mL), and N-chlorosuccinimide (17.44 g, 130.58 mmol) and palladium acetate (12.22 g, 54.41 mmol) were added. The atmosphere was purged with nitrogen three times, and the reaction was stirred at 110°C for 16 hours. The reaction solution was poured into water (1 L), and ethyl acetate (300 mL) was added. After stirring, the mixture was filtered and the filtrate was separated. The aqueous phase was extracted with ethyl acetate (200 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 1% to 25%) to obtain compound BB-10-2. MS m / z: 231.0 [M-17] + ; 1 H NMR (400MHz, CDCl3) δ11.38 (m, 1H), 7.56 (d, J = 8.4Hz, 1H), 7.15 (d, J = 8.4Hz, 1H), 2.48 (s, 3H).
[0518] Step 2: Synthesis of compound BB-10-3
[0519] Compound BB-10-2 (23.7 g, 94.99 mmol) was dissolved in DMF (237 mL) and anhydrous potassium carbonate (32.82 g, 237.49 mmol) was added. The mixture was stirred at 20°C for 30 minutes, followed by the dropwise addition of iodomethane (20.23 g, 142.49 mmol, 8.87 mL). The reaction mixture was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring it into 2% dilute ammonia water (100 mL), diluted with water (1000 mL), and the aqueous phase was extracted with ethyl acetate (200 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 10%) to obtain compound BB-10-3. MS m / z: 263.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.51 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 3.96 (s, 3H), 2.36 (s, 3H).
[0520] Step 3: Synthesis of compound BB-10-4
[0521] Compound BB-10-3 (7.7 g, 29.22 mmol) was dissolved in 1,2-dichloroethane (150 mL) and N-bromosuccinimide (5.72 g, 32.14 mmol) and benzoyl peroxide (707.80 mg, 2.92 mmol) were added. The atmosphere was purged with nitrogen three times and the reaction was stirred at 110°C under nitrogen for 40 hours. The reaction solution was poured into water (200 mL) and separated. The aqueous phase was extracted with dichloromethane (50 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound BB-10-4. MS m / z: 340.9 [M+1] + .
[0522] Step 4: Synthesis of compound BB-10-5
[0523] Compound BB-10-4 (10 g, 29.20 mmol) was dissolved in ammonia methanol solution (7 M, 208.60 mL) and stirred at 20°C for 16 hours. The reaction mixture was filtered directly, and the filter cake was rinsed with methanol (50 mL). The filter cake was collected, concentrated, and dried to obtain compound BB-10-5. MS m / z: 246.0 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.90 (br s, 1H), 7.79 (d, J = 8.4Hz, 1H), 7.43 (d, J = 8.4Hz, 1H), 4.44 (s, 2H).
[0524] Step 5: Synthesis of compound BB-10-6
[0525] Compound BB-10-5 (5.3 g, 21.50 mmol) was dissolved in tetrahydrofuran (80 mL) and di-tert-butyl dicarbonate (7.04 g, 32.25 mmol, 7.41 mL) and 4-dimethylaminopyridine (3.15 g, 25.80 mmol) were added. The reaction was stirred at 20°C for 16 hours. The reaction solution was poured into water (200 mL), separated, and the aqueous phase was extracted with ethyl acetate (50 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 5% to 25%) to obtain compound BB-10-6. MS m / z: 290.0 [M-55] + ; 1 H NMR (400MHz, CDCl3) δ7.66 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.63 (s, 2H), 1.61 (s, 9H).
[0526] Step 6: Synthesis of compound BB-10
[0527] Compound BB-10-6 (5 g, 14.43 mmol) was dissolved in N-methylpyrrolidone (50 mL) and the atmosphere was replaced with nitrogen three times. Compound BB-2-1 (1.96 g, 14.43 mmol), potassium acetate (2.83 g, 28.85 mmol), and Pd(dppf)Cl2 (1.06 g, 1.44 mmol) were added and reacted at 120°C for 2 hours. The reaction solution was poured into water (200 mL). A solid precipitated and was filtered. The filter cake was collected and dried. Compound BB-10 was isolated and purified by column chromatography (ethyl acetate / petroleum ether = 50% to 100%) to obtain compound BB-10. MS m / z: 402.2 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.99-7.96(m,1H),7.73(s,1H),7.69-7.64(m,2H),7.40-7.35(m,1H),6.84-6.78(m,1H),4.66(s,2H),1.59(s,9H).
[0528] Step 7: Synthesis of compound 17-2
[0529] Compound 17-1 (30 g, 251.84 mmol) was dissolved in DCM (300 mL) and methanol (300 mL), and tetrabutylammonium tribromide (145.72 g, 302.21 mmol) was added. The reaction was allowed to react at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure, and then dichloromethane (600 mL) was added. After stirring for 0.5 hours, the mixture was filtered and the filtrate was concentrated to obtain a crude product. The crude product was dissolved in dichloromethane (50 mL) and allowed to react at 25°C for 2 hours. The mixture was filtered and the filter cake was concentrated to obtain compound 17-2. MS m / z: 197.9 [M+1] + .
[0530] Step 8: Synthesis of compound 17-3
[0531] Compound 17-2 (8 g, 40.40 mmol) was dissolved in DCM (100 mL), followed by the addition of 4-dimethylaminopyridine (4.94 g, 40.40 mmol), di-tert-butyl dicarbonate (26.45 g, 121.20 mmol, 27.84 mL), and DIEA (15.66 g, 121.20 mmol, 21.11 mL). The reaction was incubated at 25°C for 16 hours. The reaction mixture was poured into saturated aqueous ammonium chloride (200 mL) and extracted with dichloromethane (100 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was then purified by column chromatography (ethyl acetate / petroleum ether = 10% to 25%) to afford compound 17-3. MS m / z: 241.8 [M-155] + ;1 H NMR (400MHz, CDCl3) δ7.98 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 1.50 (s, 18H).
[0532] Step 9: Synthesis of compound 17-4
[0533] Compound 17-3 (8.3 g, 20.84 mmol) was dissolved in 1,4-dioxane (100 mL), followed by the addition of potassium acetate (5.11 g, 52.10 mmol) and compound 1-2 (7.94 g, 31.26 mmol). After nitrogen was replaced, Pd(dppf)Cl2 (1.52 g, 2.08 mmol) was added and the reaction was continued at 80°C for 2 hours. The reaction solution was poured into a saturated aqueous ammonium chloride solution (50 mL) and extracted with ethyl acetate (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 17-4. MS m / z: 207.9 [M-155] + .
[0534] Step 10: Synthesis of compound 17-5
[0535] Compound 17-4 (7.5 g, 20.65 mmol) and 13-2 (8.99 g, 30.98 mmol) were dissolved in tetrahydrofuran (100 mL), followed by the addition of anhydrous potassium carbonate (7.14 g, 51.63 mmol) and Pd(PPh3)4 (2.39 g, 2.07 mmol). The reaction was incubated at 65°C for 1 hour. The reaction solution was poured into a saturated aqueous ammonium chloride solution (150 mL) and extracted with ethyl acetate (150 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 17-5 was obtained by column chromatography (ethyl acetate / petroleum ether = 10% to 50%). MS m / z: 304.0 [M-155] + ; 1 H NMR (400MHz, CDCl3) δ7.76-7.70(m,2H),5.11-5.04(m,4H),4.18-4.12(m,2H),1.53(s,18H),1.20-1.16(m,3H).
[0536] Step 11: Synthesis of compound 17-6
[0537] Raney nickel (2 g) was added to a dry hydrogenation flask. The mixture was washed with methanol three times, followed by a solution of compound 17-5 (5.1 g, 11.10 mmol) dissolved in methanol (40 mL) and triethylamine (10 mL). The hydrogen atmosphere was replaced three times, and the reaction was stirred at 25°C under a hydrogen atmosphere of 40 psi for 16 hours. The reaction solution was filtered directly, and the filtrate was concentrated to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 10% to 100%) to obtain compound 17-6. MS m / z: 418.1 [M+1] + .
[0538] Step 12: Synthesis of compound 17-7
[0539] Wet palladium on carbon (200 mg, 10% purity) was added to a dry vial. Compound 17-6 (1.5 g, 3.59 mmol) dissolved in methanol (20 mL) was then slowly added under nitrogen. The mixture was replaced with hydrogen three times and stirred at 20°C under a hydrogen atmosphere of 20 psi for 16 hours. The reaction mixture was filtered and the filtrate was concentrated to yield compound 17-7. MS m / z: 420.2 [M+1] + .
[0540] Step 13: Synthesis of compound 17-8
[0541] Compound 17-7 (1 g, 2.38 mmol) was dissolved in tetrahydrofuran (20 mL) in a dry vial. Sodium hydride (286.08 mg, 7.15 mmol, 60% purity) was added under nitrogen at 0°C. After stirring for 30 minutes, iodomethane (507.57 mg, 3.58 mmol, 222.62 μL) was added and the reaction was stirred at 20°C for 2 hours. The reaction mixture was poured into saturated aqueous ammonium chloride (20 mL), and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 15% to 100%) to obtain compound 17-8. MS m / z: 434.3 [M+1] + .
[0542] Step 14: Synthesis of compound 17-9
[0543] In a dry vial, compound 17-8 (700 mg, 1.61 mmol) was dissolved in DCM (20 mL) and trifluoroacetic acid (9.21 g, 80.74 mmol, 5.98 mL) was added. The reaction was stirred at 25°C for 16 hours. The reaction solution was directly concentrated to obtain the crude product. The crude product was separated and purified by preparative thin-layer chromatography on silica gel (methanol / dichloromethane = 10%) to obtain compound 17-9. MS m / z: 234.2 [M+1] + .
[0544] Step 15: Synthesis of compound 17-10
[0545] Compound 17-9 (95 mg, 407.26 μmol) was dissolved in tetrahydrofuran (5 mL) in a dry vial. Lithium aluminum tetrahydride (77.28 mg, 2.04 mmol) was added under nitrogen at 0°C and stirred at 60°C for 2 hours. The reaction mixture was cooled to 20°C and quenched with methanol (10 mL) dropwise before concentration. The crude product was purified by column chromatography (methanol / dichloromethane = 0% to 15%) to obtain compound 17-10. MS m / z: 220.0 [M+1] + .
[0546] Step 16: Synthesis of trifluoroacetate salt of compound 17
[0547] In a dry vial, compound 17-10 (65 mg, 296.42 μmol) and compound BB-10 (120 mg, 298.64 μmol) were dissolved in 1,4-dioxane (10 mL) and cesium carbonate (291.91 mg, 895.93 μmol) was added. Pd2(dba)3 (54.69 mg, 59.73 μmol) and Xantphos (43.20 mg, 74.66 μmol) were added under nitrogen. The reaction was stirred at 110°C under nitrogen for 2 hours. The reaction mixture was filtered and the filtrate was concentrated. The crude product was separated and purified by preparative thin-layer chromatography on silica gel (methanol / dichloromethane = 10%). The crude product was then purified by prep-HPLC (column: Phenomenex Luna 80*30mm*3μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 1%-30%, 8 min) to afford the trifluoroacetate salt of compound 17. MS m / z: 485.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.23(s,1H),8.91(s,1H),8.74(s,1H),8.54(s,1H),8.11(s,1H),7.80-7.78(m,1H),7.39(d,J=8.8Hz,1H),7.57(d,J=8 .4Hz,1H),7.27-7.24(m,1H),7.19-7.17(m,1H),4.91-4.40(m,5H),4.1 9-4.14(m,2H),3.79-3.69(m,4H),3.41-3.00(m,2H),2.83-2.67(m,2H).
[0548] Example 18
[0549] Step 1: Synthesis of trifluoroacetate salt of compound 18-1
[0550] Compound 17-7 (200 mg, 476.79 μmol) was dissolved in DCM (6 mL) in a dry vial and trifluoroacetic acid (2.72 g, 23.84 mmol, 1.77 mL) was added. The reaction was stirred at 25°C for 16 hours. The reaction solution was concentrated to obtain the trifluoroacetate salt of compound 18-1. MS m / z: 220.2 [M+1] + .
[0551] Step 2: Synthesis of compound 18-2
[0552] In a dry vial, the trifluoroacetic acid salt of compound 18-1 (109.12 mg) and compound BB-10 (100 mg, 248.87 μmol) were dissolved in 1,4-dioxane (10 mL) and cesium carbonate (243.26 mg, 746.61 μmol) was added. After stirring for 15 minutes and measuring the pH > 9, palladium acetate (11.17 mg, 49.77 μmol) and Xantphos (36.00 mg, 62.22 μmol) were added. The reaction was stirred at 100°C under nitrogen for 4 hours. The reaction mixture was filtered and the filtrate was concentrated. The crude product was separated and purified by preparative thin-layer chromatography on silica gel (methanol / dichloromethane, 10% methanol) to obtain compound 18-2. MS m / z: 585.2 [M+1] + .
[0553] Step 3: Synthesis of trifluoroacetate salt of compound 18
[0554] In a dry vial, compound 18-2 (65 mg, 111.19 μmol) was dissolved in DCM (1 mL) and trifluoroacetic acid (633.88 mg, 5.56 mmol, 411.61 μL) was added. The reaction was stirred at 20°C for 2 hours. The reaction solution was concentrated to obtain the crude product. The crude product was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10μm; mobile phase: [water (NH4HCO3)-acetonitrile]; acetonitrile percentage: 1%-25%, 8 min). Two to three drops of trifluoroacetic acid were added to the fraction, and the fraction was concentrated to obtain the trifluoroacetate salt of compound 18. MS m / z: 485.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.15(s,1H),8.89(s,1H),8.77(d,J=8.4Hz,1H),8.63- 8.62(m,1H),8.34-8.32(m,1H),8.18(s,1H),7.86-7.84(m,1H),7.78-7.76(m,1 H),7.55(d,J=8.4Hz,1H),7.32-7.30(m,1H),6.98-6.96(m,1H),5.03-4.87(m,1 H),4.40-4.35(m,4H),4.15-3.86(m,3H),3.84-3.78(m,1H),3.73-3.65(m,1H).
[0555] Example 20
[0556] Step 1: Synthesis of compound 20-1
[0557] Under nitrogen, compound BB-6 (300 mg, 863.08 μmol) was dissolved in 1,4-dioxane (6 mL). Compound BB-8 (196.74 mg, 949.39 μmol), cesium carbonate (843.63 mg, 2.59 mmol), Xantphos (74.91 mg, 129.46 μmol), and palladium acetate (19.38 mg, 86.31 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure. Compound 20-1 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 35%) to obtain compound 20-1. MS m / z: 474.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.49(s,1H),8.92(s,1H),7.30(d,J=8.4Hz,1H),6.78(d,J=8.4Hz,1H),4.73(s,2H),4.39-4.37( m,1H),4.07-4.03(m,1H),3.99-3.94(m,1H),3.91-3.89(m,1H),3.65-3.54(m,2H),3.22-3.14(m,1H),3.10-3.02(m,1H), 2.69-2.62(m,1H),1.54(s,9H).
[0558] Step 2: Synthesis of compound 20-2
[0559] Under nitrogen, compound 20-1 (142 mg, 299.64 μmol) was dissolved in 1,4-dioxane (5 mL) and water (1 mL). Compound 4-8 (109.71 mg, 449.45 μmol), potassium phosphate (127.21 mg, 599.27 μmol), and RuPhos Pd G2 (23.58 mg, 29.96 μmol) were added and reacted at 100°C for 2 hours. After cooling, the system was concentrated under reduced pressure. Compound 20-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to obtain compound 20-2. MS m / z: 570.2 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ10.12(s,1H),9.30(s,1H),8.43(d,J=5.2Hz,1H),7.18(d,J=4.8Hz, 1H),7.08(d,J=8.4Hz,1H),6.88(d,J=3.6Hz,1H),6.57(d,J=8.4Hz,1H),4.38-4.35(m,1H) ,4.21-4.12(m,1H),4.11-4.07(m,1H),3.99-3.91(m,4H),3.80-3.74(m,1H),3.53(s,2H) ,3.45-3.42(m,1H),3.36-3.28(m,1H),3.25-3.17(m,1H),2.89-2.82(m,1H),1.62(s,9H).
[0560] Step 3: Synthesis of trifluoroacetate salt of compound 20
[0561] Under nitrogen, compound 20-2 (158 mg, 277.38 μmol) was dissolved in DCM (6 mL), and trifluoroacetic acid (4.62 g, 40.52 mmol, 3 mL) was added. The mixture was reacted at 25°C for 2 hours. The solvent was concentrated under reduced pressure to obtain the crude product. The product was purified by prep-HPLC (column: Phenomenex Luna 80*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 5%-35%, 8 min). The trifluoroacetate salt of compound 20 was obtained. MS m / z: 470.1 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ9.85 (s, 1H), 9.45 (s, 1H), 9.16 (s, 1H), 8.35 (d, J = 4.8Hz, 1H), 7.57 (d, J=3.6Hz,1H),7.38(d,J=4.8Hz,1H),7.31(d,J=8.4Hz,1H),6.92(d,J=3.6Hz,1H),6.69(d,J=8 .4Hz,1H),4.71(s,2H),4.41-4.39(m,1H),4.11-4.01(m,1H),4.01-3.95(m,1H),3.93-3.89(m ,1H),3.87(s,3H),3.66-3.54(m,2H),3.26-3.15(m,1H),3.12-3.02(m,1H),2.71-2.64(m,1H).
[0562] Example 21 and Example 22
[0563] Step 1: Synthesis of trifluoroacetate salts of compound 21 and compound 22
[0564] In a dry vial, compound 18-2 (100 mg, 171.06 μmol) was dissolved in DCM (1 mL) and trifluoroacetic acid (975.20 mg, 8.55 mmol, 633.25 μL) was added. The reaction was stirred at 20°C for 2 hours. The reaction solution was concentrated to obtain the crude product, which was then purified by preparative thin-layer chromatography on silica gel plates (methanol / dichloromethane = 16%). The product was then purified by SFC (column: REGIS (S,S) WHELK-O1 (250 mm x 25 mm, 10 μm); mobile phase: A (carbon dioxide), B (ethanol, 0.1% ammonia), B%: 62%-62%, 20 min). The resulting solution was concentrated and two drops of trifluoroacetic acid were added dropwise to obtain the trifluoroacetic acid salts of compounds 21 and 22.
[0565] Trifluoroacetate salt of compound 21: MS m / z: 485.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δppm 10.14(s,1H),8.89(s,1H),8.77(d,J=8.8Hz,1H),8.61(d,J=7.2Hz,1H),8.34-8.32(m,1H),8.16(s,1H),7.84-7.82(m,1H),7.78-7.76(m, 1H),7.56-7.54(m,1H),7.32-7.30(m,1H),6.99-6.97(m,1H),4.91-4 .87(m,1H),4.40-4.36(m,4H),3.92-3.88(m,2H),3.84-3.68(m,3H). ee%=100%, retention time: 3.070 min.
[0566] Trifluoroacetate salt of compound 22: MS m / z: 485.3 [M+1] + ; 1 H NMR (400 MHz, DMSO-d6) δ ppm 10.14(s,1H),8.89(s,1H),8.77(d,J=8.8Hz,1H),8.63(d,J=6.8Hz,1H),8 .33-8.31(m,1H),8.20(s,1H),7.88-7.86(m,1H),7.79-7.77(m,1H),7.56 -7.54(m,1H),7.34-7.32(m,1H),6.99-6.97(m,1H),4.91-4.87(m,1H),4. 41-4.36(m,4H),3.92-3.85(m,2H),3.81-3.53(m,2H),3.38-3.34(m,1H). ee%=97.12%, SFC retention time: 5.061 min.
[0567] EE% analysis method: Chromatographic column: (S,S)-WHELK-O1, 50×4.6 mm ID, 3.5 μm; Mobile phase: A: carbon dioxide B: ethanol (0.1% isopropylamine, v / v); B% = 50-50%; Flow rate: 4 mL / min; Pressure: 1800 psi.
[0568] Example 23
[0569] Step 1: Synthesis of compound 23-1
[0570] Under nitrogen, compound BB-10-6 (1 g, 2.89 mmol) was dissolved in dioxane (20 mL) and water (4 mL). Compound 4-8 (1.06 g, 4.33 mmol), cesium carbonate (2.82 g, 8.66 mmol), and Pd(dppf)Cl2 (316.66 mg, 432.77 μmol) were added and reacted at 70°C for 2 hours. The mixture was cooled and concentrated under reduced pressure to obtain the crude product. Compound 23-1 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 23-1. MS m / z: 398.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.44(d,J=4.8Hz,1H),7.68(d,J=8.0Hz,1H),7.58(d,J=8.0Hz,1H),7.2 8(s,1H),7.05(d,J=4.8Hz,1H),6.28(d,J=3.6Hz,1H),4.65(s,2H),3.98(s,3H),1.57(s,9H).
[0571] Step 2: Synthesis of compound 23-2
[0572] Under nitrogen, compound 23-1 (45 mg, 113.11 μmol) was dissolved in dioxane (2 mL), and compound 18-1 (27.28 mg, 124.42 μmol), cesium carbonate (110.56 mg, 339.32 μmol), Xantphos (13.09 mg, 22.62 μmol), and palladium acetate (2.54 mg, 11.31 μmol) were added. The mixture was reacted at 110°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure. Compound 23-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to give compound 23-2. MS m / z: 581.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.87 (s, 1H), 8.81 (d, J = 8.8Hz, 1H), 8.38-8.26 (m, 2H), 7.8 1(d,J=8.4Hz,1H),7.62-7.53(m,2H),7.25(d,J=5.2Hz,1H),7.08(d,J=8.4Hz,1H) ,6.47(d,J=3.6Hz,1H),4.92-4.83(m,1H),4.80(s,2H),4.43–4.39(m,1H),4.38–4 .35(m,1H),3.97-3.86(m,5H),3.86-3.68(m,2H),3.38-3.34(m,1H),1.50(s,9H).
[0573] Step 3: Synthesis of trifluoroacetate salt of compound 23
[0574] Under nitrogen protection, compound 23-2 (69 mg, 118.84 μmol) was dissolved in DCM (2 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was allowed to react at 25°C for 2 hours. The solvent was concentrated under reduced pressure to obtain a crude product. The crude product was added to methanol (10 mL) and reacted at 25°C for 0.5 hours. The mixture was filtered, and the residue was washed with methanol (5 mL). The residue was taken and added to water (10 mL). 3 drops of trifluoroacetic acid were added and mixed well to obtain the trifluoroacetate salt of compound 23. MS m / z: 481.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H),8.84(s,1H),8.73(d,J=8.4Hz,1H),8.35-8.26(m, 2H),7.75(d,J=8.4Hz,1H),7.59(d,J=3.2Hz,1H),7.53(d,J=8.4Hz,1H),7.27(d,J=4.8Hz ,1H),6.95(d,J=8.4Hz,1H),6.47(d,J=3.2Hz,1H),4.90–4.84(m,1H),4.46(s,2H),4.42- 4.33(m,2H),3.98-3.86(m,5H),3.84-3.78(m,1H),3.73-3.69(m,1H),3.35–3.33(m,1H).
[0575] Example 24 and Example 40
[0576] Step 1: Synthesis of compound 24-1
[0577] Under nitrogen, compound 16-9 (145 mg, 618.87 μmol) was dissolved in dioxane (4 mL), and compound BB-6 (236.63 mg, 680.76 μmol), cesium carbonate (604.92 mg, 1.86 mmol), Xantphos (71.62 mg, 123.77 μmol), and palladium acetate (13.89 mg, 61.89 μmol) were added. The mixture was reacted at 110°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure. Compound 24-1 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%). MS m / z: 501.1 [M+1] + .
[0578] Step 2: Synthesis of compound 24-2
[0579] Under nitrogen, compound 24-1 (74 mg, 147.71 μmol) was dissolved in dioxane (4 mL) and water (0.8 mL). Compound 4-8 (54.08 mg, 221.57 μmol), potassium phosphate (94.06 mg, 443.13 μmol), and XPhos Pd G2 (11.62 mg, 14.77 μmol) were added and reacted at 100°C for 2 hours. After cooling, the system was concentrated under reduced pressure. Compound 24-2 was purified by column chromatography (methanol / ethyl acetate = 0% to 10%) to give compound 24-2. MS m / z: 597.2 [M+1] + .
[0580] Step 3: Synthesis of trifluoroacetate salt of compound 24-3
[0581] Under nitrogen, compound 24-2 (36 mg, 60.33 μmol) was dissolved in DCM (2.5 mL) and trifluoroacetic acid (0.5 mL) was added. The mixture was allowed to react at 25°C for 1 hour. The solvent was concentrated under reduced pressure to obtain a crude product. The crude product was purified by prep-HPLC (column: Phenomenex Luna C18 75*30mm*3μm; mobile phase: water (TFA)-acetonitrile; acetonitrile percentage: 1%-30%, 8 min) to obtain the trifluoroacetate salt of compound 24-3. MS m / z: 497.2 [M+1] + ; 1 H NMR (400MHz, CD3OD) δ10.12(s,1H),8.40(d,J=5.2Hz,1H),7.63(d,J=8.8Hz,1H),7.53-7.47(m,1H),7.40(d,J=5.2Hz,1H),7.14(d,J=8 .8Hz,1H),6.79(d,J=3.6Hz,1H),4.80-4.70(m,2H),4.67(s,2H),3.95-3.82(m,6H),3.74-3.64(m,2H),3.50-3.35(m,4H),3.10(s,3H).
[0582] Step 4: Synthesis of Compound 24, Trifluoroacetate of Compound 24, Compound 40, and Trifluoroacetate of Compound 40
[0583] The trifluoroacetate salt of compound 24-3 was subjected to SFC chiral separation (chromatographic column: DAICEL CHIRALPAK IC (250 mm*25 mm, 10 μm); mobile phase: A n-heptane, B isopropanol / acetonitrile = 2 / 1, 0.1% ammonia water, B%: 40%) to obtain compound 24 and compound 40.
[0584] Compound 24: 1H NMR(DMSO-d6,400MHz)δ9.98(s,1H),9.60(s,1H),9.18(s,1H),8.35(d,1H,J=3.6Hz),7 .57(d,1H,J=3.6Hz),7.45(d,1H,J=8.8Hz),7.38(d,1H,J=5.2Hz),7.00(d,1H,J=8.4Hz) ,6.91(d,1H,J=3.2Hz),4.71(s,2H),3.91-4.09(m,2H),3.88(s,3H),3.75-3.77(m,3H),3.50-3.68(m,1H),3.17-3.31(m,5H),2.68-3.10(m,3H);ee%=97.35%;retention time: 3.147min.
[0585] Compound 40: 1 H NMR(DMSO-d6,400MHz)δ9.99(s,1H),9.64(s,1H),9.20(s,1H),8.35(d,1H,J=3.6Hz),7 .58(d,1H,J=3.5Hz),7.45(d,1H,J=5.2Hz),7.38(d,1H,J=5.2Hz),7.07(d,1H,J=8.8Hz) ,6.91(d,1H,J=3.2Hz),4.72(s,2H),3.91-4.10(m,2H),3.88(s,3H),3.70-3.80(m,3H),3.51-3.62(m,1H),3.17-3.30(m,5H),2.66-3.10(m,3H);ee%=97.65%;retention time: 3.683min.
[0586] EE% analysis method: (Chromatographic column: DAICEL CHIRALPAK IC (50*4.6 mm 3 μm); mobile phase: A: n-heptane (0.1% DEA), B: isopropanol / acetonitrile = 2 / 1, B%: 45%).
[0587] Compound 24 (658 mg, 1.33 mmol) was dissolved in DCM (7 mL), TFA (492.61 μL) was added, and the mixture was stirred at 25°C for 1 hour. The mixture was then concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 24. MS m / z: 497.1 [M+1] + ;ee%=97.85%; 1H NMR(DMSO-d6,400MHz)δ10.03(s,1H),9.72(s,1H),9.24(s,1H),8.35(d,1H,J=5.2Hz),7.60(m,2H),7.41(d,1H, J=5.2Hz),7.17-7.24(m,1H),6.92(d,1H,J=3.6Hz),4.60(s,2H),3.88(s,3H),3.36-3.78(m,11H),3.01(s,3H).
[0588] Compound 40 (1.26 g, 2.54 mmol) was dissolved in DCM (13 mL), TFA (942.43 μL) was added, and the mixture was stirred at 25°C for 1 hour. The mixture was then concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 40. MS m / z: 497.1 [M+1] + ;ee%=97.84%; 1 H NMR(DMSO-d6,400MHz)δ10.00(s,1H),9.72(s,1H),9.25(s,1H),8.37(d,1H,J=5.2Hz),7.59(m,2H),7.41(d,1H,J=5.2 Hz),7.21(m,1H),6.92(d,1H,J=3.6Hz),4.73(s,2H),4.65-4.62(m,1H),3.88(s,3H),3.78-3.71(m,5H),3.71-3.35(m 5H),3.00(s,3H).
[0589] Example 25
[0590] Step 1: Synthesis of compound 25-1
[0591] Under nitrogen, compound 16-9 (40 mg, 170.72 μmol) was dissolved in dioxane (2 mL), and compound 23-1 (67.92 mg, 170.72 μmol), potassium carbonate (70.79 mg, 512.17 μmol), Ruphos (15.93 mg, 34.14 μmol), and Pd2(dba)3 (15.63 mg, 17.07 μmol) were added. The mixture was reacted at 110°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure. Compound 25-1 was purified by column chromatography (methanol / ethyl acetate = 0% to 10%) to give compound 25-1. MS m / z: 596.2 [M+1] + .
[0592] Step 2: Synthesis of trifluoroacetate salt of compound 25
[0593] Under nitrogen, compound 25-1 (82 mg, 137.66 μmol) was dissolved in DCM (3 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was allowed to react at 25°C for 16 hours. The solvent was concentrated under reduced pressure to obtain a crude product. The crude product was purified by prep-HPLC (column: Phenomenex C18 80*30mm*3μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 1%-30%, 8 min) to obtain the trifluoroacetate salt of compound 25. MS m / z: 496.1 [M+1] + ; 1 H NMR (400MHz, CD3OD) δ8.76(d,J=8.4Hz,1H),8.35(d,J=5.2Hz,1H),7.77(d,J=8 .4Hz,1H),7.59(d,J=8.8Hz,1H),7.49(d,J=3.6Hz,1H),7.30(d,J=5.2Hz,1H),7 .08(d,J=8.8Hz,1H),6.53(d,J=3.2Hz,1H),4.85-4.60(m,3H),4.49(s,2H),3.9 5(s,3H),3.93-3.82(m,3H),3.76-3.60(m,2H),3.51-3.34(m,3H),3.08(s,3H).
[0594] Example 26
[0595] Step 1: Synthesis of compound 26-1
[0596] Compound 23-1 (0.1 g, 251.35 μmol) and 4-6 (52.09 mg, 251.35 μmol) were added to anhydrous dioxane (2 mL), followed by potassium carbonate (104.21 mg, 754.05 μmol), Ruphos (17.59 mg, 37.70 μmol), and Pd2(dba)3 (23.02 mg, 25.13 μmol). The mixture was reacted at 110°C for 2 hours. The reaction solution was added to water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 26-1. MS m / z: 569.2 [M+1] + .
[0597] Step 2: Synthesis of trifluoroacetate salt of compound 26
[0598] Compound 26-1 (0.12 g, 211.04 μmol) was added to DCM (2 mL) followed by trifluoroacetic acid (1 mL). The mixture was allowed to react at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by prep-HPLC (column: Phenomenex Luna C18 75*30mm*3μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 10%-40%, 8 min) to obtain the trifluoroacetate salt of compound 26. MS m / z: 469.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δppm 9.85(s,1H),8.74(s,1H),8.47(d,J=8.6Hz,1H),8.31(d,J=5.0Hz,1H) ,7.71(d,J=8.6Hz,1H),7.58(s,1H),7.30-7.26(m,2H),6.60(d,J=8.4H z,1H),6.47(s,1H),4.45(s,2H),4.39–4.36(m,1H),4.06–4.01(m,5H) ,3.92–3.87(m,3H),3.20–3.17(m,1H),3.04(s,1H),2.68-2.65(m,1H).
[0599] Example 27
[0600] Step 1: Synthesis of compound 27-1
[0601] In a dry vial, compound 17-9 (40 mg, 171.48 μmol) and compound 23-1 (68.22 mg, 171.48 μmol) were dissolved in dioxane (8 mL) and cesium carbonate (167.62 mg, 514.44 μmol) was added. After stirring for 15 minutes and measuring pH > 9, palladium acetate (7.7 mg, 34.3 μmol) and Xantphos (12.40 mg, 21.43 μmol) were added. The reaction was stirred at 110°C under nitrogen for 1 hour. The reaction mixture was filtered, and the filtrate was concentrated. Compound 27-1 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 10%).
[0602] Step 2: Synthesis of trifluoroacetate salt of compound 27
[0603] In a dry vial, compound 27-1 (70 mg, 117.71 μmol) was dissolved in DCM (1 mL) and trifluoroacetic acid (671.09 mg, 5.89 mmol, 435.77 μL) was added. The reaction was stirred at 25°C for 2 hours. The reaction solution was concentrated to obtain the crude product, which was purified by prep-HPLC (column: Phenomenex luna C18 100*40mm*3μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 10%-48%, 8 min) to obtain the trifluoroacetate salt of compound 27. MS m / z: 495.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.167(s,1H),8.84(s,1H),8.71(d,J=8.4Hz,1H),8.12 (d,J=4.8Hz,1H),7.77(d,J=8.4Hz,1H),7.59(s,1H),7.50(d,J=8.0Hz,1H),7.28 (d,J=5.2Hz,1H),6.98(d,J=8.4Hz,1H),6.49(s,1H),5.30(d,J=15.2Hz,1H),4.46-4.43(m,4H),4. 03-3.99(m,1H),3.97-3.92(m,2H),3.90(s,3H),3.72-3.67(m,1H),3.30-3.27(m,1H),2.94(s,3H).
[0604] Example 28
[0605] Step 1: Synthesis of compound BB-11-2
[0606] Under nitrogen protection, compound BB-11-1 (40 g, 188.64 mmol) was added to concentrated sulfuric acid (2000 mL), cooled to -10°C, and concentrated nitric acid (21.55 mL) was slowly added dropwise. The reaction was carried out at -10°C for 2 hours, and then the temperature was raised to 20°C for 2 hours. The reaction solution was slowly poured into ice water (2000 mL), filtered, and the filter cake was rinsed with water (200 mL). The filter cake was dried to obtain a crude product, which was added to ethanol (400 mL) and stirred for 2 hours, then filtered. The filter cake was concentrated under reduced pressure to obtain compound BB-11-2. 1 H NMR (400MHz, CDCl3) δ7.87 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.44 (s, 1H), 4.47 (s, 2H).
[0607] Step 2: Synthesis of compound BB-11-3
[0608] Under nitrogen, compound BB-11-2 (51 g, 198.41 mmol) was added to dioxane (510 mL), followed by di-tert-butyl dicarbonate (64.95 g, 297.62 mmol, 68.37 mL), 4-dimethylaminopyridine (2.42 g, 19.84 mmol), and triethylamine (60.23 g, 595.24 mmol, 82.85 mL). The mixture was allowed to react at 20°C for 12 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then added to methyl tert-butyl ether (250 mL) and stirred for 2 hours. The mixture was filtered and the filter cake was dried to obtain compound BB-11-3. 1 H NMR (400MHz, CDCl3) δ7.84 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 4.65 (s, 2H), 1.49 (s, 9H).
[0609] Step 3: Synthesis of compound BB-11-4
[0610] Under nitrogen, compound BB-11-3 (15 g, 42.00 mmol) and compound 4-8 (10.25 g, 42.00 mmol) were added to a mixture of dioxane (150 mL) and water (30 mL). Potassium phosphate (17.83 g, 84.00 mmol) and XPhos Pd G2 (4.96 g, 6.30 mmol) were added, and the temperature was raised to 70°C for 2 hours. The reaction solution was added to water (200 mL) and extracted with ethyl acetate (200 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (ethyl acetate / petroleum ether = 0% to 20%) to obtain compound BB-11-4. MS m / z: 409.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.39 (d, J=5.0Hz, 1H), 7.80 (d,J=2.0Hz,2H),7.24-7.19(m,1H),6.99(d,J=5.0Hz,1H),6.19(d,J=3.6Hz,1H),4.64(s,2H),3.91(s,3H),1.48(s,9H).
[0611] Step 4: Synthesis of Compound BB-11
[0612] Under nitrogen, compound BB-11-4 (11.7 g, 28.65 mmol) was added to a mixture of ethanol (220 mL) and water (44 mL). Iron powder (8.00 g, 143.24 mmol) and ammonium chloride (7.66 g, 143.24 mmol) were also added, and the mixture was heated to 60°C for 2 hours. The mixture was cooled, filtered, and the filter cake was rinsed with a mixture of dichloromethane and methanol (10:1, 200 mL). The filtrate was concentrated under reduced pressure, and water (100 mL) was added. The mixture was extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound BB-11. MS m / z: 379.0 [M+1] + .
[0613] Step 5: Synthesis of compound 28-2
[0614] Under nitrogen, compound 28-1 (5 g, 22.48 mmol) was dissolved in DCM (50 mL), and Dess-Martin periodinane (11.44 g, 26.97 mmol, 8.35 mL) was added. The mixture was reacted at 25°C for 2 hours. Saturated sodium carbonate solution (50 mL) was added, and the aqueous phase was extracted with dichloromethane (50 mL × 3). The layers were separated, and the organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The organic phase was filtered and concentrated under reduced pressure to obtain the crude product. Compound 28-2 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 28-2. MS m / z: 222.0, 220.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ10.11 (s, 1H), 7.99 (d, J = 8.4Hz, 1H), 7.41 (d, J = 8.4Hz, 1H).
[0615] Step 6: Synthesis of compound 28-3
[0616] Methanol (21 mL), compound 28-2 (420 mg, 1.91 mmol), and methylamine hydrochloride (257.27 mg, 3.81 mmol) were added to a thumb flask and stirred. Potassium acetate (392.66 mg, 4.00 mmol) was then added and stirred at 25°C for 2 hours. NaBH(OAc)3 (1.21 g, 5.72 mmol) was then added and stirring continued at 25°C for 1 hour. The reaction mixture was poured into a saturated sodium carbonate solution (50 mL). The aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (dichloromethane:methanol = 2% to 10%) to yield compound 28-3. MS m / z: 234.8, 236.8 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ 8.10 (d, J = 8.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 3.84 (s, 2H), 2.34 (s, 3H).
[0617] Step 7: Synthesis of compound 28-5
[0618] Under nitrogen, compound 28-3 (400 mg, 1.70 mmol) was dissolved in DMF (4 mL), and compound 28-4 (470.26 mg, 2.18 mmol), HATU (968.70 mg, 2.55 mmol), and DIEA (658.52 mg, 5.10 mmol, 887.50 μL) were added. The mixture was reacted at 25°C for 0.5 h. The reaction system was concentrated, water (5 mL) was added, and the aqueous phase was extracted with ethyl acetate (10 mL). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 28-5 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 30% to 50%) to obtain compound 28-5. MS m / z: 432.2, 434.2 [M+1] + .
[0619] Step 8: Synthesis of the hydrochloride salt of compound 28-6
[0620] Compound 28-5 (312 mg, 720.99 μmol) was added to hydrochloric acid / ethyl acetate (4 M, 5 mL) and reacted at 25°C for 2 hours. The reaction system was concentrated to obtain the hydrochloride salt of compound 28-6. MS m / z: 332.0, 334.0 [M+1] + .
[0621] Step 9: Synthesis of compound 28-7
[0622] Under nitrogen, the hydrochloride salt of compound 28-6 (294 mg) was dissolved in dioxane (3 mL), and cesium carbonate (1.04 g, 3.19 mmol) and Xantphos Pd G4 (76.66 mg, 79.66 μmol) were added. The reaction was allowed to react at 110°C for 2 hours. The reaction system was concentrated, and water (10 mL) was added. The aqueous phase was extracted with ethyl acetate (10 mL). The layers were separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 28-7 was purified by column chromatography (ethyl acetate / petroleum ether = 30% to 60%) to obtain compound 28-7. MS m / z: 252.1 [M+1] + ; 1H NMR (400MHz, CDCl3) δ6.99(d,J=8.6Hz,1H),6.65(d,J=8.6Hz,1H),5.40(d,J=16.8Hz,1H),4.90 (m,1H),3.98(d,J=17.0Hz,1H),3.23-3.12(m,2H),3.05(s,3H),2.59(m,1H),2.03-1.85(m,3H).
[0623] Step 10: Synthesis of compound 28-8
[0624] Under nitrogen, compound BB-11 (50 mg, 132.13 μmol) was dissolved in dioxane (1 mL), and compound 28-7 (39.91 mg, 158.55 μmol), cesium carbonate (86.10 mg, 264.25 μmol), palladium acetate (2.97 mg, 13.21 μmol), and BINAP (12.34 mg, 19.82 μmol) were added. The reaction was allowed to react at 110°C for 2 hours. The reaction system was concentrated, water (10 mL) was added, and the aqueous phase was extracted with ethyl acetate (10 mL). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 28-8 was purified by preparative thin-layer chromatography on silica gel (ethyl acetate / petroleum ether = 30%) to obtain compound 28-8. MS m / z: 594.5 [M+1] + .
[0625] Step 11: Synthesis of compound 28
[0626] Under nitrogen, compound 28-8 (30 mg, 50.53 μmol) was dissolved in DCM (1 mL), trifluoroacetic acid (1 mL) was added, and the mixture was reacted at 25°C for 2 hours. The reaction system was concentrated under reduced pressure, saturated sodium bicarbonate (5 mL) was added, and the aqueous phase was extracted with ethyl acetate (5 mL). The layers were separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 28 was purified by preparative thin-layer chromatography on silica gel (ethyl acetate). MS m / z: 494.2 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ9.76(s,1H),8.72(s,1H),8.38(d,J=8.6Hz,1H),8.30(d,J=5.0Hz,1H),7 .70(d,J=8.6Hz,1H),7.57(d,J=3.6Hz,1H),7.25(d,J=5.0Hz,1H),6.99(d,J=8.8Hz,1H),6.93(d, J=8.6Hz,1H),6.47(d,J=3.6Hz,1H),5.67(d,J=16.9Hz,1H),5.01-5.09(m,1H),4.45(s,2H),4.0 5(d,J=17.0Hz,1H),3.87(s,3H),3.02(s,3H),2.42(m,2H),1.84-1.93(m,2H),1.37-1.13(m,2H).
[0627] Example 29
[0628] Step 1: Synthesis of compound 29-2
[0629] Compound 29-1 (5 g, 26.73 mmol) and di-tert-butyl dicarbonate (17.50 g, 80.20 mmol, 18.42 mL) were added to tetrahydrofuran (50 mL), followed by 4-dimethylaminopyridine (326.59 mg, 2.67 mmol). The mixture was allowed to react at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 1%) to obtain compound 29-2. MS m / z: 386.9, 388.9 [M+1] + .
[0630] Step 2: Synthesis of compound 29-3
[0631] Compound 29-2 (2.5 g, 6.46 mmol) was added to 1,2-dichloroethane (25 mL), followed by N-bromosuccinimide (1.72 g, 9.68 mmol) and azobisisobutyronitrile (106.01 mg, 645.55 μmol). The reaction mixture was heated to 80°C and allowed to react for 12 hours. The reaction mixture was added to water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated by column chromatography (ethyl acetate / petroleum ether = 0% to 2%) to obtain compound 29-3. MS m / z: 466.6, 468.7 [M+1] + .
[0632] Step 3: Synthesis of compound 29-5
[0633] Compound 29-3 (0.9 g, 1.93 mmol) and compound 29-4 (264.45 mg, 2.32 mmol) were added to acetonitrile (27 mL), followed by DIEA (748.57 mg, 5.79 mmol, 1.01 mL). The mixture was allowed to react at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure, and the crude product was separated by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 29-5. MS m / z: 499.0, 501.0 [M+1] + .
[0634] Step 4: Synthesis of compound 29-6
[0635] Compound 29-5 (0.85 g, 1.70 mmol) was added to dioxane (17 mL), along with cesium carbonate (1.11 g, 3.40 mmol) and Xantphos Pd G4 (163.80 mg, 170.21 μmol). The reaction mixture was heated to 110°C and allowed to react for 4 hours. Water (50 mL) was added to the reaction system, and the aqueous phase was extracted with ethyl acetate (50 mL × 3). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 29-6 was then separated by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to afford compound 29-6. MS m / z: 419.1 [M+1] + .
[0636] Step 5: Synthesis of compound 29-7
[0637] Compound 29-6 (0.5 g, 1.19 mmol) was added to trifluoroacetic acid (2 mL) and DCM (4 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure, dissolved in water (10 mL) and dichloromethane (10 mL), and added to a saturated aqueous sodium carbonate solution (50 mL). The mixture was extracted with a mixture of dichloromethane and methanol (10:1) (50 mL x 5) and separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain compound 29-7. MS m / z: 218.9 [M+1] + .
[0638] Step 6: Synthesis of compound 29-8
[0639] Compound 23-1 (60 mg, 150.81 μmol) and compound 29-7 (39.50 mg, 180.97 μmol) were added to dioxane (2 mL), followed by potassium carbonate (41.69 mg, 301.62 μmol), Ruphos (14.07 mg, 30.16 μmol), and Pd2(dba)3 (13.81 mg, 15.08 μmol). The temperature was raised to 110°C and the reaction mixture was reacted for 2 hours. Water (50 mL) was added to the reaction system, and the aqueous phase was extracted with ethyl acetate (50 mL × 3). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 29-8. MS m / z: 580.2 [M+1] + .
[0640] Step 7: Synthesis of trifluoroacetate salt of compound 29
[0641] Compound 29-8 (60 mg, 103.51 μmol) was added to DCM (2 mL) and trifluoroacetic acid (1 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure and purified by prep-HPLC (Phenomenex Luna 80*30 mm*3 μm column; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 1%-25%, 8 min) to obtain the trifluoroacetate salt of compound 29. MS m / z: 480.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ11.17(m,1H),10.45(s,1H),8.92-8.89(m,2H),8.34(d,J=4.8Hz,1 H),7.80–7.72(m,2H),7.60(d,J=3.6Hz,1H),7.28(d,J=4.8Hz,1H),6.89(d,J=8.2Hz,1H), 6.45(d,J=3.4Hz,1H),4.60–4.57(m,1H),4.50(s,3H),4.20-4.08(m,2H),3.72–3.70(m,1H ),3.67-3.65(m,2H),3.28-3.27(m,1H),2.17(s,1H),2.16-2.13(m,1H),1.94-1.90(m,2H).
[0642] Example 30
[0643] Step 1: Synthesis of compound 30-2
[0644] Under nitrogen, compound 30-1 (75 g, 363.25 mmol) was dissolved in tetrahydrofuran (750 mL), cooled to -65°C, and a 2M solution of lithium diisopropylamide in tetrahydrofuran (217.95 mL) was added. The mixture was allowed to react at -65°C for 1 hour. Dimethyl carbonate (65.44 g, 726.51 mmol, 61.16 mL) was added, and the temperature was raised to 20°C for 3 hours. The reaction was quenched with saturated ammonium chloride (200 mL), and water (500 mL) was added. The mixture was extracted with ethyl acetate (1000 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 30-2 was purified by column chromatography (ethyl acetate / petroleum ether = 1% to 10%) to obtain compound 30-2. MS m / z: 264.0, 266.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.20(s,1H),3.93(s,3H),2.04(s,3H).
[0645] Step 2: Synthesis of compound 30-3
[0646] Under nitrogen, compound 30-2 (8.2 g, 31.00 mmol) was dissolved in 1,2-dichloroethane (80 mL), and N-bromosuccinimide (16.55 g, 93.00 mmol) and azobisisobutyronitrile (1.02 g, 6.20 mmol) were added. The mixture was allowed to react at 80°C for 5 hours. The mixture was cooled and quenched with saturated sodium sulfite solution (80 mL). The mixture was extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to obtain compound 30-3. MS m / z: 343.8 [M+1] + .
[0647] Step 3: Synthesis of compound 30-4
[0648] Under nitrogen, compound 30-3 (11.86 g, 34.54 mmol) was dissolved in a 7M ammonia / methanol solution (200 mL) and reacted at 25°C for 16 hours. The mixture was filtered and the residue was washed with methanol (20 mL) to obtain compound 30-4. 1 H NMR (400MHz, DMSO-d6) δ8.55 (s, 1H), 4.35 (s, 2H).
[0649] Step 4: Synthesis of compound 30-5
[0650] Under nitrogen, compound 30-4 (2.94 g, 11.88 mmol) was dissolved in tetrahydrofuran (30 mL), and di-tert-butyl dicarbonate (3.89 g, 17.82 mmol, 4.09 mL) and 4-dimethylaminopyridine (290.27 mg, 2.38 mmol) were added. The mixture was allowed to react at 25°C for 1 hour. The solvent was concentrated under reduced pressure, and the mixture was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0-10%) to obtain compound 30-5. MS m / z: 347.0 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.64(s,1H),4.67(s,2H),1.53(s,9H).
[0651] Step 5: Synthesis of compound 30-6
[0652] Under nitrogen protection, compound 30-5 (3.07 g, 8.83 mmol) was added to dioxane (60 mL) and water (12 mL). Compound 4-8 (2.16 g, 8.83 mmol), potassium carbonate (2.44 g, 17.66 mmol), and Pd(dppf)Cl2 (646.26 mg, 883.22 μmol) were added and reacted at 70°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure to obtain a crude product. The crude product was added to water (10 mL) and ethyl acetate (20 mL) and stirred for 1 hour. The mixture was filtered and the filter residue was washed with ethyl acetate (10 mL). The filter residue was collected to obtain compound 30-6. MS m / z: 399.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ8.95(s,1H),8.43(d,J=4.8Hz,1H),7.65(d,J=3.6Hz,1H),7 .41(d,J=4.8Hz,1H),6.69(d,J=3.6Hz,1H),4.92(s,2H),3.89(s,3H),1.51(s,9H).
[0653] Step 6: Synthesis of compound 30-7
[0654] Compound 30-6 (30 mg, 75.22 μmol) and compound 29-7 (19.70 mg, 90.26 μmol) were added to dioxane (2 mL), followed by Xantphos Pd G4 (7.24 mg, 7.52 μmol) and cesium carbonate (73.52 mg, 225.65 μmol). The temperature was raised to 110°C and the reaction mixture was reacted for 2 hours. Water (30 mL) was added to the reaction system, and the aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 30-7. MS m / z: 581.2 [M+1] + .
[0655] Step 7: Synthesis of trifluoroacetate salt of compound 30
[0656] Compound 30-7 (50 mg, 86.11 μmol) was added to dioxane (2 mL) and trifluoroacetic acid (1 mL) and allowed to react at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure. The trifluoroacetic acid salt of compound 30 was purified by prep-HPLC (Phenomenex Luna 80*30 mm*3 μm column; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 1%-25%, 8 min). MS m / z: 481.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ11.31(br s,1H),10.23(s,1H),10.03(s,1H),9.30(s,1H),8.38(d,J=4.8Hz,1H),7.82(br d,J=8.4Hz,1H),7.60(d,J=3.4Hz,1H),7.42(d,J=5.0Hz,1H),6.98(d,J=8.2Hz,1H),6.91(d,J=3.6Hz,1H),4.76(s,2H),4.61-4.5 8(m,1H),4.53-4.52(m,1H),4.23-4.18(m,1H),3.88(s,3H),3.32(s,1H),2.61-2.58(m,2H),2.17-2.15(m,1H),1.94-1.88(m,2H).
[0657] Example 31
[0658] Step 1: Synthesis of compound 31-1
[0659] Compound 29-7 (50 mg, 229.09 μmol) and iodomethane (35.12 mg, 247.42 μmol, 15.40 μL) were added to DMF (1 mL). The temperature was cooled to 0°C, and sodium hydride (9.90 mg, 247.42 μmol, 60% purity) was added. The mixture was stirred at 25°C for 1 hour. The reaction mixture was slowly added to saturated aqueous ammonium chloride (30 mL), and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 31-1. MS m / z: 232.9 [M+1] + .
[0660] Step 2: Synthesis of compound 31-2
[0661] Compound 23-1 (20 mg, 50.27 μmol) and compound 31-1 (14.01 mg, 60.32 μmol) were added to dioxane (2 mL), followed by cesium carbonate (32.76 mg, 100.54 μmol), Pd(OAc)2 (1.13 mg, 5.03 μmol), and Xantphos (5.82 mg, 10.05 μmol). The temperature was raised to 110°C and the mixture was reacted for 2 hours. The reaction mixture was added to water (20 mL) and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the filtrate was filtered and concentrated under reduced pressure to obtain compound 31-2. MS m / z: 594.4 [M+1] + .
[0662] Step 3: Synthesis of trifluoroacetate salt of compound 31
[0663] Compound 31-2 (30 mg, 50.53 μmol) was added to DCM (2 mL) and trifluoroacetic acid (1 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure and purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 20%-50%, 8 min). The organic solvent was removed by concentration and added to saturated aqueous sodium bicarbonate (10 mL). The mixture was extracted with dichloromethane (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Methanol (0.2 mL) was added for dissolution. Trifluoroacetic acid (5 μL) was added, followed by deionized water (3 mL) to obtain the trifluoroacetate salt of compound 31. MS m / z: 494.4 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.50(s,1H),8.94(s,1H),8.62(d,J=8.4Hz,1H),8.33(d, J=5.0Hz,1H),7.83(d,J=8.4Hz,2H),7.60(d,J=3.6Hz,1H),7.29(d,J=4.8Hz,1H),7 .00(d,J=8.4Hz,1H),6.47(d,J=3.4Hz,1H),4.50(s,3H),3.70-3.65(m,3H),3.54( s,3H),3.17-3.16(m,2H),2.26-2.16(m,2H),1.94-1.84(m,2H),1.26-1.24(m,2H).
[0664] Example 32
[0665] Step 1: Synthesis of compound 32-2
[0666] Under nitrogen, compound 16-1 (5 g, 23.23 mmol) was added to DCM (120 mL), followed by compound 32-1 (5.98 g, 23.23 mmol) and acetic acid (1.39 g, 23.23 mmol, 1.33 mL). The mixture was allowed to react at 20°C for 1 hour. NaBH(OAc)3 (7.38 g, 34.84 mmol) was then added and the mixture was allowed to react at 20°C for 16 hours. The reaction was quenched with saturated aqueous sodium bicarbonate (50 mL) and extracted with dichloromethane (50 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 32-2 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 20%). MS m / z: 457.2 [M+1] + ; 1 H NMR(400MHz, CDCl3) δ7.25(d,J=8.4Hz,4H),6.84(d,J=8.4Hz,4H),4.30-3.96(m,1H),3.9 0(d,J=11.6Hz,1H),3.80(s,6H),3.73-3.42(m,7H),3.41-3.28(m,1H),2.68(s,3H),1.48( S ,9H).
[0667] Step 2: Synthesis of compound 32-3
[0668] Under nitrogen, compound 32-2 (8.4 g, 18.40 mmol) was dissolved in DCM (40 mL), and hydrochloric acid / methanol (4 M, 140 mL) was added. The mixture was allowed to react at 20°C for 16 hours. The solvent was concentrated under reduced pressure, and dichloromethane (40 mL) and aqueous ammonia (5 mL) were added. The mixture was dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain compound 32-3. MS m / z: 357.2 [M+1] + .
[0669] Step 3: Synthesis of compound 32-4
[0670] Under nitrogen, compound 32-3 (4 g, 11.22 mmol) was dissolved in DMF (80 mL), and compound BB-1-1 (2.75 g, 13.47 mmol) and DIEA (4.35 g, 33.66 mmol, 5.86 mL) were added. The mixture was allowed to react at 100°C for 16 hours. The mixture was cooled, quenched with water (100 mL), and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 32-4 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 32-4. MS m / z: 540.1 [M+1] + ; 1 H NMR(400MHz, CDCl3)δ9.83(s,1H),7.45(d,J=8.8Hz,1H),6.98(d,J=8.8Hz,1H),6.92-6.86(m,4H),6.85-6.78(m,4H),4.07-4.03(m,1H), 3.91-3.74(m,8H),3.67-3.56(m,1H),3.54-3.41(m,3H),3.10-2.97(m,3H),2.86-2.81(m,1H),2.67(d,J=12.0Hz,1H),2.53-2.48(m,1H).
[0671] Step 4: Synthesis of compound 32-5
[0672] Under nitrogen, compound 32-4 (6 g, 11.10 mmol) was dissolved in trifluoroacetic acid (63.29 g, 555.10 mmol, 41.10 mL) and reacted at 60°C for 16 hours. The mixture was cooled and concentrated under reduced pressure. Dichloromethane (60 mL) and NaBH(OAc)3 (7.06 g, 33.31 mmol) were added and reacted at 25°C for 2 hours. The reaction was quenched with saturated sodium bicarbonate solution (50 mL), extracted with dichloromethane (50 mL × 3), and the organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 32-5 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 32-5. MS m / z: 404.0, 406.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.24(d,J=9.6Hz,3H),7.09(d,J=8.4Hz,1H),6.85(d,J=8.4Hz,2H),4.04(s,2H),3.89-3.81(m,5 H),3.71-3.63(m,3H),3.59-3.51(m,1H),3.35-3.27(m,2H),3.26-3.17(m,1H),3.09-3.01(m,1H),2.63-2.54(m,1H).
[0673] Step 5: Synthesis of compound 32-6
[0674] Under nitrogen, compound 32-5 (50 mg, 132.13 μmol) was dissolved in dioxane (2 mL), and compound BB-11 (53.42 mg, 132.13 μmol), cesium carbonate (129.15 mg, 396.38 μmol), Xantphos (15.29 mg, 26.43 μmol), and palladium acetate (2.97 mg, 13.21 μmol) were added. The mixture was reacted at 110°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure. Compound 32-6 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to give compound 32-6. MS m / z: 702.2 [M+1] + .
[0675] Step 6: Synthesis of trifluoroacetate salt of compound 32
[0676] Under nitrogen, compound 32-6 (60 mg, 85.49 μmol) was dissolved in trifluoroacetic acid (6 mL) and reacted at 80°C for 72 hours. The mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by prep-HPLC (column: Phenomenex luna C18 100*40mm*3μm; mobile phase: [water(TFA(-acetonitrile]; B%: 10%-55%, 8 min)) to obtain the trifluoroacetate salt of compound 32. MS m / z: 482.2 [M+1] + ; 1 H NMR (400MHz, CD3OD) δ8.75(d,J=8.8Hz,1H),8.35(d,J=5.2Hz,1H),7.77(d,J=8.8 Hz,1H),7.60(d,J=8.8Hz,1H),7.49(d,J=3.6Hz,1H),7.31(d,J=5.2Hz,1H),7.08 (d,J=8.8Hz,1H),6.53(d,J=3.6Hz,1H),4.66-4.52(m,2H),4.49(s,2H),3.98-3. 91(m,4H),3.90-3.82(m,2H),3.77-3.70(m,1H),3.48(s,3H),3.40-3.35(m,2H).
[0677] Example 33
[0678] Step 1: Synthesis of compound 33-1
[0679] Under nitrogen, compound 32-5 (1.0 g, 2.47 mmol) was added to trifluoroacetic acid (20.00 mL) and allowed to react at 80°C for 24 hours. The mixture was concentrated under reduced pressure, methanol (20 mL) was added, and solid sodium bicarbonate was added to quench the reaction. The residue was filtered, washed with methanol (20 mL), and the filtrate was concentrated under reduced pressure. Compound 33-1 was purified by column chromatography (methanol / dichloromethane = 0% to 20%) to obtain compound 33-1. MS m / z: 284.0 [M+1] + .
[0680] Step 2: Synthesis of compound 33-2
[0681] Under nitrogen, compound 33-1 (100 mg, 351.92 μmol) was dissolved in DMF (1 mL), and potassium carbonate (97.28 mg, 703.85 μmol) and iodoethane (54.89 mg, 351.92 μmol, 28.15 μL) were added. The mixture was allowed to react at 25°C for 16 hours. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10 mL) and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 33-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 70%) to obtain compound 33-2. MS m / z: 312.2 [M+1] + .
[0682] Step 3: Synthesis of compound 33-3
[0683] Under nitrogen, compound BB-11 (40 mg, 105.70 μmol) was dissolved in dioxane (2 mL), and compound 33-2 (33.00 mg, 105.70 μmol), cesium carbonate (103.32 mg, 317.11 μmol), and [9,9-dimethyl-4,5-bis(diphenyl)xanthene](2-methylamino-1,1-biphenyl-2-yl)palladium(II) methanesulfonate (10.17 mg, 10.57 μmol) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled and concentrated under reduced pressure. Compound 33-3 was purified by column chromatography (methanol / ethyl acetate = 0% to 10%) to give compound 33-3. MS m / z: 610.2 [M+1] + .
[0684] Step 4: Synthesis of trifluoroacetate salt of compound 33
[0685] Under nitrogen, compound 33-3 (30 mg, 49.20 μmol) was dissolved in DCM (1.5 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was allowed to react at 25°C for 2 hours. The mixture was concentrated under reduced pressure to obtain a crude product. The product was purified by prep-HPLC (column: Phenomenex Luna C18 150*30mm*5μm; mobile phase: [water (TFA)-acetonitrile]; B%: 1%-30%, 8 min). The trifluoroacetate salt of compound 33-3 was obtained. MS m / z: 510.1 [M+1] + ; 1H NMR (400MHz, CD3OD) δ8.75(d,J=8.4Hz,1H),8.36(d,J=5.2Hz,1H),7.78(d,J=8 .4Hz,1H),7.59(d,J=8.8Hz,1H),7.51(d,J=3.6Hz,1H),7.33(d,J=5.2Hz,1H), 7.09(d,J=8.8Hz,1H),6.55(d,J=3.6Hz,1H),4.80-4.62(m,3H),4.49(s,2H),4 .01-3.82(m,7H),3.72-3.59(m,2H),3.53-3.40(m,4H),1.47(t,J=7.2Hz,3H).
[0686] Example 34
[0687] Step 1: Synthesis of compound 34-2
[0688] Under nitrogen, compound 28-2 (1.5 g, 6.80 mmol) was added to DCM (15 mL), followed by 2,4-dimethoxybenzylamine (1.25 g, 7.48 mmol, 1.13 mL) and AcOH (408.59 mg, 6.80 mmol). The mixture was allowed to react at 25°C for 1 hour. NaBH(OAc)3 (1.73 g, 8.17 mmol) was then added, and the mixture was allowed to react at 25°C for 15 hours. The reaction was quenched with saturated aqueous sodium bicarbonate (50 mL), extracted with dichloromethane (50 mL × 3), and the organic phase was washed with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 34-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to yield compound 34-2. MS m / z: 371.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.72 (d, J = 8.4Hz, 1H), 7.18 (d, J = 8.8Hz, 1H), 7.06 (d, J = 8. 4Hz,1H),6.46-6.39(m,2H),3.98(s,2H),3.82(s,3H),3.81(s,2H),3.80(s,3H).
[0689] Step 2: Synthesis of compound 34-4
[0690] Under nitrogen, compound 34-2 (240 mg, 2.16 mmol) was dissolved in DMF (6 mL), and DIEA (6.48 mmol, 1.13 mL), HATU (1.23 g, 3.24 mmol), and compound 34-3 (802.87 mg, 2.16 mmol) were added. The mixture was allowed to react at 25°C for 2 hours. The reaction was quenched with water (20 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10 mL) and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 34-4 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to obtain compound 34-4. MS m / z: 485.9 [M+Na] + .
[0691] Step 3: Synthesis of compound 34-5
[0692] Under nitrogen, compound 34-4 (604 mg, 1.30 mmol) was dissolved in DMF (6 mL), and 1,10-phenanthroline (46.84 mg, 259.93 μmol), cesium carbonate (1.27 g, 3.90 mmol), and cuprous iodide (24.75 mg, 129.97 μmol) were added. The mixture was reacted at 140°C for 16 hours. The mixture was cooled and quenched with water (30 mL). The mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. Compound 34-5 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 34-5. MS m / z: 384.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.59(d,J=8.4Hz,1H),7.35(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),7.18-7.1 6(m,1H),7.06-7.05(m,1H),6.50-6.38(m,3H),4.76(s,2H),4.48(s,2H),3.82(s,3H),3.76(s,3H).
[0693] Step 4: Synthesis of compound 34-6
[0694] Under nitrogen, compound 34-5 (70 mg, 184.98 μmol) was dissolved in dioxane (4 mL), and compound BB-11 (71.00 mg, 184.98 μmol), cesium carbonate (180.81 mg, 554.93 μmol), 2-dicyclohexylphosphino-2-(N-dimethylamino)-biphenyl (14.56 mg, 37.00 μmol), and palladium acetate (4.15 mg, 18.50 μmol) were added. The mixture was reacted at 110°C for 4 hours. The mixture was cooled and concentrated under reduced pressure. The product was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to obtain compound 34-6. MS m / z: 726.1 [M+1] + .
[0695] Step 5: Synthesis of compound 34
[0696] Under nitrogen, compound 34-6 (60 mg, 82.67 μmol) was dissolved in trifluoroacetic acid (4 mL) and reacted at 25°C for 16 hours, then heated to 60°C for 6 hours. The mixture was concentrated under reduced pressure to obtain the crude product. The product was purified by prep-HPLC (column: Phenomenex C18 80*30mm*3μm; mobile phase: [water (TFA)-acetonitrile]; B%: 10%-40%, 8 min). The mixture was concentrated under reduced pressure, adjusted to pH 8 with aqueous ammonia, and extracted with dichloromethane (20 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain compound 34. MS m / z: 476.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.40-10.33(m,1H),8.87(s,1H),8.76(d,J=8.4Hz,1H),8.42-8.37 (m,1H),8.32(d,J=4.8Hz,1H),7.91(d,J=8.8Hz,1H),7.78(d,J=8.4Hz,1H),7.59(d,J=3.6H z,1H),7.50(d,J=2.0Hz,1H),7.28(d,J=4.8Hz,1H),7.16(d,J=8.8Hz,1H),6.90-6.89(m,1H ), 6.47 (d, J = 3.6Hz, 1H), 6.44-6.41 (m, 1H), 4.48 (s, 2H), 4.24 (d, J = 4.8Hz, 2H), 3.87 (s, 3H).
[0697] Example 35
[0698] Step 1: Synthesis of compound 35-2
[0699] Under nitrogen, compound 35-1 (125 mg, 540.55 μmol) was dissolved in DCM (2 mL), and DIEA (209.59 mg, 1.62 mmol, 282.46 μL), HATU (308.30 mg, 810.83 μmol), and compound 34-2 (200.90 mg, 540.55 μmol) were added. The mixture was reacted at 25°C for 2 hours. The reaction was quenched with water (20 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated brine (10 mL) and dried over anhydrous sodium sulfate. The filtrate was filtered, and concentrated under reduced pressure. Compound 35-2 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%) to obtain compound 35-2. MS m / z: 605.9, 607.9 [M+Na] + .
[0700] Step 2: Synthesis of compound 35-3
[0701] Under nitrogen, compound 35-2 (600 mg, 1.03 mmol) was dissolved in DCM (6 mL), zinc bromide (1.16 g, 5.13 mmol, 256.69 μL) was added, and the mixture was reacted at 25°C for 2 hours. The mixture was filtered, and the residue was washed with dichloromethane (10 mL). The filtrate was collected, and water (10 mL) was added. The mixture was extracted with dichloromethane (10 mL × 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 35-3 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to obtain compound 35-3. MS m / z: 484.0, 486.0 [M+1] + .
[0702] Step 3: Synthesis of compound 35-4
[0703] Under nitrogen, compound 35-3 (320 mg, 660.11 μmol) was dissolved in dioxane (6 mL). Cesium carbonate (645.23 mg, 1.98 mmol), 2-di-tert-butylphosphino-2'-N,N-dimethylaminobiphenyl (51.96 mg, 132.02 μmol), and palladium acetate (14.82 mg, 66.01 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (10 mL). The filtrate was concentrated under reduced pressure. Compound 35-4 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 70%) to obtain compound 35-4. MS m / z: 404.1 [M+1] + .
[0704] Step 4: Synthesis of compound 35-5
[0705] Under nitrogen, compound 35-4 (79 mg, 195.61 μmol) was dissolved in dioxane (4 mL). Benzophenone imine (42.54 mg, 234.74 μmol, 39.39 μL), sodium tert-butoxide (37.60 mg, 391.23 μmol), BINAP (24.36 mg, 39.12 μmol), and Pd2(dba)3 (17.91 mg, 19.56 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled and quenched with saturated sodium bicarbonate solution (10 mL). The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure to give compound 35-5. MS m / z: 549.2 [M+1] + .
[0706] Step 5: Synthesis of compound 35-6
[0707] Under nitrogen, compound 35-5 (107 mg, 195.03 μmol) was dissolved in DCM (2 mL), and trifluoroacetic acid (667.14 mg, 5.85 mmol, 433.21 μL) was added. The mixture was reacted at 25°C for 1 hour. The mixture was concentrated under reduced pressure, and dichloromethane (10 mL) and saturated sodium carbonate solution (10 mL) were added. The mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure. Compound 35-6 was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to give compound 35-6. MS m / z: 385.2 [M+1] + .
[0708] Step 6: Synthesis of compound 35-7
[0709] Under nitrogen, compound 30-6 (65 mg, 162.97 μmol) was dissolved in dioxane (3 mL), and compound 35-6 (62.65 mg, 162.97 μmol), cesium carbonate (159.30 mg, 488.92 μmol), and [9,9-dimethyl-4,5-bis(diphenyl)xanthene](2-methylamino-1,1-biphenyl-2-yl)palladium(II) methanesulfonate (15.68 mg, 16.30 μmol) were added. The mixture was reacted at 110°C for 2 hours. After cooling, the solvent was concentrated under reduced pressure. Compound 35-7 was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0% to 100%) to give compound 35-7. MS m / z: 747.2 [M+1] + .
[0710] Step 7: Synthesis of trifluoroacetate salt of compound 35
[0711] Under nitrogen, compound 35-7 (69 mg, 92.39 μmol) was dissolved in trifluoroacetic acid (2.5 mL) and reacted at 60°C for 16 hours. The solvent was concentrated under reduced pressure to obtain the crude product. The trifluoroacetic acid salt of compound 35 was purified by prep-HPLC (column: Phenomenex Luna C18 75*30mm*3μm; mobile phase: [water(trifluoroacetic acid)-acetonitrile]; acetonitrile percentage: 10%-40%, 8 min). MS m / z: 497.2 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ10.01(s,1H),9.68(s,1H),9.20(s,1H),8.40-8.35(m,2H), 7.67-7.54(m,2H),7.39(d,J=4.8Hz,1H),7.13(d,J=8.8Hz,1H),6.90(d,J=3.6Hz,1 H),4.72(s,3H),4.06-4.00(m,1H),3.97-3.90(m,2H),3.87(s,3H),3.78-3.71(m,1 H), 3.70-3.63 (m, 1H), 3.53-3.49 (m, 1H), 3.24-3.21 (m, 1H), 2.99 (d, J = 11.6Hz, 1H).
[0712] Example 36
[0713] Step 1: Synthesis of compound 36-1
[0714] In a dry vial, compound 32-5 (1 g, 2.47 mmol) was dissolved in dioxane (2 mL). Compound 16-7 (421.00 mg, 4.95 mmol) and cesium carbonate (2.42 g, 7.42 mmol) were added to the solution. After stirring for 15 minutes, when the pH was >9, Pd2(dba)3 (421.00 mg, 4.95 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (286.23 mg, 494.68 μmol) were added. The reaction was stirred at 110°C under nitrogen for 2 hours. The reaction mixture was filtered and the filtrate was concentrated. Compound 36-1 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 5%). MS m / z: 409.1 [M+1] + ; 1H NMR(400MHz, CDCl3)δ8.51(s,1H),8.05-8.01(m,1H),7.35-7.27(m,2H),6.92-6.88(m,2H),3.95-3.78(m,7H),3 .74-3.55(m,4H),3.37-3.18(m,3H),3.07-3.01(m,1H),2.68-2.64(m,1H),1.62-1.57(m,1H),1.11-1.02(m,4H).
[0715] Step 2: Synthesis of compound 36-2
[0716] In a dry vial, compound 36-1 (750 mg, 1.84 mmol) was dissolved in water (5 mL), methanol (20 mL) was added, and sodium hydroxide (1.10 g, 27.54 mmol) was added to the solution. The reaction was stirred at 80°C under nitrogen for 16 hours. The mixture was concentrated under reduced pressure and extracted with dichloromethane (20 mL x 5). The organic phases were combined and washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 36-2. MS m / z: 341.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 7.27-7.24(m,2H),7.14(d,J=8.4Hz,1H),6.87-6.84(m,2H),6.40(d,J=8. 4Hz,1H),4.19(s,2H),4.02-3.82(m,2H),3.80(s,3H),3.67-3.664(m,1H) ,3.63-3.61(m,1H),3.41-3.39(m,1H),3.11-3.09(m,1H),3.06-3.04(m,2 H),2.85(m,2H),2.61-2.59(m,1H),2.38-2.36(m,1H),2.05-2.03(m,1H).
[0717] Step 3: Synthesis of compound 36-3
[0718] In a dry vial, compound 36-2 (180 mg, 528.76 μmol) and compound 30-6 (210.89 mg, 528.76 μmol) were dissolved in dioxane (3 mL). Cesium carbonate (516.84 mg, 1.59 mmol) was added and stirred for 15 minutes until the pH was >9. Methanesulfonic acid (4,5-bis(diphenylphosphino-9,9-dimethylxanthene)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II)) (101.77 mg, 105.75 μmol) was added under nitrogen. The reaction was stirred at 110°C under nitrogen for 2 hours. The reaction solution was concentrated, and ethyl acetate (20 mL) and water (20 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by column chromatography (ethyl acetate / petroleum ether = 0% to 15%) to obtain compound 36-3. MS m / z: 703.3 [M+1] + ; 1 H NMR (400MHz, CDCl3) δppm 10.30(s,1H),9.42(s,1H),8.45(d,J=3.2Hz,1H),7.30-7.27(m,4H),7.21-7.19(m,1H),6.89-6.82(m,4H),4.95(s ,2H),4.17-4.11(m,1H),3.97(s,3H),3.95-3.80(m,9H),3.77-3.74(m,1H),3.38-3.14(m,3H),3.10-3.00(m,1H), 2.68-2.61(m,1H),1.62(s,9H).
[0719] Step 4: Synthesis of trifluoroacetate salt of compound 36
[0720] Compound 36-3 (42 mg, 59.76 μmol) was dissolved in trifluoroacetic acid (2 mL) in a dry vial and stirred at 85°C for 48 hours. The reaction solution was concentrated to obtain the crude product, which was then purified by prep-HPLC (column: Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile percentage: 5%-35%, 8 min) to obtain the trifluoroacetate salt of compound 36. MS m / z: 483.22 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δppm 10.01(s,1H),9.71(s,1H),9.24-9.16(m,2H),8.36(d,J=4.8Hz,1H),7.60-7.57(m,2H),7.39(d,J=4.8Hz,1H),7.19(d, J=8.8Hz,1H),6.89(d,J=3.2Hz,1H),4.72(s,2H),4.56-4.50(m,2H),3.87(s,3H),3.68-3.46(m,5H),3.27-3.14(m,4H).
[0721] Example 37
[0722] Step 1: Synthesis of trifluoroacetate salt of compound 37
[0723] In a dry vial, compound 36 (6.00 mg, 12.43 μmol) and acetone (2.17 mg, 37.30 μmol, 2.74 μL) were added to methanol (1 mL). Potassium acetate (2.44 mg, 24.87 μmol) and acetic acid (746.68 μg, 12.43 μmol) were added to the solution. The reaction was stirred for 10 minutes, followed by the addition of NaBH(OAc)₃ (7.91 mg, 37.30 μmol). The reaction was stirred at 25°C for 1 hour. The reaction solution was concentrated to obtain the crude product, which was then purified by prep-HPLC (column: Phenomenex Luna C₁₈ 75*30 mm*3 μm; mobile phase: [water (trifluoroacetic acid)-acetonitrile]; acetonitrile percentage: 10%-40%, 8 min) to afford the trifluoroacetate salt of compound 37. MS m / z: 525.3 [M+1] + .
[0724] Example 38
[0725] Step 1: Synthesis of compound BB-12
[0726] Compound BB-12-1 (30 g, 157.07 mmol) and triethylamine (47.68 g, 471.20 mmol, 65.59 mL) were added to DCM (300 mL), cooled to 0°C, and compound BB-12-2 (49.26 g, 471.20 mmol, 42.83 mL) was added. The mixture was allowed to react at 25°C for 16 hours. The reaction solution was poured into saturated aqueous ammonium chloride (300 mL), separated, and the aqueous phase was extracted with dichloromethane (50 mL × 2). The combined organic phases were washed with water (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was added to acetonitrile (200 mL), stirred for 3 hours, filtered, and the filter cake was dried to obtain compound BB-12. MS m / z: 258.9, 280.9 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.06(s,1H),7.94–7.92(m,1H),7.85–7.80(m,1H),1.49–1.47(m,1H),1.07–1.04(m,2H),0.89–0.85(m,2H).
[0727] Step 2: Synthesis of compound 38-2
[0728] Compound BB-12 (0.5 g, 1.93 mmol) and potassium tert-butoxide (866.25 mg, 7.72 mmol) were added to dimethyl sulfoxide (5 mL), followed by compound 5-1 (417.40 mg, 1.93 mmol), and the mixture was allowed to react at 25°C for 16 hours. The reaction mixture was poured into a saturated aqueous sodium carbonate solution (20 mL) to quench the mixture. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by column chromatography (methanol / dichloromethane = 0% to 10%) and purified to obtain compound 38-2. MS m / z: 455.0, 456.9 [M+1] + ; 1 H NMR(400MHz, CDCl3)δ8.17(s,1H),7.76–7.74(m,1H),7.68–7.66(m,1H),4.35–3.93(m,4H),3. 12–2.78(m,5H),2.62(s,1H),1.87(s,1H),1.47(s,9H),1.12–1.09(m,2H).0.89–0.85(m,2H).
[0729] Step 3: Synthesis of compound 38-3
[0730] To a solution of compound 38-2 (0.7 g, 1.54 mmol) in dioxane (10 mL) were added 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (177.90 mg, 307.46 μmol) and cesium carbonate (1.00 g, 3.07 mmol). The atmosphere was purged with nitrogen three times, and palladium acetate (34.51 mg, 153.73 μmol) was added. Under nitrogen protection, the mixture was reacted at 110°C for 2 hours. The reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (methanol / dichloromethane = 0% to 10%) to obtain compound 38-3. MS m / z: 375.0 [M+1] + ; 1 H NMR(400MHz, CDCl3)δ7.90(s,1H),7.60–7.40(m,1H),7.09–7.07(m,1H),4.39–4.36(m,1H),4.14–4.09(m,3H),3.59– 3.56(m,1H),3.05–3.00(m,2H),2.70–2.67(m,2H),1.67(s,1H),1.49(s,9H),11.07–1.05(m,2H).0.87–0.83(m,2H).
[0731] Step 4: Synthesis of the hydrochloride salt of compound 38-4
[0732] Compound 38-3 (0.38 g, 1.01 mmol) was added to hydrochloric acid / ethyl acetate (4 M, 7.6 mL) and reacted at 25°C for 2 hours. The reaction system was concentrated to obtain the hydrochloride salt of compound 38-4. MS m / z: 275.4 [M+1] + .
[0733] Step 5: Synthesis of compound 38-5
[0734] The hydrochloride salt of compound 38-4 (0.33 g) was dissolved in DCM (3 mL), and 37% aqueous formaldehyde (861.70 mg, 10.62 mmol, 790.56 μL) and acetic acid (637.66 mg, 10.62 mmol, 607.30 μL) were added. The mixture was reacted at 25°C for 0.5 hour. NaBH(OAc)3 (450.10 mg, 2.12 mmol) was added, and the mixture was reacted at 25°C for 0.5 hour. Water (5 mL), dichloromethane (5 mL), and aqueous ammonia (5 mL) were added, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 38-5 was purified by column chromatography (methanol / dichloromethane = 10%) to give compound 38-5. MS m / z: 289.4 [M+1] + .
[0735] Step 6: Synthesis of compound 38-6
[0736] Compound 38-5 (50 mg, 173.40 μmol) was added to methanol (1 mL) and water (0.25 mL), followed by sodium hydroxide (69.36 mg, 1.73 mmol) and the reaction was continued at 80°C for 12 hours. The reaction system was concentrated, water (2 mL) was added, and the aqueous phase was extracted with a mixture of dichloromethane and methanol (10:1, 10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield compound 38-6. MS m / z: 221.4 [M+1] + .
[0737] Step 7: Synthesis of compound 38-7
[0738] Under nitrogen, compound 30-6 (50 mg, 125.36 μmol) was added to dioxane (1 mL), followed by compound 38-6 (30.38 mg, 137.90 μmol), methanesulfonic acid [9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene] (2-methylamino-1,1-biphenyl-2-yl) palladium (II) (12.06 mg, 12.54 μmol), and cesium carbonate (81.69 mg, 250.73 μmol). The mixture was reacted at 110°C for 2 hours. Water (5 mL) was added, and the mixture was extracted with ethyl acetate (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 38-7 was purified by column chromatography (methanol / dichloromethane = 5% to 10%) to give compound 38-7. MS m / z: 583.2 [M+1] + .
[0739] Step 8: Synthesis of trifluoroacetic acid of compound 38
[0740] Under nitrogen, compound 38-7 (50 mg, 85.81 μmol) was dissolved in DCM (1 mL), trifluoroacetic acid (1.00 mL) was added, and the mixture was allowed to react at 25°C for 1 hour. The reaction system was concentrated under reduced pressure to obtain the crude product. The product was purified by prep-HPLC (column: Phenomenex luna C18 100*40mm*3μm; mobile phase: (TFA)-acetonitrile; acetonitrile percentage: 1%-40%, 8 min) to obtain the trifluoroacetate salt of compound 38. MS m / z: 483.5 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ9.87 (s, 1H), 9.52 (s, 1H), 9.18 (s, 1H), 8.36 (d, J = 5.0Hz, 1H) ,7.60-7.54(m,1H),7.49-7.43(m,1H),7.38(d,J=5.0Hz,1H),6.94-6.90(m,1H),6.77 (d,J=8.4Hz,1H),4.72(s,2H),4.53–4.46(m,1H),4.21-4.16(m,1H),4.09–4.06(m,1H ),3.88(s,3H),3.58-3.52(m,2H),3.24-3.06(m,2H),2.97–2.93(m,2H),2.89(s,3H).
[0741] Example 39
[0742] Step 1: Synthesis of compound 39-2
[0743] Compound BB-12 (1 g, 3.86 mmol) and potassium tert-butoxide (1.73 g, 15.44 mmol) were added to dimethyl sulfoxide (10 mL), followed by compound 39-1 (834.80 mg, 3.86 mmol) and allowed to react at 25°C for 16 hours. The reaction mixture was poured into a saturated aqueous sodium carbonate solution (100 mL) for quenching. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 39-2 was purified by column chromatography (methanol / dichloromethane = 0% to 10%) to obtain compound 39-2. MS m / z: 455.0, 456.9 [M+1] + .
[0744] Step 2: Synthesis of compound 39-3
[0745] To a solution of compound 39-2 (1.35 g, 2.96 mmol) in dioxane (10 mL) were added 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (343.10 mg, 592.96 μmol) and cesium carbonate (1.93 g, 5.93 mmol). The atmosphere was purged with nitrogen three times, and palladium acetate (66.56 mg, 296.48 μmol) was added. Under nitrogen protection, the mixture was reacted at 110°C for 2 hours. The reaction solution was concentrated to obtain the crude product. Compound 39-3 was separated and purified by column chromatography (methanol / dichloromethane = 1% to 10%) to obtain compound 39-3. MS m / z: 375.0 [M+1] + .
[0746] Step 3: Synthesis of the hydrochloride salt of compound 39-4
[0747] Compound 39-3 (0.87 g, 2.32 mmol) was added to hydrochloric acid / ethyl acetate (4 M, 8.70 mL) and reacted at 25°C for 2 hours. The reaction system was concentrated to obtain the hydrochloride salt of compound 39-4. MS m / z: 275.3 [M+1] + .
[0748] Step 4: Synthesis of compound 39-5
[0749] The hydrochloride salt of compound 39-4 (0.4 g, 1.29 mmol) was dissolved in DCM (4 mL), and 37% aqueous formaldehyde solution (1.04 g, 12.87 mmol, 958.38 μL) and acetic acid (772.90 mg, 12.87 mmol, 736.09 μL) were added. The mixture was reacted at 25°C for 0.5 h. NaBH(OAc)3 (545.57 mg, 2.57 mmol) was added, and the mixture was reacted at 25°C for 0.5 h. Water (5 mL), dichloromethane (5 mL), and aqueous ammonia (5 mL) were added, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 39-5 was purified by column chromatography (methanol / dichloromethane = 10%) to give compound 39-5. MS m / z: 289.4 [M+1] + .
[0750] Step 5: Synthesis of compound 39-6
[0751] Compound 39-5 (50 mg, 173.40 μmol) was added to methanol (1 mL) and water (0.25 mL), followed by sodium hydroxide (69.36 mg, 1.73 mmol) and the reaction was continued at 80°C for 12 hours. The reaction system was concentrated, water (2 mL) was added, and the aqueous phase was extracted with a mixture of dichloromethane and methanol (10:1, 10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield compound 39-6. MS m / z: 221.4 [M+1] + .
[0752] Step 6: Synthesis of compound 39-7
[0753] Under nitrogen, compound 30-6 (50 mg, 125.36 μmol) was added to dioxane (1 mL), followed by compound 39-6 (30.38 mg, 137.90 μmol), methanesulfonic acid [9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene] (2-methylamino-1,1-biphenyl-2-yl) palladium (II) (12.06 mg, 12.54 μmol), and cesium carbonate (81.69 mg, 250.73 μmol). The mixture was reacted at 110°C for 2 hours. Water (5 mL) was added, and the mixture was extracted with ethyl acetate (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 39-7 was purified by column chromatography (methanol / dichloromethane = 5% to 10%) to give compound 39-7. MS m / z: 583.1 [M+1] + .
[0754] Step 7: Synthesis of trifluoroacetate salt of compound 39
[0755] Under nitrogen, compound 39-7 (36 mg, 61.79 μmol) was dissolved in DCM (1 mL), trifluoroacetic acid (719.98 μL) was added, and the mixture was allowed to react at 25°C for 1 hour. The reaction system was concentrated under reduced pressure to obtain the crude product. The product was purified by prep-HPLC (column: Phenomenex luna C18 100*40mm*3μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 1%-35%, 8 min) to obtain the trifluoroacetate salt of compound 39. MS m / z: 483.5 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.88(s,1H),9.52(s,1H),9.18(s,1H),8.36(d,J=5.0Hz,1H),7. 57(d,J=3.4Hz,1H),7.46(d,J=8.8Hz,1H),7.38(d,J=5.0Hz,1H),6.91(d,J=3.6Hz,1H), 6.77(d,J=8.4Hz,1H),4.72(s,2H),4.53-4.47(m,1H),4.21-4.17(m,1H),4.11-4.04(m, 1H),3.88(s,3H),3.61-3.55(m,2H),3.21-3.08(m,2H),3.03-2.92(m,2H),2.89(s,3H).
[0756] Example 41
[0757] Step 1: Synthesis of compound BB-13-1
[0758] Compound 30-3 (8.9 g, 25.92 mmol) was dissolved in tetrahydrofuran (100 mL) in a bottle. 2,4-dimethoxybenzylamine (8.67 g, 51.83 mmol) was added dropwise at 0°C. The reaction mixture was returned to 25°C and stirred for 5 hours. The mixture was then concentrated to obtain the crude product. The mixture was stirred for 16 hours with methyl tert-butyl ether, ethyl acetate, and ethanol (50 mL each), filtered, and the filter cake dried to obtain compound BB-13-1. MS m / z: 397.0, 399.0 [M+1, M+3] + .
[0759] Step 2: Synthesis of compound BB-13-2
[0760] To a mixed solution of compound BB-13-1 (4.1 g, 10.31 mmol) in dioxane (80 mL) and water (16 mL) were added compound 4-8 (2.52 g, 10.31 mmol) and sodium carbonate (2.19 g, 20.62 mmol). The atmosphere was replaced with nitrogen three times, and Pd(PPh3)4 (1.19 g, 1.03 mmol) was added. Under nitrogen protection, the mixture was reacted at 100°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product. Methanol (50 mL) was added, stirred, and filtered; the filter cake was washed with methanol (20 mL) to obtain BB-13-2. MS m / z: 449.1 [M+1] + .
[0761] Step 3: Synthesis of compound BB-13-3
[0762] To a solution of compound BB-13-2 (295 mg, 657.16 μmol) in dioxane (5 mL) were added BocNH2 (153.97 mg, 1.31 mmol), Pd2(dba)3 (60.18 mg, 65.72 μmol), and RuPhos (61.33 mg, 131.43 μmol). The atmosphere was purged with nitrogen three times, and potassium phosphate (418.48 mg, 1.97 mmol) was added. Under nitrogen protection, the mixture was reacted at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane (10 mL). The filtrate was concentrated under reduced pressure. Compound BB-13-3 was isolated and purified by column chromatography (mobile phase: 0-70% EA / PE) to obtain compound BB-13-3. MS m / z: 530.1 [M+1] + .
[0763] Step 4: Synthesis of compound BB-13-4
[0764] To compound BB-13-3 (463 mg, 874.27 μmol) was added TFA (7.70 g, 67.53 mmol) and the mixture was allowed to react at 25°C for 16 hours. The mixture was concentrated under reduced pressure to obtain a crude product. Dichloromethane (10 mL) was added and the pH was adjusted to >10 with saturated sodium carbonate solution (20 mL). The product was extracted with dichloromethane (10 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure to obtain the crude product. Compound BB-13-4 was isolated and purified by column chromatography (0-100% EA / PE). MS m / z: 430.1 [M+1] + .
[0765] Step 5: Synthesis of compound 41-2
[0766] Compound 41-1 (10 g, 45.20 mmol) was dissolved in THF (300 mL) in a dry vial. s-BuLi (1.3 M, 62.58 mL) was slowly added dropwise under nitrogen at -30°C. The reaction was stirred at -30°C for 30 minutes, followed by the gradual introduction of carbon dioxide gas at -30°C. The temperature was then slowly raised to 25°C and stirred for 16 hours. The reaction mixture was poured into water (200 mL) and separated. The aqueous phase was washed with methyl tert-butyl ether (100 mL x 2) and then adjusted to pH 3-4 with 0.5N dilute hydrochloric acid. The aqueous phase was then extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 10:1 to 2:1) to yield compound 41-2. 1 H NMR (400MHz, CDCl3) δ5.15-4.93(m,1H),4.19-4.07(m,1H),3.34-3.23(m,1H),2.80-2.71(m,1H),2.23-1.78(m,3H),1.49-1.45(m,9H).
[0767] Step 6: Synthesis of compound 41-3
[0768] In a dry vial, compound 28-2 (2.6 g, 11.79 mmol) and p-methoxybenzylamine (1.78 g, 12.97 mmol) were dissolved in DCM (50 mL) and AcOH (708.23 mg, 11.79 mmol) was added. The reaction was stirred at 25°C for 1 hour, and then NaBH(OAc)3 (3.0 g, 14.15 mmol) was added. The reaction was stirred at 25°C for another 2 hours. 50 mL of saturated sodium carbonate solution was added to the reaction solution and stirred until the pH was >8. The layers were separated, and the aqueous phase was extracted with DCM (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 10:1 to 1:1) to obtain compound 41-3. MS m / z: 340.8 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ = 7.75 (d, J = 8.4Hz, 1H), 7.31-7.27 (m, 2H), 7.10 (d, J = 8.4Hz, 1H), 6.89-6.86 (m, 2H), 3.99 (s, 2H), 3.81 (s, 5H).
[0769] Step 7: Synthesis of compound 41-4
[0770] In a dry vial, compound 41-3 (1.02 g, 2.99 mmol) and compound 41-2 (793 mg, 2.99 mmol) were dissolved in DMF (30 mL) and DIEA (772.77 mg, 5.98 mmol), HOBt (807.93 mg, 5.98 mmol), and HATU (2.27 g, 5.98 mmol) were added. The reaction was stirred at 25°C for 16 hours. 1M dilute hydrochloric acid solution (10 mL) was added to the solution to adjust the pH to 6. The concentrate was extracted with dichloromethane (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography (dichloromethane:methanol (v / v) = 100:0 to 90:10) to obtain compound 41-4. MS m / z: 588.0 [M+1] + ; 1H NMR (400MHz, CDCl3) δ7.78-7.73(m,1H),7.25-7.21(m,1H),7.20-7.04(m,2H),6.92-6.88(m,1H),6.85-6.73(m,1H),5.02-4. 50(m,5H),3.99-3.95(m,1H),3.85-3.71(m,4H),2.74-2.57(m,1H),2.49-2.07(m,2H),2.03-1.85(m,1H),1.48-1.38(m,9H).
[0771] Step 8: Synthesis of compound 41-5
[0772] To a flask containing a solution of compound 41-4 (1 g, 1.70 mmol) in DCM (30 mL) was added ZnBr2 (1.91 g, 8.49 mmol) and the mixture was stirred at 25°C for 16 hours. The reaction solution was concentrated, and 20 mL of ethyl acetate and 20 mL of water were added and stirred. The mixture was separated and extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography (petroleum ether:ethyl acetate = 100:0 to 30:70) to obtain compound 41-5. MS m / z: 487.9 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ = 7.21 (d, J = 8.8Hz, 1H), 7.12 (d, J = 8.8Hz, 2H), 6.92 (d, J = 8.4Hz, 1H), 6.83 (d, J = 8.8H) z,2H),5.07-4.87(m,2H),3.74(s,2H),3.71(s,3H),3.57-3.51(m,1H),3.11-2.99(m,2H),1.92–1.78(m,4H).
[0773] Step 9: Synthesis of compound 41-6
[0774] To a flask containing a solution of compound 41-5 (100 mg, 204.60 μmol) in 1,4-dioxane (5 mL) was added Cs2CO3 (133.33 mg, 409.20 μmol). The reaction system was alkaline, and BINAP (50.96 mg, 81.84 μmol) and Pd(OAc)2 (9.19 mg, 40.92 μmol) were added under nitrogen. The reaction was stirred at 110°C under nitrogen for 16 hours. The mixture was concentrated, and 10 mL of ethyl acetate and 10 mL of water were added with stirring. The layers were separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain the crude product. Compound 41-6 was separated and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 100:0 to 60:40) to obtain compound 41-6. MS m / z: 407.9 [M+1] + .
[0775] Step 10: Synthesis of compound 41-7
[0776] In a round-bottom flask, compound 41-6 (70 mg, 171.64 μmol) was dissolved in THF (3 mL). BH3.THF (1 M, 1.72 mL) was added at 0°C under nitrogen. Under nitrogen, the reaction mixture was gradually heated to 60°C and stirred for 16 hours. Methanol (10 mL) was added to the reaction mixture under nitrogen to quench the reaction. The mixture was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (petroleum ether:ethyl acetate (v / v) = 100:0 to 70:30) to obtain compound 41-7. MS m / z: 394.0 [M+1] + .
[0777] Step 11: Synthesis of compound 41-8
[0778] To a solution of compound 41-7 (4 mg, 10.16 μmol) and compound BB-13-4 (4.36 mg, 10.16 μmol) in 1,4-dioxane (2 mL) in a round-bottom flask, Cs2CO3 (9.93 mg, 30.48 μmol) was added. The reaction system was alkaline, and Xantphos Pd G4 (1.95 mg, 2.03 μmol) was added under nitrogen. The reaction was stirred at 110°C under nitrogen for 5 hours. The crude product was purified by preparative chromatography (dichloromethane:methanol = 10:1, Rf = 0.4) to afford compound 41-8. MS m / z: 787.5 [M+1] + .
[0779] Step 12: Synthesis of trifluoroacetate salt of compound 41
[0780] To a solution of compound 41-8 (8.00 mg, 10.17 μmol) in DCM (1 mL) was added TfOH (30.52 mg, 203.34 μmol) in a flask, and the reaction was stirred at 25°C for 16 hours. The reaction solution was concentrated, and aqueous ammonia (2 mL) was added. The pH of the reaction system was checked to 9, and 1 mL of DMF was added to the solution. The solution was separated and purified by prep-HPLC (column: Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile; acetonitrile %: 5%-35%, 8 min]) to obtain the trifluoroacetate salt of compound 41. MS m / z: 517.2 [M+1] + ;1H NMR(400MHz,DMSO-d6)δ10.04(s,1H),9.72(s,1H),9.22-9.06(m,2H),8.36-8.35(m,1H),7.61-7.58(m,2H),7.38(s,1H),7.12-7.0 9(m,1H),6.95-6.89(m,1H),4.73(s,2H),44.55-4.38(m,2H),3.87(s,3H),3.45-3.42(m,3H),3.26-3.22(m,3H),2.22-2.10(m,3H).
[0781] Example 42
[0782] Step 1: Synthesis of compound 42-1
[0783] To a solution of compound 41-6 (30 mg, 73.56 μmol) and compound BB-13-4 (29.24 mg, 73.56 μmol) in 1,4-dioxane (5 mL) were added Cs2CO3 (71.90 mg, 220.67 μmol), BINAP (13.74 mg, 22.07 μmol), and Pd(OAc)2 (3.30 mg, 14.71 μmol). The reaction was stirred at 110°C under nitrogen for 16 hours. The mixture was filtered, the filter cake was rinsed with ethyl acetate (20 mL x 2), and the filtrate was concentrated to obtain the crude product. Purification by preparative chromatography (dichloromethane:methanol = 20:1) afforded compound 42-1. MS m / z: 801.2 [M+1] + .
[0784] Step 2: Synthesis of trifluoroacetate salt of compound 42
[0785] To a flask containing compound 42-1 (50 mg, 65.03 μmol) in DCM (2 mL) was added TfOH (488.00 mg, 3.25 mmol), and the reaction was stirred at 25°C for 16 hours. Aqueous ammonia was added to adjust the pH to 8-9, and the reaction solution was concentrated under reduced pressure. The crude product was separated and purified by prep-HPLC (column: Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 20%-50%, 8 min) to obtain the trifluoroacetate salt of compound 42. MS m / z: 531.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.01(s,1H),9.67(s,1H),9.19(s,1H),8.49(s,1H),8.35-8.34(m,1H),7.61-7.58(m,2H),7.38(s,1H),7.12-7.09(m,1 H),6.90(s,1H),4.77-4.71(m,3H),4.01-3.99(m,1H),3.87(s,3H),3.5 3-3.48(m,2H),3.23-3.16(m,1H),2.38-2.34(m,2H),2.32-2.22(m,2H).
[0786] Example 43
[0787] Step 1: Synthesis of compound 43-2
[0788] Under nitrogen, compound 43-1 (248.53 mg, 2.18 mmol) was dissolved in methanol (10 mL), and compound 28-2 (400 mg, 1.81 mmol) and acetic acid (108.96 mg, 1.81 mmol) were added. The mixture was allowed to react at 20°C for 1 hour. Sodium acetate borohydride (576.84 mg, 2.72 mmol) was added, and the mixture was allowed to react at 20°C for 15 hours. The mixture was concentrated under reduced pressure and quenched with saturated sodium carbonate solution (20 mL). The mixture was extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated to give compound 43-2, which was then separated by column chromatography (methanol / dichloromethane = 0% to 10%). MS m / z: 318.0, 320.0 [M+1] + .
[0789] Step 2: Synthesis of compound 43-3
[0790] Under nitrogen, compound 43-2 (223 mg, 699.94 μmol) was dissolved in tetrahydrofuran (5 mL), and triethylamine (212.48 mg, 2.10 mmol) and Boc2O (229.14 mg, 1.05 mmol) were added. The mixture was reacted at 20°C for 2 hours. Saturated sodium bicarbonate solution (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated under reduced pressure to obtain compound 43-3, which was purified by column chromatography (ethyl acetate / petroleum ether = 0% to 50%). MS m / z: 440.0, 442.0 [M+Na] + .
[0791] Step 3: Synthesis of compound 43-4
[0792] Under nitrogen, compound 43-3 (229 mg, 546.91 μmol) was dissolved in 1,4-dioxane (8 mL). N,N-dimethylethylenediamine (9.64 mg, 109.38 μmol), cesium carbonate (534.59 mg, 1.64 mmol), and cuprous iodide (10.42 mg, 54.69 μmol) were added and reacted at 110°C for 20 hours. The mixture was cooled to room temperature, filtered, and the filter cake was washed with dichloromethane (10 mL). The filtrate was concentrated under reduced pressure to obtain the crude product. Purification by column chromatography (ethyl acetate / dichloromethane = 0% to 40%) afforded compound 43-4. MS m / z: 360.2 [M+Na] + ; 1 H NMR (400MHz, CDCl3) δ7.80(d,J=8.4Hz,1H),7.30(d,J=8.0Hz,1H),4.88(d,J=16.0Hz,1H),4.30-4.06(m,2H) ,3.93-3.81(m,1H),3.22-3.08(m,1H),2.77-2.50(m,2H),2.48-2.32(m,1H),1.97-1.82(m,1H),1.39(s,9H).
[0793] Step 4: Synthesis of compound 43-5
[0794] Under nitrogen, compound BB-13-4 (100 mg, 232.85 μmol) was dissolved in 1,4-dioxane (4 mL). Compound 43-4 (86.52 mg, 256.13 μmol), cesium carbonate (227.60 mg, 698.54 μmol), Ruphos (21.73 mg, 46.57 μmol), and Pd2(dba)3 (21.32 mg, 23.28 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled to room temperature and filtered. The filter cake was washed with dichloromethane (20 mL), and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by column chromatography (ethyl acetate / petroleum ether = 0% to 60%) afforded compound 43-5. MS m / z: 731.3 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ10.46(s,1H),9.85(s,1H),8.41(d,J=5.2Hz,1H),7.71(d,J=8.4Hz,1H),7.47-7.38(m,1H) ,7.13-7.01(m,1H),6.88(d,J=8.4Hz,2H),6.53-6.41(m,2H),5.02(d,J=15.6Hz,1H),4.76(s,2H),4.59-4.49(m, 1H),4.31-4.17(m,2H),4.07-3.90(m,3H),3.84(s,5H),3.80(s,3H),3.17-3.03(m,1H),2.74-2.53(m,3H),2.52-2.32(m,2H),1.42(s,9H).
[0795] Step 5: Synthesis of trifluoroacetate salt of compound 43
[0796] Under nitrogen, compound 43-5 (126 mg, 172.41 μmol) was dissolved in TfOH (22.60 mmol, 2 mL) and reacted at 40°C for 16 hours. The mixture was slowly poured into dilute ammonia (5% concentration) (10 mL) and extracted with dichloromethane:methanol = 10:1 (V / V, 20 mL x 5). The organic phases were combined and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated to obtain the crude product. Purification by prep-HPLC (column: Phenomenex luna C18 100*40 mm*3 μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; B%: 1.00%-30.00%, 8.00 min) afforded the trifluoroacetic acid salt of compound 43. MS m / z: 481.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ10.12(s,1H),9.96(s,1H),9.30(s,1H),8.37(d,J=4.8Hz,1H),7.80(d,J=8.8Hz,1H),7.59(d,J=3.6Hz,1H),7.41(d,J=4 .8Hz,1H),7.25(d,J=8.8Hz,1H),6.90(d,J=3.6Hz,1H),4.74(s,2H),4.5 1-4.47(m,3H),4.00-3.82(m,5H),2.43-2.40(m,4H),1.86-1.84(m,1H). The trifluoroacetate of compound 43 was added to a sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 43.
[0797] Example 44
[0798] Step 1: Synthesis of trifluoroacetate salt of compound 44
[0799] Compound 43 (30 mg, 62.43 μmol) was dissolved in MeOH (2 mL) in a round-bottom flask. 37% aqueous formaldehyde (25.34 mg, 312.16 μmol, 23.24 μL) and acetic acid (3.75 mg, 62.43 μmol) were added. After stirring at 15°C for 1 hour, NaBH(OAc)3 (26.46 mg, 124.86 μmol) was added and stirring continued at 15°C for 16 hours. The reaction mixture was filtered directly, and the filtrate was concentrated. The crude product was purified by prep-HPLC (column: Phenomenex luna C18 100*40 mm*3 μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; B%: 1.00%-30.00%, 8.00 min) to afford the trifluoroacetate salt of compound 44. MS m / z: 495.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ10.37-9.96(m,2H),9.29(s,1H),8.37(d,J=4.8Hz,1H),7.81-7.80(m,1H),7.60(d,J=7.6Hz,1H),7.41(d,J=4.8H z,1H),7.27(d,J=8.8Hz,1H),6.90(d,J=3.6Hz,1H),4.78-4.59(m,4H),3.97-3.88(m,4H),3.65-3.54(m,2H),3.39-3.12(m,3H),2.67(br s,1H),2.46-2.33(m,2H),1.83-1.80(m,1H).
[0800] Example 45
[0801] Step 1: Synthesis of compound 45-2
[0802] Compound 45-1 (6.1 g, 18.51 mmol) was dissolved in DCM (61 mL) in a round-bottom flask. The atmosphere was purged with nitrogen three times, and bis-methoxybenzylamine (4.76 g, 18.51 mmol) and acetic acid (1.11 g, 18.51 mmol) were added. The reaction was allowed to proceed at 25°C for 0.5 h. NaBH(OAc)3 (7.85 g, 37.03 mmol) was added, and the reaction was continued for 0.5 h. Water (50 mL) was added, the layers separated, and the organic phase was washed with saturated sodium bicarbonate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Purification by column chromatography (petroleum ether:ethyl acetate = 3:1) afforded compound 45-2. MS m / z: 571.3 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.29-7.26(m,4H),6.88-6.82(m,4H),4.11-3.90(m,3H),3.81(s,6H),3.76-3.75( m,2H),3.44-3.10(m,4H),2.68-2.48(m,1H),1.93-1.76(m,2H),1.47(s,9H),0.85(s,9H),0.00(s,6H).
[0803] Step 2: Synthesis of compound 45-3
[0804] Compound 45-2 (2 g, 3.50 mmol) was dissolved in DCM (50 mL) in a round-bottom flask. ZnBr2 (3.95 g, 17.52 mmol) was added and the reaction was stirred at 25°C for 16 hours. The mixture was poured into water (100 mL) and the layers separated. The aqueous phase was extracted with DCM (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Purification by column chromatography (petroleum ether:ethyl acetate = 5:1 to 0:1) afforded compound 45-3. MS m / z: 471.1 [M+1] + .
[0805] Step 3: Synthesis of compound 45-4
[0806] Under nitrogen, compound 45-3 (400 mg, 849.77 μmol) was dissolved in DMF (5 mL), and compound 28-2 (190.68 mg, 934.74 μmol) and DIEA (329.48 mg, 2.55 mmol) were added. The mixture was reacted at 100°C for 1 hour. After cooling, the reaction was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure. Compound 45-4 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 15%). MS m / z: 654.2, 656.1 [M+1] + .
[0807] Step 4: Synthesis of compound 45-5
[0808] Under nitrogen, compound 45-4 (140 mg, 213.84 μmol) was dissolved in TFA (67.53 mmol, 5 mL) and reacted at 60°C for 16 hours. The mixture was cooled and concentrated under reduced pressure. DCM (1 mL) and NaBH(OAc)3 (135.96 mg, 641.51 μmol) were added and reacted at 25°C for 1 hour. The reaction was quenched with saturated sodium carbonate solution (10 mL) and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated under reduced pressure to obtain compound 45-5, which was separated by column chromatography (ethyl acetate / petroleum ether = 0% to 100%). MS m / z: 404.1, 406.1 [M+1] +;1H NMR (400MHz, DMSO-d6) δ7.30(d,J=8.4Hz,1H),7.21(d,J=8.4Hz,2H),7.04(d,J=8.8Hz,1H ),6.88(d,J=8.8Hz,2H),5.08(d,J=4.0Hz,1H),4.33-4.24(m,1H),4.07(d,J=14.4Hz,1H), 3.74(s,4H),3.72-3.64(m,1H),3.56(s,2H),3.50(d,J=14.4Hz,1H),3.1 0-3.04(m,1H),2.90-2.87(m,1H),1.93-1.87(m,1H),1.66-1.63(m,1H).
[0809] Step 5: Synthesis of compound 45-6
[0810] Under nitrogen, compound BB-13-4 (75 mg, 174.63 μmol) was dissolved in 1,4-dioxane (5 mL), and compound 45-5 (70.60 mg, 174.63 μmol), cesium carbonate (170.70 mg, 523.90 μmol), and Xantphos Pd G4 (16.81 mg, 17.46 μmol) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled, filtered, washed with dichloromethane (10 mL), and the filtrate was concentrated under reduced pressure. Compound 45-6 was obtained by column chromatography (methanol / ethyl acetate = 0% to 10%). MS m / z: 753.3 [M+Na] + .
[0811] Step 6: Synthesis of trifluoroacetate salt of compound 45
[0812] Under nitrogen, compound 45-6 (85 mg, 112.90 μmol) was dissolved in TfOH (45.20 mmol, 4 mL) and reacted at 40°C for 5 hours. After cooling to room temperature, the mixture was slowly added to dilute aqueous ammonia (10 mL). Extraction was performed with dichloromethane:methanol = 10:1 (20 mL x 4). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. This was then purified by prep-HPLC (column: Phenomenex luna C18 80*30 mm*3 μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; acetonitrile %: 1%-20%, 8.00 min) to afford the trifluoroacetate salt of compound 45. MS m / z: 483.2 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ9.99(s,1H),9.63(s,1H),9.19(s,1H),8.36(d,J=4.8Hz,1H),7.5 7(d,J=3.6Hz,1H),7.44(d,J=8.8Hz,1H),7.38(d,J=4.8Hz,1H),7.14(d,J=8.8Hz,1H),6. 89 (d, J = 3.6 Hz, 1H), 4.71 (s, 3H), 4.43-4.34 (m, 1H), 4.25-4.16 (m, 1H), 3.87 (s, 3H), 3.37-3.32 (m, 4H), 3.31-3.22 (m, 2H), 3.14-3.05 (m, 1H), 2.11-2.00 (m, 1H), 1.90-1.87 (m, 1H). The trifluoroacetic acid salt of compound 45 was added to a sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 45.
[0813] Example 46
[0814] Step 1: Synthesis of trifluoroacetate salt of compound 46
[0815] Under nitrogen, compound 45 (40 mg, 82.90 μmol) was dissolved in methanol (5 mL). 37% aqueous formaldehyde (33.64 mg, 414.48 μmol) and acetic acid (14.93 mg, 248.69 μmol) were added and the mixture was allowed to react at 25°C for 1 hour. NaBH(OAc)3 (35.14 mg, 165.79 μmol) was added and the mixture was allowed to react at 25°C for 1 hour. Saturated sodium carbonate solution (10 mL) was added and the mixture was extracted with dichloromethane:methanol = 10:1 (20 mL x 4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Compound 46 was purified by prep-HPLC (column: Phenomenex luna C18 80*30mm*3μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; B%: 1%-25%, 8.00 min) to obtain the trifluoroacetic acid salt. MS m / z: 497.2 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.62-10.10(m,1H),10.09-9.90(m,1H),9.80-9.51(m,1 H),9.20(d,J=6.8Hz,1H),8.44-8.25(m,1H),7.58(d,J=2.4Hz,1H),7.52-7.27(m ,2H),7.18-7.11(m,1H),6.91(d,J=2.4Hz,1H),4.78-4.57(m,3H),4.51-4.31(m, 3H),3.48-3.21(m,5H),3.18-2.85(m,5H),2.12-1.96(m,1H),1.88-1.75(m,1H).
[0816] Example 47
[0817] Step 1: Synthesis of compound 47-2
[0818] Compound BB-3-1 (2 g, 13.78 mmol) and compound 47-1 (2.75 g, 16.53 mmol) were added to DMF (10 mL), followed by DIEA (1.78 g, 13.78 mmol). The mixture was reacted at 100°C for 16 hours. The reaction solution was added to semi-saturated brine (50 mL) and extracted with methyl tert-butyl ether (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Column chromatography (petroleum ether:ethyl acetate (v / v) = 95:5-85:15) afforded compound 47-2. MS m / z: 292.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.38-8.37(m,1H),8.29-8.26(m,1H),7.13-7.10(m,1H),4.73(s,1H),4 .46–4.44(m,1H),3.99–3.93(m,2H),3.77–3.73(m,2H),3.71–3.68(m,3H),3.26–3.22(m,1H).
[0819] Step 2: Synthesis of compound 47-3
[0820] The hydrogenation flask was replaced with argon twice, and Raney-Ni (441.23 mg, 5.15 mmol) was added, along with MeOH (2 mL) and compound 47-2 (1.5 g, 5.15 mmol). The mixture was reacted at 50°C under hydrogen (50 psi) for 12 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain compound 47-3. MS m / z: 266.0 [M+1]+ .
[0821] Step 3: Synthesis of compound 47-4
[0822] Compound 47-3 (0.7 g, 2.64 mmol) was added to MeOH (14 mL), followed by sodium tert-butoxide (1.27 g, 13.19 mmol), and the mixture was allowed to react at 25°C for 16 hours. The crude product was concentrated under reduced pressure and separated by column chromatography (petroleum ether:ethyl acetate = 100:0 to 0:100 to ethyl acetate:methanol = 97:3) to afford compound 47-4. MS m / z: 233.9 [M+1] + .
[0823] Step 4: Synthesis of compound 47-5
[0824] Compound 47-4 (0.2 g, 857.39 μmol) was added to THF (20 mL), cooled to 0°C, and BH3.THF (1 M, 8.57 mL) was added. The mixture was reacted at 60°C under nitrogen protection for 12 hours. Methanol (10 mL) and 2M dilute hydrochloric acid (20 mL) were added dropwise to the reaction mixture at room temperature under nitrogen protection, and the mixture was stirred at 65°C for 16 hours. The crude product was concentrated under reduced pressure, added to saturated aqueous sodium carbonate solution (30 mL), adjusted to pH = 8, and extracted with ethyl acetate (20 mL × 3). The aqueous phase was concentrated under reduced pressure, stirred with a mixture of DCM and MeOH (DCM:MeOH = 3:1, 50 mL) for 10 minutes, and then filtered. The organic phases were combined and concentrated under reduced pressure to give compound 47-5. MS m / z: 220.0 [M+1] + .
[0825] Step 5: Synthesis of compound 47-6
[0826] Compound 47-5 (0.2 g, 912.07 μmol) was added to THF (6 mL), followed by TEA (276.87 mg, 2.74 mmol) and Boc2O (199.06 mg, 912.07 μmol). The mixture was allowed to react at 25°C for 2 hours. The reaction solution was added to saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 100:0-80:20) to afford compound 47-6. MS m / z: 319.6 [M+1] + .
[0827] Step 6: Synthesis of compound 47-7
[0828] Compound 30-6 (50 mg, 125.36 μmol) and compound 47-6 (48.05 mg, 150.44 μmol) were added to dioxane (4 mL), followed by Cs2CO3 (81.69 mg, 250.73 μmol), BINAP (15.61 mg, 25.07 μmol), and Pd(OAc)2 (2.81 mg, 12.54 μmol). The mixture was reacted at 100°C for 2 hours. The reaction mixture was added to water (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound 47-7. MS m / z: 682.4 [M+1] + .
[0829] Step 7: Synthesis of trifluoroacetate salt of compound 47
[0830] Compound 47-7 (50 mg, 73.34 μmol) was added to TFA (2 mL) and DCM (4 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was then purified by prep-HPLC (column: Phenomenex luna C18 80*30 mm*3 μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; B%: 5%-45%, 8.00 min) to obtain the trifluoroacetic acid salt of compound 47. MS m / z: 482.1 [M+1] + ; 1 H NMR(400MHz, DMSO-d6)δ9.10(s,1H),8.98–8.92(m,2H),8.76–8.75(m,2H),8.36(d,J=4.8Hz,1H),7.57–7.56(m,1H),7.48–7.46(m,2H),7 .38–7.36(m,1H),7.16(d,J=8.8Hz,1H),6.89–6.88(m,1H),4.73(s,2H),4.39-4.29(m,3H),3.87(s,3H),3.32-3.20(m,5H),3.05(s,2H).
[0831] Examples 48 and 49
[0832] Step 1: Synthesis of compound 48-1
[0833] Compound 45-5 (255 mg, 630.72 μmol) was dissolved in DCM (5 mL), replaced with nitrogen three times, cooled to -78°C, and DAST (508.32 mg, 3.15 mmol) was added dropwise. The temperature was raised to 25°C and allowed to react for 16 hours. The reaction was quenched with saturated sodium bicarbonate (20 mL) and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure to obtain the crude product. Compound 48-1 was obtained by column chromatography (ethyl acetate / petroleum ether = 0% to 30%). MS m / z: 406.1, 408.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.24(d,J=8.0Hz,3H),6.95-6.84(m,3H),4.31-4.16(m,1H),3.89(d,J=14.4Hz,1H),3.81(s,3H),3.78-3.5 9(m,3H),3.58-3.46(m,1H),3.44-3.25(m,2H),2.98(d,J=11.6Hz,1H),2.76-2.62(m,1H),2.59-2.39(m,1H),1.94-1.78(m,1H).
[0834] Step 2: Synthesis of compound 48-2
[0835] Under nitrogen, compound BB-13-4 (31 mg, 72.18 μmol) was dissolved in 1,4-dioxane (2 mL). Compound 48-1 (29.33 mg, 72.18 μmol), cesium carbonate (70.55 mg, 216.55 μmol), Pd2(dba)3 (6.61 mg, 7.22 μmol), and Ruphos (6.74 mg, 14.44 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the filter cake was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product. Compound 48-2 was isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 100%). MS m / z: 755.3 [M+Na] + .
[0836] Step 3: Synthesis of trifluoroacetate salt of compound 48
[0837] Under nitrogen, compound 48-2 (49 mg, 64.91 μmol) was dissolved in TfOH (11.30 mmol, 1 mL) and reacted at 40°C for 5 hours. After cooling to room temperature, the mixture was slowly added to dilute aqueous ammonia (10 mL) and extracted with dichloromethane:methanol = 10:1 (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure. Compound 48 was purified by prep-HPLC (column: Phenomenex luna C18 80*30 mm*3 μm; mobile phase: [A: aqueous phase (0.1% TFA); B: acetonitrile]; B%: 5%-35%, 8.00 min) to obtain the trifluoroacetate salt. MS m / z: 485.2 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ10.02(s,1H),9.68(s,1H),9.50-9.36(m,1H),9.23(s,1H), 8.36(d,J=4.8Hz,1H),7.58(d,J=3.6Hz,1H),7.49-7.33(m,2H),7.17(d,J=8.8Hz,1 H), 6.90 (d, J = 3.6 Hz, 1H), 5.55-5.29 (m, 1H), 4.72 (s, 3H), 4.30-4.25 (m, 1H), 3.87 (s, 3H), 3.49-3.47 (m, 4H), 3.14-2.98 (m, 1H), 2.78-2.65 (m, 1H), 2.07-1.90 (m, 1H). The trifluoroacetic acid salt of compound 48 was added to a sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 48.
[0838] Step 4: Synthesis of trifluoroacetate salt of compound 49
[0839] Under nitrogen, compound 48 (30 mg, 61.92 μmol) was dissolved in methanol (2 mL). 37% aqueous formaldehyde (25.12 mg, 309.58 μmol) and acetic acid (11.15 mg, 185.75 μmol) were added and the mixture was allowed to react at 20°C for 1 hour. NaBH(OAc)3 (26.25 mg, 123.83 μmol) was added and the mixture was allowed to react at 20°C for 15 hours. Saturated sodium carbonate solution (10 mL) was added and the mixture was extracted with dichloromethane:methanol (10:1) (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated to obtain the product, which was then separated by prep-HPLC (column: Phenomenex C18 80*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 5%-35%; 8 min) to afford the trifluoroacetate salt of compound 49. MS m / z:499.2[M+1]+ ; 1 H NMR(400MHz,DMSO-d6)δ10.11-9.91(m,1H),9.74(s,1H),9.23(s,1H),8.36( d,J=4.8Hz,1H),7.63-7.30(m,3H),7.29-7.10(m,1H),6.91(d,J=3.2Hz,1H) ,5.59-5.30(m,1H),5.08-4.82(m,1H),4.78-4.40(50-1m,4H),3.87(s,6H), 3.54-3.43(m,2H),3.29(d,J=1.6Hz,1H),3.14(s,2H),2.90(d,J=6.0Hz,1H).
[0840] Examples 50A and 50
[0841] Step 1: Synthesis of compound 50-2
[0842] Compound 50-1 (1 g, 5.08 mmol) was added to DMF (20 mL), cooled to 0°C, and NaH (405.99 mg, 10.15 mmol, 60% content) was added. The mixture was stirred at 0°C for 0.5 hours. CD3I (882.84 mg, 6.09 mmol) was added, and the mixture was allowed to react at 25°C for 1.5 hours. After the reaction, the reaction solution was slowly added to water (50 mL), extracted with ethyl acetate (50 mL × 2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 50-2 was obtained by column chromatography (PE:EA = 100:0-85:15). MS m / z: 214.1, 216.1 [M+1] + .
[0843] Step 2: Synthesis of compound 50-3
[0844] Compound 50-2 (0.2 g, 934.24 μmol) and bis-naphthalene boronate (355.86 mg, 1.40 mmol) were added to dioxane (4 mL), followed by KOAc (275.06 mg, 2.80 mmol) and Pd(dppf)Cl2.CH2Cl2 (76.29 mg, 93.42 μmol). The mixture was reacted at 100°C for 12 hours. The reaction mixture was added to water (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was then purified by preparative chromatography (PE:EA = 3:1) to afford compound 50-3. MS m / z: 180.2 [M-81] + .
[0845] Step 3: Synthesis of compound 50-4
[0846] Compound BB-13-1 (0.18 g, 452.66 μmol) and compound 50-3 (118.21 mg, 452.66 μmol) were added to dioxane (4 mL) and water (0.8 mL). Pd(dppf)Cl2 (33.12 mg, 45.27 μmol) and potassium carbonate (125.12 mg, 905.32 μmol) were added and reacted at 100°C for 6 hours. The mixture was cooled to room temperature and slowly added dropwise to 6 mL of methanol with stirring. After the addition was complete, the mixture was stirred for 10 minutes, filtered, and the filter cake was dried under reduced pressure to obtain compound 50-4. MS m / z: 452.1 [M+H] + .
[0847] Step 4: Synthesis of compound 50-5
[0848] Compound 50-4 (0.12 g, 265.53 μmol) and Boc2O (62.21 mg, 531.07 μmol) were added to dioxane (4 mL). Potassium phosphate (169.09 mg, 796.60 μmol), RuPhos (24.78 mg, 53.11 μmol), and Pd2(dba)3 (24.32 mg, 26.55 μmol) were also added. The mixture was reacted at 110°C for 2 hours. The reaction solution was added to 20 mL of water and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The product was separated by preparative chromatography (PE:EA = 1:1) to obtain compound 50-5. MS m / z: 533.2 [M+1] + .
[0849] Step 5: Synthesis of compound 50-6
[0850] Compound 50-5 (0.12 g, 225.31 μmol) was added to TFA (3 mL) and reacted at 25°C for 2 hours. The reaction solution was concentrated under reduced pressure, dissolved in 10 mL of dichloromethane, and poured into 30 mL of saturated sodium carbonate aqueous solution. Extraction was performed with 10 mL of dichloromethane twice. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 50-6. MS m / z: 433.2 [M+1] + .
[0851] Step 6: Synthesis of compound 50-7
[0852] Compound 50-6 (100.00 mg, 231.22 μmol) and compound 45-5 (93.48 mg, 231.22 μmol) were added to dioxane (4 mL), followed by Cs2CO3 (150.67 mg, 462.44 μmol) and Xantphos Pd G4 (22.25 mg, 23.12 μmol). The mixture was reacted at 100°C for 2 hours. The reaction solution was added to water (20 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by preparative chromatography (DCM:MeOH = 20:1) to obtain compound 50-7. MS m / z: 756.3 [M+1] + .
[0853] Step 7: Synthesis of compound 50-8
[0854] Compound 50-7 (0.1 g, 132.30 μmol) was added to TfOH (2 mL) and reacted at 40°C for 2 hours. The reaction solution was slowly added to 10 mL of aqueous ammonia until the pH was > 10. Extraction was performed with dichloromethane:methanol = 10:1 (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 50A. MS m / z: 486.3 [M+1] + .
[0855] Step 8: Synthesis of compound 50
[0856] Compound 50A (80 mg, 164.76 μmol) and 37% aqueous formaldehyde solution (823.80 μmol, 61.33 μL) were added to MeOH (2 mL), followed by AcOH (29.68 mg, 494.28 μmol) and the mixture was allowed to react at 25°C for 1 hour. NaBH(OAc)3 (69.84 mg, 329.52 μmol) was then added and the mixture was allowed to react at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was then separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 1%-30%, 8 min) to afford the trifluoroacetate salt of compound 50. MS m / z: 500.2 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.12–9.97(m,2H),9.69–9.49(m,1H),8.39–8.36 (m,1H),7.61–7.58(m,3H),7.40–7.19(m,1H),6.91–6.88(m,1H),4.97–4.8 6(m,1H),4.72(s,1H),4.42–4.41(m,1H),4.38–4.37(m,2H),3.66–3.55(m, 6H),3.09–3.08(m,2H),3.92(s,1H),2.07–2.06(m,1H),1.85–1.81(m,1H).
[0857] Examples 51 and 52
[0858] Step 1: Synthesis of compound 51-2
[0859] Compound 51-1 (0.8 g, 3.37 mmol) was added to DCM (20 mL) and cooled to 0°C. Dess-Martin periodinane (1.72 g, 4.05 mmol) was then added and allowed to react at 25°C for 12 hours. 3 g of solid sodium carbonate was added to the reaction solution, stirred for 0.5 hours, and filtered. The filtrate was added to a saturated sodium bicarbonate solution (20 mL) and extracted with dichloromethane (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by column chromatography (PE:EA = 100:0 to 85:15) afforded 51-2.
[0860] Step 2: Synthesis of compound 51-3
[0861] Compound 51-2 (0.2 g, 850.24 μmol) and compound 34-2 (347.60 mg, 935.27 μmol) were added to DCM (4 mL), followed by AcOH (25.53 mg, 425.12 μmol) and the reaction was continued at 25°C for 1 hour. NaBH(OAc)3 (360.40 mg, 1.70 mmol) was added and the reaction was continued at 25°C for 2 hours. The reaction solution was added to saturated aqueous sodium bicarbonate (20 mL) and extracted with dichloromethane (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 51-3. MS m / z: 590.1, 592.1 [M+1] + .
[0862] Step 3: Synthesis of compound 51-4
[0863] Compound 51-3 (0.38 g, 643.10 μmol) was added to DCM (10 mL), followed by ZnBr2 (724.14 mg, 3.22 mmol), and the mixture was allowed to react at 25°C for 12 hours. The reaction mixture was added to 20 mL of saturated sodium bicarbonate aqueous solution and extracted with dichloromethane (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield compound 51-4. MS m / z: 490.0, 492.0 [M+1] + .
[0864] Step 4: Synthesis of compound 51-5
[0865] Compound 51-4 (0.2 g, 407.52 μmol) was added to 1,4-dioxane (9 mL), followed by Cs2CO3 (265.56 mg, 815.05 μmol), Pd2(dba)3 (37.32 mg, 40.75 μmol), and RuPhos (38.03 mg, 81.50 μmol). The mixture was reacted at 105°C for 2 hours. The reaction solution was added to water (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 51-5 was obtained by column chromatography (PE:EA = 100:0-80:20). MS m / z: 410.1 [M+1] + .
[0866] Step 5: Synthesis of compound 51-6
[0867] Compound BB-13-4 (60 mg, 139.71 μmol) and compound 51-5 (62.99 mg, 153.68 μmol) were added to 1,4-dioxane (2 mL). Cs2CO3 (136.56 mg, 419.12 μmol), Pd2(dba)3 (12.79 mg, 13.97 μmol), and RuPhos (13.04 mg, 27.94 μmol) were also added, and the mixture was reacted at 110°C for 2 hours. The reaction solution was added to water (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 51-6 was obtained by column chromatography (PE:EA = 50:50-20:80). MS m / z: 803.3 [M+1] + .
[0868] Step 6: Synthesis of trifluoroacetate salt of compound 51
[0869] Compound 51-6 (80 mg, 99.64 μmol) was added to TfOH (2 mL) and reacted at 40°C for 2 hours. The reaction solution was slowly added dropwise to 6 mL of aqueous ammonia and extracted with dichloromethane (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 10%-40%, 8 min) was used to separate the trifluoroacetate salt of compound 51. MS m / z: 503.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.04(s,1H),9.72(s,1H),9.49-9.10(m,3H),8.39-8.36(m,1H),7.61-7.58(m,1H),7.51(d,J=8.8Hz,1H),7.40-7.39(m, 1H),7.21-7.19(m,1H),6.90-6.89(m,1H),4.76-4.73(m,2H),4.65(s,1H ),4.62-4.61(m,1H),3.88(s,3H),3.70-3.60(m,4H),3.16-3.10(m,2H). The trifluoroacetate of compound 51 was added to a sodium bicarbonate solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 51.
[0870] Step 7: Synthesis of trifluoroacetate salt of compound 52
[0871] Compound 51 (35 mg, 69.65 μmol) and 37% aqueous formaldehyde solution (28.26 mg, 348.25 μmol) were added to MeOH (2 mL). AcOH (12.55 mg, 208.95 μmol) was added and stirred at 25°C for 1 hour. NaBH(OAc)3 (29.52 mg, 139.30 μmol) was added and the mixture was allowed to react at 25°C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain the crude product. HLPC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 10%-40%, 8 min) was used to separate the trifluoroacetate salt of compound 52. MS m / z: 517.2 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.29-10.10(m,1H),9.74-9.65(m,1H),8.41–8.37(m,1H),7.63–7.60(m,2H),7.41-7.39(m,1H),7.37(s,1H),6.91-6.8 8(m,1H),4.97(s,2H),4.88(s,2H),4.86-4.72(m,1H),4.68-4.55(m,1H ),3.89(s,5H),3.66-3.60(m,3H),3.17-3.14(m,2H),3.10-2.88(m,2H).
[0872] Example 53
[0873] Step 1: Synthesis of compound 53-1
[0874] Compound 33-1 (55 mg, 193.56 μmol) was added to THF (1 mL), and the atmosphere was replaced with nitrogen three times. The mixture was cooled to -20°C and NaH (23.22 mg, 580.68 μmol, 60% content) was added and stirred for 0.5 hours. CD3I (22.45 mg, 154.85 μmol, 9.64 μL) was added and the mixture was allowed to react at 20°C for 2.5 hours. The reaction mixture was added to 20 mL of water and extracted with ethyl acetate (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 53-1 was separated by preparative chromatography (EA:MeOH = 20:1) to obtain compound 53-1. MS m / z: 301.1, 303.1 [M+1] + .
[0875] Step 2: Synthesis of compound 53-2
[0876] Compound BB-13-4 (20 mg, 46.57 μmol) and compound 53-1 (15.43 mg, 51.23 μmol) were added to dioxane (2 mL), followed by Xantphos Pd G4 (4.48 mg, 4.66 μmol) and Cs2CO3 (45.52 mg, 139.71 μmol). The mixture was reacted at 110°C for 2 hours. The reaction mixture was added to water (20 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 53-2. MS m / z: 650.3 [M+1] + .
[0877] Step 3: Synthesis of trifluoroacetate salt of compound 53
[0878] Compound 53-2 (20 mg, 30.78 μmol) was added to TfOH (1 mL) and reacted at 40°C for 1 hour. The reaction solution was slowly added dropwise to aqueous ammonia (4 mL) and extracted with dichloromethane (10 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The trifluoroacetic acid salt of compound 53 was separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 5%-35%, 8 min). MS m / z: 500.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.28-10.23(m,1H),10.03-10.02(m,1H),9.77-9.72(m,1H),9.23(s,1H),8.37(d,J=5.0Hz,1H),7.63-7.59(m ,2H),7.40(d,J=5.0Hz,1H),7.24-7.19(m,1H),6.91(d,J=3.4Hz,1H),4.78-4.73(m,3H),3.88(s,4H),3.78(s,5H),3.74-3.71(m,3H).
[0879] Example 54 and Example 57
[0880] Step 1: Synthesis of compound 54-1
[0881] Compound 50-6 (50 mg, 115.61 μmol) and compound 16-6 (37.92 mg, 127.17 μmol) were added to dioxane (1 mL), followed by Xantphos Pd G4 (22.25 mg, 23.12 μmol) and Cs2CO3 (113.00 mg, 346.83 μmol). The mixture was reacted at 110°C for 2 hours. The reaction mixture was added to water (20 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 54-1. MS m / z: 650.3 [M+1] + .
[0882] Step 2: Synthesis of trifluoroacetate salt of compound 54-2
[0883] Compound 54-1 (50 mg, 76.95 μmol) was added to TfOH (2 mL) and reacted at 40°C for 12 hours. The reaction solution was added to aqueous ammonia (6 mL) and extracted with dichloromethane (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. Prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 5%-35%, 8 min) was used to separate the trifluoroacetate salt of compound 54-2. MS m / z: 500.2 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.34-10.28(m,1H),10.02(s,1H),9.76-9.71(m,1H),9.22(s,1H),8.36(d,J=5.0Hz,1H),7.62-7.58(m,2H ),39-7.38(m,1H),7.22-7.18(m,1H),6.90(d,J=3.4Hz,1H),4.75-4.72(m,4H),4.63-4.60(m,1H),3.47-3.26(m,6H),3.05(s,4H).
[0884] Step 3: Synthesis of Compound 54, Compound 57, Trifluoroacetate of Compound 54 and Trifluoroacetate of Compound 57
[0885] The trifluoroacetate salt of compound 54-2 (30.04 g) was subjected to SFC chiral separation (chromatographic column: DAICEL CHIRALPAK IC (250 mm*25 mm, 10 μm); mobile phase: A: n-heptane, B: isopropanol / acetonitrile = 2 / 1, 0.1% ammonia water, B%: 40%), and the separated liquid was concentrated to obtain compound 54 and compound 57.
[0886] Compound 54: 1H NMR(DMSO-d6,400MHz)δ9.97(s,1H),9.59(s,1H),9.18(s,1H),8.35(d,1H,J=4.8Hz ),7.57(d,1H,J=3.6Hz),7.44(d,1H,J=8.8Hz),7.38(d,1H,J=5.0Hz),7.01(d,1H,J= 8.8Hz), 6.91(d, 1H, J = 3.2Hz), 4.71(s, 2H), 3.91-4.09(m, 2H), 3.74-3.77(m, 3H), 3.67-3.70(m, 1H), 3.10-3.40(m, 6H), 2.48-2.55(m, 2H); ee% = 89.99%; retention time: 3.160min.
[0887] Compound 57: 1 H NMR(DMSO-d6,400MHz)δ9.97(s,1H),9.59(s,1H),9.19(s,1H),8.35(d,1H,J=5.0Hz),7.58(d,1H, J=3.5Hz),7.57(d,1H,J=8.8Hz),7.38(d,1H,J=5.0Hz),7.06-7.08(m,1H),6.91(d,1H,J=3.2Hz), 4.71 (s, 2H), 3.94-4.16 (m, 2H), 3.67-3.76 (m, 3H), 3.50-3.52 (m, 1H), 3.18-3.31 (m, 6H), 2.48-2.68 (m, 2H); ee% = 95.86%; retention time: 3.681 min.
[0888] EE% analysis method: (Chromatographic column: DAICEL CHIRALPAK IC (50*4.6 mm 3 μm); mobile phase: A: n-heptane (0.1% DEA), B: isopropanol / acetonitrile = 2 / 1, B%: 45%).
[0889] Compound 54 (440 mg, 880 μmol) was dissolved in DCM (5 mL), and TFA (4.40 mmol, 327.12 μL) was added. The mixture was stirred at 25°C for 1 hour and then concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 54. MS m / z: 250.7 [(M+1) / 2] + ;ee%=98.97%; 1H NMR(DMSO-d6,400MHz)δ9.97(s,1H),9.72(s,1H),9.23(s,1H),8.37(d,1H,J=5.2Hz),7.59-7.61(m,2H),7.40(d,1H,J=5.2Hz),7.20(br d,1H,J=8.8Hz),6.91(d,1H,J=3.6Hz),4.71(s,2H),3.71-3.79(m,4H),3.36-3.61(m,4H),3.3-3.5(m,3H),3.01(s,3H).
[0890] Compound 57 (1.16 g, 2.32 mmol) was dissolved in DCM (12 mL), and TFA (11.61 mmol, 862.39 μL) was added. The mixture was stirred at 25°C for 1 hour and then concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 57. MS m / z: 250.8 [(M+1) / 2] + ;ee%=96.40%; 1 H NMR(400MHz,DMSO-d6)δppm 10.02(s,1H),9.73(s,1H),9.26(s,1H),8.38(d,J=4.80Hz,1H),7.57-7.61(m,2H),7.40-7.43(m,2H), 6.93(d,J=3.2Hz,1H),4.73(s,2H),3.71-3.79(m,5H),3.26-3.46(m,4H),3.3-3.5(m,3H),3.01(s,3H).
[0891] Examples 55 and 56
[0892] Step 1: Synthesis of compound 55-1
[0893] Compound 45-5 (300 mg, 742.02 μmol) was dissolved in THF (5 mL) in a dry vial. NaH (89.04 mg, 2.23 mmol, 60% purity) was slowly added under nitrogen at 0°C. After stirring for 30 minutes, MeI (84.26 mg, 593.62 μmol) was slowly added dropwise. The reaction mixture was heated to 15°C and stirred for 16 hours. The reaction mixture was poured into saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 55-1 was obtained by column chromatography (petroleum ether:ethyl acetate = 30-100%). MS m / z: 417.9 [M+H] + ; 1H NMR (400MHz, CDCl3) δ7.27-7.22(m,3H),6.91-6.85(m,3H),4.31-4.27(m,1H),4.14-4.06(m,1H),3.81-3.76(m,4H),3.69-3.64(m,3H) ,3.48-3.45(m,1H),3.38-3.34(m,3H),3.23-3.21(m,1H),2.97-2.94(m,1H),2.55-2.51(m,1H),2.08-2.05(m,1H),1.76-1.73(m,1H).
[0894] Step 2: Synthesis of compound 55-2
[0895] In a dry vial, compound 55-1 (179 mg, 427.90 μmol) and compound BB-13-4 (275.65 mg, 641.84 μmol) were dissolved in 1,4-dioxane (5 mL). Cs2CO3 (418.25 mg, 1.28 mmol) was added. When the pH was >9, Xantphos Pd G4 (82.36 mg, 85.58 μmol) was added. The atmosphere was purged with nitrogen three times and stirred at 110°C for 4 hours. The mixture was filtered, and the filter cake was rinsed with ethyl acetate (10 mL x 2). The filtrate was concentrated and separated by column chromatography (dichloromethane:methanol = 100:0 to 10:1) to afford compound 55-2. MS m / z: 767.5 [M+1] + .
[0896] Step 3: Synthesis of trifluoroacetate salt of compound 55
[0897] Compound 55-2 (50.18 mg, 65.43 μmol) was added to TfOH (1 mL) and reacted at 40°C for 2 hours. The reaction solution was cooled and slowly added dropwise to aqueous ammonia (4 mL). Extraction was performed with dichloromethane (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 5%-35%, 8 min) was used to separate the trifluoroacetate salt of compound 55. MS m / z: 497.2 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.00(s, 1H),9.64(s,1H),9.30-9.29(m,1H),9.20(s,1H),9.04–9.01(m,1H),8.36(d,J=5.0Hz,1H ),7.57(d,J=3.4Hz,1H),7.47(d,J=9.0Hz,1H),7.38(d,J=5.0Hz,1H),7.15(d,J=8.8Hz,1 H),6.89(d,J=3.6Hz,1H),4.72(s,2H),4.68-4.63(m,1H),4.23-4.18(m,1H),4.11-4.08( m,1H),3.87(s,4H),3.33(s,4H),3.10-3.08(m,2H),2.18-2.14(m,1H),1.97-1.93(m,1H).
[0898] Step 4: Synthesis of trifluoroacetate salt of compound 56
[0899] The trifluoroacetic acid salt of compound 55 (50 mg, 100.69 μmol) and 37% formaldehyde solution (40.86 mg, 503.46 μmol) were added to MeOH (2 mL), followed by the addition of AcOH (18.14 mg, 302.08 μmol) and the reaction was allowed to proceed at 25°C for 1 hour. NaBH(OAc)3 (42.68 mg, 201.38 μmol) was then added and the reaction continued for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was then separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 5%-35%, 8 min) to afford the trifluoroacetic acid salt of compound 56. MS m / z: 511.3 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ10.15-9.96(m,2H),9.70-9.60(m,1H),9.21-9.19(m, 1H),8.37-8.36(m,1H),7.59-7.51(m,2H),7.40-7.38(m,1H),7.19-7.14(m,1H ),6.91-6.90(m,1H),4.76-4.72(m,3H),4.46-4.43(m,1H),4.22-4.00(m,2H), 3.88(s,3H),3.67-3.60(m,3H),3.31-3.26(m,3H),3.09-3.08(m,2H),2.91(br s,1H),2.21-2.19(m,1H),1.90-1.88(m,1H).
[0900] Example 58
[0901] Step 1: Synthesis of compound 58-1
[0902] Under nitrogen, compound 48-1 (140 mg, 213.84 μmol) was dissolved in DCM (4 mL), and TfOH (2.77 g, 18.46 mmol) was added. The mixture was allowed to react at 20°C for 2 hours. Aqueous ammonia (3 mL) was slowly added to the system, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate. Filtered, and the filtrate was concentrated under reduced pressure to obtain compound 58-1. MS m / z: 286.0, 288.0 [M+1] + .
[0903] Step 2: Synthesis of compound 58-2
[0904] Under nitrogen, compound 58-1 (67 mg, 234.15 μmol) was dissolved in tetrahydrofuran (1 mL). Sodium hydride (28.10 mg, 702.45 μmol, 60% purity) was added at -20°C and allowed to react for 0.5 hours. A solution of CD3I (27.15 mg, 187.32 μmol) in tetrahydrofuran (1 mL) was slowly added dropwise and allowed to react at 20°C for 15.5 hours. The temperature was lowered to 0°C, saturated ammonium chloride solution (5 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 58-2 was isolated by column chromatography (methanol / dichloromethane = 0% to 5%). MS m / z: 303.1, 305.1 [M+1] + .
[0905] Step 3: Synthesis of compound 58-3
[0906] Under nitrogen, compound BB-13-4 (38 mg, 88.48 μmol) was dissolved in 1,4-dioxane (1 mL), and compound 58-2 (26.83 mg, 88.48 μmol), cesium carbonate (86.49 mg, 265.44 μmol), Ruphos (8.26 mg, 17.70 μmol), and Pd2(dba)3 (8.10 mg, 8.85 μmol) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the filter cake was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product, which was then separated by column chromatography (methanol / dichloromethane = 0% to 15%) to obtain compound 58-3. MS m / z: 652.3 [M+1] + .
[0907] Step 4: Synthesis of trifluoroacetate salt of compound 58
[0908] Under nitrogen, compound 58-3 (54.00 mg, 82.85 μmol) was dissolved in DCM (3 mL), and TfOH (1.70 g, 11.30 mmol) was added. The mixture was reacted at 40°C for 16 hours. After cooling to room temperature, the mixture was slowly added to aqueous ammonia (10 mL) and extracted with dichloromethane:methanol = 10:1 (20 mL x 4). The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure to obtain the crude product. The trifluoroacetic acid salt of compound 58 was separated by prep-HPLC (column: Phenomenex C18 80*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 1%-30%, 8 min). MS m / z: 502.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ9.88-9.60(m,1H),9.39-9.09(m,1H),8.36-8.35(m,1H),7.68-7.28(m,4H), 7.24-7.05(m,1H),7.00-6.80(m,1H),5.60-5.26(m,1H),5.20-4.86(m,1H), 4.81-4.58(m,3H),4.57-4.28(m,2H),3.96-3.77(m,6H),2.23-1.66(m,2H).
[0909] Example 61
[0910] Step 1: Synthesis of compound 61-1
[0911] In a dry vial, compound 45-5 (500 mg, 1.24 mmol) was dissolved in DCM (10 mL), and TfOH (9.28 g, 61.84 mmol) was added. The reaction was stirred at 40°C for 16 hours. The reaction solution was poured into 5% dilute ammonia water (100 mL), and the aqueous phase was extracted with dichloromethane (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Column chromatography (petroleum ether:ethyl acetate = 1:1 to dichloromethane:methanol = 10:1) afforded compound 61-1. MS m / z: 284.1, 286.1 [M+1] + .
[0912] Step 2: Synthesis of compound 61-2
[0913] In a dry vial, compound 61-1 (135 mg, 475.10 μmol) was dissolved in THF (5 mL). Imidazole (97.03 mg, 1.43 mmol) and TBSCl (214.82 mg, 1.43 mmol) were added and stirred at 15°C for 16 hours. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. 61-2 was obtained by column chromatography (petroleum ether:ethyl acetate = 5:1 to 0:100). MS m / z: 397.8, 397.9 [M+1] + .
[0914] Step 3: Synthesis of compound 61-3
[0915] Compound 61-2 (100 mg, 251.00 μmol) was dissolved in THF (0.5 mL) in a dry vial. NaH (30.12 mg, 752.99 μmol, 60% purity) was slowly added under nitrogen at -20°C. After stirring for 15 minutes, a solution of CD3I (28.50 mg, 200.80 μmol) in THF (0.5 mL) was added dropwise. The reaction mixture was slowly allowed to return to 15°C and stirred for 16 hours. The reaction mixture was poured into saturated ammonium chloride solution (10 mL). The aqueous phase was extracted with ethyl acetate (5 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 61-3 was purified by preparative plate separation (dichloromethane:methanol = 20:1) to yield compound 61-3. MS m / z: 415.0, 416.9 [M+1] + .
[0916] Step 4: Synthesis of compound 61-4
[0917] In a dry vial, compound 61-3 (15 mg, 36.10 μmol) and compound BB-13-4 (18.61 mg, 43.33 μmol) were dissolved in dioxane (1 mL). Cs2CO3 (35.29 mg, 108.31 μmol) was added. The pH of the system was checked to be >9. Xantphos Pd G4 (6.95 mg, 7.22 μmol) was then added. The nitrogen atmosphere was replaced three times. Under nitrogen protection, the reaction was allowed to proceed at 110°C for 4 hours. The reaction solution was directly filtered, and the filter cake was rinsed with ethyl acetate (10 mL x 2). The filtrate was concentrated to obtain the crude product, which was then purified on a preparative plate (dichloromethane:methanol = 10:1) to obtain compound 61-4. MS m / z: 764.4 [M+1] + .
[0918] Step 5: Synthesis of trifluoroacetate salt of compound 61
[0919] Compound 61-4 (25 mg, 32.72 μmol) was dissolved in TfOH (0.5 mL) in a dry vial and stirred at 40°C for 1 hour. The reaction mixture was poured into 5% dilute ammonia water (10 mL). The aqueous phase was extracted with dichloromethane:methanol (5:1) (5 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile percentage: 5%-35%, 8 min) to obtain the trifluoroacetate salt of compound 61. MS m / z: 500.1 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ10.49-9.94(m,1H),9.70-9.59(m,1H),9.21-9.19 (m,1H),8.36-8.35(m,1H),7.58-7.49(m,1H),7.39-7.38(m,2H),7.18-7.1 4(m,1H),6.91-6.90(m,1H),4.75-4.45(m,3H),4.39-4.28(m,3H),3.87(s, 4H),3.43-3.35(m,1H),3.17(s,3H),2.14-2.00(m,1H),1.83-1.77(m,1H).
[0920] Example 62
[0921] Step 1: Synthesis of compound 62-2
[0922] Under nitrogen, compound 62-1 (1 g, 4.62 mmol) was dissolved in acetonitrile (7 mL). A solution of sodium bicarbonate (15.12 g, 14.40 mmol) in water (7 mL) and benzyl chloroformate (1.18 g, 6.94 mmol) were added, and the mixture was allowed to react at 25°C for 2 hours. The solvent was concentrated under reduced pressure, and a saturated aqueous sodium carbonate solution (10 mL) was added. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated under reduced pressure to obtain compound 62-2, which was then isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 50%). MS m / z: 373.1 [M+Na] + ; 1H NMR (400MHz, CDCl3) δ7.48-7.27(m,5H),5.17(s,2H),4.31-4.13(m,2H),4. 08-3.94(m,1H),3.93-3.79(m,1H),3.60(s,2H),3.01(s,3H),1.47(s,9H).
[0923] Step 2: Synthesis of compound 62-3
[0924] Under nitrogen, compound 62-2 (1.41 g, 4.02 mmol) was dissolved in DCM (28 mL), and Dess-Martin periodinane (1.88 g, 4.43 mmol) was added. The mixture was reacted at 25°C for 16 hours. Saturated sodium carbonate solution (20 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 62-3 was isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 50%). MS m / z: 371.1 [M+Na] + .
[0925] Step 3: Synthesis of compound 62-4
[0926] Under nitrogen, compound 62-3 (1.33 g, 3.82 mmol) was added to DCM (25 mL), followed by (PMB)2NH (982.35 mg, 3.82 mmol) and acetic acid (229.25 mg, 3.82 mmol). The mixture was allowed to react at 25°C for 1 hour. Sodium acetate borohydride (1.21 g, 5.73 mmol) was added, and the reaction was continued at 25°C for 1 hour. Saturated aqueous sodium carbonate (20 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered, and concentrated under reduced pressure to obtain the crude product. Compound 62-4 was isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 40%). MS m / z: 590.4 [M+1] + .
[0927] Step 4: Synthesis of compound 62-5
[0928] Under nitrogen, compound 62-4 (1.85 g, 3.14 mmol) was dissolved in hydrogen chloride / methanol (4 M, 100 mL) and reacted at 25°C for 2 hours. The solvent was concentrated under reduced pressure, and dichloromethane (20 mL) and saturated aqueous sodium carbonate (20 mL) were added. The mixture was extracted with dichloromethane (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure to obtain compound 62-5. MS m / z: 490.2 [M+1] + .
[0929] Step 5: Synthesis of compound 62-6
[0930] Under nitrogen, compound 62-5 (1.47 g, 3.00 mmol) was dissolved in DMF (15 mL), and compound BB-1-1 (734.98 mg, 3.60 mmol) and DIEA (1.16 g, 9.01 mmol) were added. The mixture was reacted at 100°C for 16 hours. After cooling, water (20 mL) and saturated sodium carbonate solution (20 mL) were added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered, and concentrated under reduced pressure to obtain the crude product. Compound 62-6 was isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 30%). MS m / z: 673.0, 675.0 [M+1] + .
[0931] Step 6: Synthesis of compound 62-7
[0932] Under nitrogen, compound 62-6 (480 mg, 712.59 μmol) was dissolved in trifluoroacetic acid (15.40 g, 135.06 mmol) and reacted at 60°C for 16 hours. The mixture was cooled and concentrated under reduced pressure. DCM (10 mL) and sodium acetate borohydride (453.08 mg, 2.14 mmol) were added and reacted at 25°C for 1 hour. Saturated sodium carbonate solution (30 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 5), washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 62-7 was isolated by column chromatography (methanol / dichloromethane = 0% to 20%). MS m / z: 403.0, 405.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.30 (d, J = 8.4Hz, 1H), 7.25 (d, J = 8.8Hz, 2H), 7.06 (d, J = 8. 4Hz,1H),6.86(d,J=8.4Hz,2H),4.16(d,J=14.4Hz,1H),3.96(d,J=14.4Hz,1H), 3.80(s,3H),3.75-3.69(m,1H),3.65-3.58(m,1H),3.49(s,1H),3.21-3.13(m,2 H),3.10-3.02(m,2H),3.00-2.90(m,2H),2.86-2.81(m,1H),2.63-2.89(m,1H).
[0933] Step 7: Synthesis of compound 62-8
[0934] Under nitrogen, compound 62-7 (150 mg, 371.92 μmol) was dissolved in methanol (3 mL), and 37% aqueous formaldehyde (150.91 mg, 1.86 mmol) and acetic acid (67.00 mg, 1.12 mmol) were added. The mixture was reacted at 25°C for 1 hour. Sodium acetate borohydride (157.65 mg, 743.84 μmol) was added, and the mixture was reacted at 25°C for 1 hour. Saturated aqueous sodium carbonate (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The filtrate was filtered, and concentrated under reduced pressure to obtain the crude product. Compound 62-8 was isolated by column chromatography (methanol / ethyl acetate = 0% to 10%). MS m / z: 417.0, 419.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.30(s,1H),7.27-7.22(m,2H),7.06(d,J=8.4Hz,1H),6.86(d,J=8.4Hz,2H),4.18-4.07(m,1H),4.03-3.93(m, 1H),3.81(s,3H),3.75-3.57(m,2H),3.46-3.32(m,2H),2.90-2.77(m,1H),2.70-2.57(m,2H),2.48-2.33(m,3H),1.87-1.66(m,4H).
[0935] Step 8: Synthesis of compound 62-9
[0936] Under nitrogen, compound BB-13-4 (70 mg, 162.99 μmol) was dissolved in 1,4-dioxane (2 mL), and compound 62-8 (81.63 mg, 195.59 μmol), cesium carbonate (159.32 mg, 488.97 μmol), and Xantphos Pd G4 (15.69 mg, 16.30 μmol) were added. The mixture was reacted at 110°C for 2 hours. The mixture was cooled, filtered, and the residue was washed with dichloromethane (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product. Compound 62-9 was isolated by column chromatography (methanol / dichloromethane = 0% to 20%). MS m / z: 766.2 [M+1] + .
[0937] Step 9: Synthesis of trifluoroacetate salt of compound 62
[0938] Under nitrogen, compound 62-9 (50 mg, 65.28 μmol) was dissolved in TfOH (4.25 g, 28.32 mmol) and reacted at 40°C for 16 hours. After cooling to room temperature, the mixture was slowly added to dilute aqueous ammonia (5%, 10 mL). Extraction was performed with dichloromethane (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated under reduced pressure to obtain the crude product. The trifluoroacetate salt of compound 62 was separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 1%-25%, 8 min). MS m / z: 496.3 [M+1] + ; 1 H NMR(400MHz, DMSO-d6)δ10.04(s,1H),9.75(s,1H),9.23(s,1H),8.36(d,J=5.2Hz,1H),7.73-7.48(m,2H),7.39(d,J=4.8Hz,1H),7.29(d,J=8.8Hz,1H),6 .89(d,J=3.6Hz,1H),4.73(s,2H),4.57-4.48(m,1H),4.45-4.35(m,1H ), 3.87 (s, 3H), 3.55 (d, J = 3.8Hz, 6H), 3.26-3.16 (m, 4H), 2.91 (s, 3H).
[0939] Example 63
[0940] Step 1: Synthesis of compound 63-1
[0941] Under nitrogen, compound 4-6 (1 g, 4.83 mmol) was added to 1,2-dibromoethane (10 mL), followed by copper bromide (538.90 mg, 2.41 mmol). Isoamyl nitrite (621.85 mg, 5.31 mmol) was slowly added, and the mixture was allowed to react at 20°C for 2 hours. Copper bromide (1.08 g, 4.83 mmol) was then added, and the mixture was allowed to react at 20°C for 2 hours. The mixture was filtered, and the filter cake was washed with dichloromethane (20 mL). The filtrate was collected and concentrated under reduced pressure to obtain the crude product. Compound 63-1 was isolated by column chromatography (ethyl acetate / petroleum ether = 0% to 40%). MS m / z: 271.1, 273.1 [M+1] + .
[0942] Step 2: Synthesis of compound 63-2
[0943] Under nitrogen, compound 50-6 (160 mg, 369.95 μmol) was dissolved in 1,4-dioxane (4 mL). Compound 63-1 (100.30 mg, 369.95 μmol), potassium phosphate (157.06 mg, 739.90 μmol), Ruphos (51.79 mg, 110.99 μmol), and Pd2(dba)3 (67.75 mg, 73.99 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled and concentrated under reduced pressure to obtain the crude product. Compound 63-2 was isolated by column chromatography (methanol / ethyl acetate = 0% to 100%). MS m / z: 623.2 [M+1] + .
[0944] Step 3: Synthesis of trifluoroacetate salt of compound 63
[0945] Under nitrogen, compound 63-2 (218 mg, 350.10 μmol) was dissolved in DCM (5 mL), and TfOH (3.39 g, 22.60 mmol) was added. The mixture was allowed to react at 40°C for 16 hours. The reaction was quenched with aqueous ammonia (5 mL) and extracted with dichloromethane:methanol = 10:1 (V / V, 20 mL x 4). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The crude product was filtered and concentrated under reduced pressure to obtain the crude product. Compound 63 was separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (TFA)-acetonitrile]; acetonitrile %: 15%-45%, 8 min). MS m / z: 473.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.85(s,1H),9.47(s,1H),9.18(s,1H),8.36(s,1H),7.58(s,1H),7.43-7.24(m,2H),6.94(s,1H),6.69(d,J=6.8Hz,1 H), 4.71 (s, 2H), 4.39 (d, J = 9.6Hz, 1H), 4.12-3.84 (m, 3H), 3.60 (d, J = 4.8Hz, 2H), 3.22-3.18 (m, 1H), 3.06 (d, J = 0.8Hz, 1H), 2.71-2.59 (m, 1H).
[0946] Example 64
[0947] Step 1: Synthesis of compound 64-2
[0948] Under nitrogen, compound 64-1 (8.5 g, 40.27 mmol) was dissolved in DMF (85 mL), and Select-F (14.27 g, 40.27 mmol) was added. The mixture was stirred at 60°C for 16 hours. The mixture was poured into water (300 mL), and the aqueous phase was extracted with MTBE (50 mL x 4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 64-2 was obtained by column chromatography (PE:EA = 100:0 to 4:1). MS m / z: 229.1, 231.1 [M+1] + .
[0949] Step 2: Synthesis of compound 64-3
[0950] Under nitrogen protection, compound 64-2 (1 g, 4.37 mmol) was dissolved in 1,4-dioxane (20 mL), and bis-pinacol borate (1.66 g, 6.55 mmol) and Pd(dppf)Cl were added. 2. CH2Cl2 (356.53 mg, 436.59 μmol) and potassium acetate (1.29 g, 13.10 mmol) were stirred at 85°C for 16 hours. The mixture was poured into water (50 mL) and extracted with EA (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 64-3 was obtained by column chromatography (PE:EA = 100:0 to 2:1). MS m / z: 195.2 [M-81] + ; 1 H NMR (400MHz, DMSO-d6) δ8.35(d,J=4.4Hz,1H),7.41(d,J=4.4Hz,1H),7.01(s,1H),3.84(s,3H),1.41(s,12H).
[0951] Step 3: Synthesis of compound 64-4
[0952] Under nitrogen, compound 64-3 (360 mg, 1.30 mmol) and compound BB-13-1 (518.46 mg, 1.30 mmol) were dissolved in 1,4-dioxane (20 mL). A solution of Pd(dppf)Cl2 (190.80 mg, 260.76 μmol) and K3PO4 (830.28 mg, 3.91 mmol) / H2O (4 mL) was added, and the mixture was stirred at 60°C for 2 hours. The mixture was filtered, and the filter cake was rinsed with EA (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 64-4 was then separated by column chromatography (DCM:MeOH = 100:0 to 95:5) to afford compound 64-4. MS m / z: 467.1 [M+1] + .
[0953] Step 4: Synthesis of compound 64-5
[0954] Under nitrogen, compound 64-4 (120 mg, 257.02 μmol) and BocNH2 (60.22 mg, 514.04 μmol) were dissolved in 1,4-dioxane (10 mL). K3PO4 (163.67 mg, 771.06 μmol) was added, and the pH was determined to be >9. Pd2(dba)3 (47.07 mg, 51.40 μmol) and RuPhos (35.98 mg, 77.11 μmol) were added, and the mixture was stirred at 110°C for 3 hours. The mixture was filtered, and the filter cake was rinsed with EA (20 mL x 3). The combined organic phases were concentrated to obtain the crude product, which was then separated by preparative chromatography (EA) to afford compound 64-5. MS m / z: 548.2 [M+1] + .
[0955] Step 5: Synthesis of compound 64-6
[0956] Compound 64-5 (55 mg, 100.44 μmol) was dissolved in DCM (2 mL), and TFA (25.35 mmol, 1.88 mL) was added. The mixture was stirred at 15°C for 2 hours. The mixture was poured into a saturated sodium carbonate solution (20 mL). When the pH of the solution was >8, the aqueous phase was extracted with DCM:MeOH = 5:1 (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 64-6. MS m / z: 448.0 [M+1] + .
[0957] Step 6: Synthesis of compound 64-7
[0958] Compound 64-6 (45 mg, 100.57 μmol) and compound 63-1 (27.26 mg, 100.57 μmol) were dissolved in 1,4-dioxane (5 mL). K₃PO₄ (64.04 mg, 301.70 μmol) was added, followed by Pd₂(dba)₃ (18.42 mg, 20.11 μmol) and RuPhos (14.08 mg, 30.17 μmol). The mixture was stirred at 110°C for 3 hours under nitrogen. The mixture was filtered, and the filter cake was rinsed with ethyl acetate (20 mL). The organic phases were combined and concentrated to obtain the crude product, which was separated by preparative chromatography (DCM:MeOH = 20:1) to obtain compound 64-7. MS m / z: 638.2 [M+1] + .
[0959] Step 7: Synthesis of compound 64
[0960] Compound 64-7 (50 mg, 78.41 μmol) was dissolved in TfOH (53.67 mmol, 4.75 mL) and stirred at 40°C for 1 hour. The mixture was poured into 5% dilute ammonia (20 mL). The aqueous phase was extracted with DCM:MeOH = 10:1 (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The trifluoroacetic acid salt of compound 64 was separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 15%-45%). MS m / z: 488.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.78 (s, 1H), 9.34 (s, 1H), 9.08 (s, 1H), 8.38 (d, J = 4.8Hz, 1H),7.59(s,1H),7.36(d,J=4.8Hz,1H),7.31(d,J=8.4Hz,1H),6.68(d,J=8.4Hz,1 H),4.53(s,2H),4.39-4.36(m,1H),4.05-4.00(m,1H),3.89-3.88(m,1H),3.87-3 .86(m,1H),3.82(s,3H),3.60-3.45(m,3H),3.22-3.17(m,1H),2.66-2.64(m,1H).
[0961] Example 65
[0962] Step 1: Synthesis of compound 65-1
[0963] Compound 16-6 (70 mg, 234.76 μmol) and compound 64-6 (105.05 mg, 234.76 μmol) were dissolved in 1,4-dioxane (5 mL). K3PO4 (149.50 mg, 704.28 μmol) was added, along with Pd2(dba)3 (42.99 mg, 46.95 μmol) and RuPhos (32.86 mg, 70.43 μmol). The mixture was stirred at 110°C under nitrogen for 3 hours. The mixture was filtered, and the filter cake was rinsed with EA (10 mL x 2). The combined organic phases were concentrated to obtain the crude product, which was then separated by preparative chromatography (DCM:MeOH = 10:1) to obtain compound 65-1. MS m / z: 665.3 [M+1] + .
[0964] Step 2: Synthesis of compound 65
[0965] Compound 65-1 (60 mg, 90.26 μmol) was dissolved in DCM (2 mL) and TfOH (1.61 g, 10.76 mmol) was added. The mixture was stirred at 40°C for 16 hours. The mixture was poured into 5% dilute ammonia (20 mL) and extracted with DCM:MeOH (10:1) (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The trifluoroacetate salt of compound 65 was separated by prep-HPLC (column: Phenomenex C18 80*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 10%-40%). MS m / z: 515.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.98-9.96(m,1H),9.66-9.60(m,1H),9.16(s,1H),8.40(d,J=4.8Hz,1H),7.61-7.58(m,2H),7.37-7.36(m, 1H),7.22-7.17(m,1H),4.75-7.73(m,1H),4.59-4.55(m,3H),3.83(s,3H),3.71-3.60(m,3H),3.35-2.99(m,6H),2.98-2.97(m,3H).
[0966] Example 66
[0967] Step 1: Synthesis of compound 66-2
[0968] Under nitrogen, compound 30-1 (38.5 g, 186.47 mmol) was dissolved in THF (500 mL). LDA (2 M, 111.88 mL) was added at -78°C and stirred for 1 hour. CO₂ was then introduced until the system no longer showed significant temperature changes. The temperature was slowly raised to 25°C and allowed to react for 2 hours. The mixture was poured into water (1000 mL) and extracted with EA (200 mL × 3). The aqueous phase was adjusted to pH 1 with 2 M hydrochloric acid. Extraction was then performed with DCM (200 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield compound 66-2.
[0969] Step 2: Synthesis of compound 66-3
[0970] Under nitrogen, compound 66-2 (26 g, 103.80 mmol) was dissolved in DMF (300 mL), and K2CO3 (43.04 g, 311.41 mmol) and MeI (29.47 g, 207.60 mmol) were added. The mixture was stirred at 15°C for 2 hours. The mixture was poured into water (3000 mL) and extracted with EA (1000 mL × 3). The organic phases were combined, washed with semi-saturated brine (500 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Compound 66-3 was obtained by column chromatography (EA / PE = 0% to 10%).
[0971] Step 3: Synthesis of compound 66-4
[0972] Under nitrogen, compound 66-3 (7 g, 26.46 mmol) was dissolved in 1-methyl-2-pyrrolidone (70 mL). 1,3,5-triazine (4.29 g, 52.93 mmol) was slowly added dropwise at 0°C. After stirring at 0°C for 0.5 hours, potassium tert-butoxide (5.94 g, 52.93 mmol) was added. The temperature was raised to 110°C and stirred for 1 hour. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product. Compound 66-4 was then separated by column chromatography (EA / PE = 0% to 10% to MeOH / EA = 0% to 5%). MS m / z: 258.7, 260.7 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ11.98 (s, 1H), 8.40-8.36 (m, 1H), 6.63 (d, J = 7.6Hz, 1H).
[0973] Step 4: Synthesis of compound 66-5
[0974] Under nitrogen protection, compound 66-4 (2.5 g, 6.74 mmol) was dissolved in 1,4-dioxane (30 mL) and water (6 mL), and compound 66-4a (1.74 g, 6.74 mmol), potassium phosphate (4.29 g, 20.23 mmol), Pd(dppf)Cl 2. CH2Cl2 (550.75 mg, 674.41 μmol) was stirred at 90°C for 1 hour. The mixture was poured into water (200 mL) and extracted with EA (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. Compound 66-5 was obtained by column chromatography (EA / PE = 10% to 100%). MS m / z: 310.8 [M+1] + .
[0975] Step 5: Synthesis of compound 66-6
[0976] Under nitrogen, compound 66-5 (1.5 g, 4.83 mmol) was dissolved in tetrahydrofuran (5 mL). 1,8-diazabicyclo[5.4.0]undec-7-ene (3.67 g, 24.14 mmol, 3.64 mL) was slowly added dropwise at 0°C. The mixture was stirred at 0°C for 0.5 hours. 2-(Trimethylsilyl)ethoxymethyl chloride (3.22 g, 19.31 mmol) was slowly added, and the temperature was raised to 15°C and stirred for 16 hours. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (EA / PE = 10% to 50%) to obtain compound 66-6. MS m / z: 441.0 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.76 (s, 1H), 8.49 (d, J = 4.8Hz, 1H), 7.27-7.23 (m, 3H), 6.50 (d, J = 7.6Hz, 1H) ,6.27(d,J=3.2Hz,1H),5.41(s,2H),3.97(s,3H),3.71-3.66(m,2H),0.99–0.95(m,2H),0.01(s,9H).
[0977] Step 6: Synthesis of compound 66-7
[0978] Under nitrogen, compound 66-6 (100 mg, 226.76 μmol) was dissolved in 1,4-dioxane (2 mL). Compound 4-6 (46.99 mg, 226.76 μmol), potassium phosphate (144.40 mg, 680.28 μmol), Ruphos (21.16 mg, 45.35 μmol), and Pd2(dba)3 (20.76 mg, 22.68 μmol) were added, and the mixture was stirred at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with DCM (20 mL). The filtrate was concentrated under reduced pressure. Compound 66-7 was obtained by column chromatography (MeOH / EA = 0% to 2%). MS m / z: 612.2 [M+1] + .
[0979] Step 7: Synthesis of compound 66
[0980] Under nitrogen, compound 66-7 (80 mg, 130.77 μmol) was dissolved in TFA (26.93 mmol, 2.00 mL) and stirred at 20°C for 16 hours. The mixture was concentrated under reduced pressure, and DCM (10 mL) was added. Dilute ammonia (5%, 3 mL) was added to adjust the pH to 8, and the layers were separated. The aqueous phase was extracted with dichloromethane (10 mL x 3). The combined organic phases were washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The crude product was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Compound 66 (trifluoroacetic acid salt) was isolated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 15%-45%). MS m / z: 482.1 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.03-11.93(m,1H),11.86(s,1H),9.79(s,1H),8.39(d,J =4.4Hz,1H),7.56(d,J=3.6Hz,1H),7.37-7.28(m,1H),7.21(d,J=3.6Hz,2H),6.73 -6.60(m,1H),6.41-6.30(m,1H),6.26(d,J=3.6Hz,1H),4.41-4.32(m,2H),4.10-3 .94(m,3H),3.88(s,4H),3.62-3.57(m,1H),3.23-3.15(m,1H),3.12-3.03(m,1H).
[0981] Example 68
[0982] Step 1: Synthesis of compound 68-1
[0983] Under nitrogen, compound 66-6 (100 mg, 226.76 μmol) was dissolved in 1,4-dioxane (1 mL). Compound 16-9 (58.44 mg, 249.43 μmol), potassium phosphate (144.40 mg, 680.28 μmol), Ruphos (21.16 mg, 45.35 μmol), and Pd2(dba)3 (20.76 mg, 22.68 μmol) were added and stirred at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with DCM (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product. Compound 68-1 was obtained by flash column chromatography (MeOH / EA = 0% to 15%). MS m / z: 639.3 [M+1] + .
[0984] Step 2: Synthesis of trifluoroacetate salt of compound 68
[0985] Compound 68-1 (120 mg, 187.84 μmol) was dissolved in TFA (67.31 mmol, 5 mL), and the reaction was stirred at 15°C for 16 hours. The solvent was concentrated under reduced pressure, and dichloromethane (20 mL) and dilute aqueous ammonia (5%, 20 mL) were added. The mixture was separated, and the aqueous phase was extracted with DCM:MeOH = 10:1 (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The trifluoroacetic acid salt of compound 68 was separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 10%-40%). MS m / z: 509.1 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ=12.31-12.26(m,1H),11.96-11.95(m,1H),10.05( s,1H),8.40(d,J=5.2Hz,1H),7.62-7.56(m,2H),7.28-7.21(m,2H),7.16-7. 14(m,1H),6.36-6.34(m,1H),6.24-6.23(m,1H),4.75-4.73(m,1H),4.65-4 .33(m,1H),3.89(s,3H),3.78-3.61(m,5H),3.43-3.26(m,4H),2.98(s,3H).
[0986] Example 69
[0987] Step 1: Synthesis of compound 69-2
[0988] Under nitrogen protection, compound 30-5 (2.1 g, 6.04 mmol) was dissolved in 1,4-dioxane (30 mL) and water (6 mL), and compound BB-2 (5.86 g, 6.04 mmol), potassium carbonate (2.50 g, 18.12 mmol), Pd(dppf)Cl 2. CH2Cl2 (442.06 mg, 604.16 μmol) was stirred at 70°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with DCM (20 mL). The filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (EA / PE = 0% to 100%) to give compound 69-2. MS m / z: 403.1 [M+1] + ; 1H NMR (400MHz, CDCl3) δ10.14-9.94(m,1H),8.75(s,1H),8.06(s,1H),7.42-7.39(m,1H),7.03-6.87(m,1H),5.00(s,2H),1.25(s,9H).
[0989] Step 2: Synthesis of compound 69-3
[0990] Under nitrogen, compound 69-2 (200 mg, 496.52 μmol) was dissolved in 1,4-dioxane (4 mL). Compound 4-6 (102.89 mg, 496.52 μmol), potassium phosphate (316.18 mg, 1.49 mmol), Ruphos (46.34 mg, 99.30 μmol), and Pd2(dba)3 (45.47 mg, 49.65 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with DCM (10 mL). The filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (MeOH / EA = 0% to 20%) to obtain compound 69-3. MS m / z: 574.2 [M+1] + .
[0991] Step 3: Synthesis of compound 69
[0992] Under nitrogen, compound 69-3 (120 mg, 209.21 μmol) was dissolved in DCM (3 mL), and TFA (6.73 mmol, 0.5 mL) was added. The mixture was reacted at 20°C for 16 hours. The crude product was concentrated under reduced pressure and separated by prep-HPLC (column: Phenomenex C18 75*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 10%-40%) to afford the trifluoroacetate salt of compound 69. MS m / z: 474.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ10.10-9.97(m,1H),9.87(s,1H),9.44-9.26(m,2H),8.27(s,1H),7.85-7.75(m,1H),7.38-7.25(m,2H),6.68(d,J=8. 0Hz,1H),4.73(s,2H),4.40(d,J=9.6Hz,1H),4.09-4.01(m,2H),3.98- 3.89(m,2H),3.64-3.56(m,2H),3.22-3.17(m,1H),3.12-3.02(m,1H).
[0993] Example 70
[0994] Step 1: Synthesis of compound 70-1
[0995] Under nitrogen, compound 69-2 (200 mg, 496.52 μmol) was dissolved in 1,4-dioxane (4 mL). Compound 16-9 (116.33 mg, 496.52 μmol), potassium phosphate (316.18 mg, 1.49 mmol), Ruphos (46.34 mg, 99.30 μmol), and Pd2(dba)3 (45.47 mg, 49.65 μmol) were added and reacted at 110°C for 2 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with DCM (10 mL). The filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by column chromatography (MeOH / DCM = 0% to 10%) to obtain compound 70-1. MS m / z: 601.2 [M+1] + .
[0996] Step 2: Synthesis of compound 70
[0997] Under nitrogen, compound 70-1 (110 mg, 183.14 μmol) was dissolved in DCM (3 mL), and TFA (6.73 mmol, 0.5 mL) was added. The mixture was stirred at 20°C for 16 hours. The crude product was concentrated under reduced pressure and separated by prep-HPLC (column: Phenomenex C18 80*30 mm*3 μm; mobile phase: [water (0.1% TFA)-acetonitrile]; acetonitrile percentage: 1%-30%) to obtain the trifluoroacetate salt of compound 70. MS m / z: 501.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.96 (s, 2H), 9.65 (s, 1H), 9.36 (s, 1H), 8.19 (s, 1H), 7.71 (d, J = 8.8Hz, 1H), 7.59 (d, J = 8.4Hz, 1H), 7.33-7.25 (m, 1H), 7 .17(d,J=8.4Hz,1H),4.77(s,2H),4.63-4.57(m,1H),3.80-3.68(m,5H) ,3.61-3.54(m,1H),3.43-3.36(m,3H),3.32-3.25(m,1H),3.01(s,3H).
[0998] Biological test data
[0999] Experimental Example 1: In vitro enzyme activity test of the compounds of the present invention
[1000] Method 1: Use 33P isotope-labeled kinase activity assay to determine IC 50 The inhibitory ability of the test compound on human HPK1 was evaluated by PCR. [10...
Claims
1. A compound represented by formula (P), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, in, X is selected from O and S; Y is selected from C(R8)2 and C(R8)=C(R8); T is selected from CH and N; T1 is selected from CH and N; T2 and T3 are independently selected from CH, CF and N; T4 is selected from CR6 and N; R2 is selected from 5-membered and 6-membered heteroaryl, wherein the 5-membered and 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R a replace; R3 and R4 together with the carbon atoms to which they are attached form E and E1 are each independently selected from -C(R7)2-, -O- and -N(R5)-; n and m are independently selected from 0 and 1; R5 is selected from H and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 R groups; R6 is selected from H, halogen and -C 1-3 Alkyl-C 1-3 Alkylamino; R7 is selected from H, F, Cl, Br, I, OH, NH2, C 1-3 Alkyl and C 1-3 alkoxy; R8 is selected from H and D; Each R a are independently selected from D, halogen, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkyl and C 1-3 The alkoxy groups are each independently optionally substituted with 1, 2 or 3 R; Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens; Or, 2 R b Together with the carbon atom to which they are attached, they form a C=O or cyclopropyl group; Each R is independently selected from halogen and D.
2. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, which is selected from: in, X, T, T1, T2, T3, T4, R2, R3, R4 and R8 are as defined in claim 1.
3. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R a Each is independently selected from D, F, CH3 and CD3.
4. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Each R b Each is independently selected from H, D, F, OH, CH3 and CF3.
5. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from pyrrolopyridinyl and imidazopyridinyl, wherein the pyrrolopyridinyl and imidazopyridinyl are optionally substituted by 1, 2 or 3 R a replace.
6. The compound according to claim 5, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: R2 is selected from 7. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R6 is selected from H, F and -CH2-N(CH3)2.
8. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R5 is selected from H, CH3, CD3, CH2CH3 and CH(CH3)2.
9. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R7 is selected from H, F, OH, CH3 and OCH3.
10. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: E and E1 are independently selected from -CH2-, -CHF-, -CF2-, -CH(OH)-, -CH(CH3)-, -O-, -NH-, -N(CH3)-, -N(CD3)-, -N(CH2CH3)- 11. The compound according to claim 1 or 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R3 and R4 together with the carbon atoms to which they are attached form 12. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R3 and R4 together with the carbon atoms to which they are attached form Each R b are independently selected from H, D, OH, halogen and C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with 1, 2 or 3 halogens.
13. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R3 and R4 together with the carbon atoms to which they are attached form 14. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, which is selected from the group consisting of: in, E, E1, T, T1, R2 and m are as defined in claim 1, E2 is selected from N and CH.
15. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, which is selected from the group consisting of: in, E, E1, T, T1, R2 and m are as defined in claim 1.
16. The following compound, its stereoisomer or a pharmaceutically acceptable salt thereof:
17. The compound according to claim 16, its stereoisomer or pharmaceutically acceptable salt thereof, which is selected from:
18. Use of the compound according to any one of claims 1 to 17, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating various types of tumors.
Citation Information
Patent Citations
Compounds and compositions as kinase inhibitors
CN101990539A
Compound used as HPK1 kinase inhibitor and preparation method and application thereof
CN114315796A
HPK1 inhibitors and uses thereof
CN114940683A
Heterocyclic compounds as HPK1 inhibitors
CN115536656A
HPK1 antagonists and uses thereof
WO2021050964A1
